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Thrombospondin (TSP), a glycoprotein of wide cellular
distribution, exhibits several activities important in platelet
aggregation, haemostasis and cell adhesion. The aim of this project
was to investigate the production and role of TSP in human tissues
and fluids; particularly its source in the breast and relation to
malignant disease.
Most circulating TSP was contained within platelet oc-granules
and released upon activation of these cells. Infused TSP appeared
to be rapidly bound, while its clearance from the circulation was
relatively slow. Extra-platelet sources contributed substantially
to basal plasma levels; platelet-associated TSP may therefore be a
better indicator of platelet activation than plasma concentration.
TSP concentration in breast cyst fluids varied according to cyst
type and correlated inversely with epidermal growth factor. TSP was
present in milk at high levels compared with plasma and its pattern
of secretion resembled that of IgA; it may be that white cells
which infiltrate the mammary gland are a major source of TSP in
breast secretions.
Very high levels of TSP were found in malignant breast tissue
compared with non-malignant breast and were associated with the
centre of the tumour mass. Positive correlation between TSP and von
Willebrand factor suggested that endothelium contributes to the
high levels of both proteins in malignant breast, whereas lack of
correlation between TSP and tissue plasminogen activator argued
ii
against epithelium being the source of TSP in breast cancer.
Studies of TSP in cultured cells confirmed and extended
knowledge of its ubiquitous nature. Factors which were important in
determining the amount of TSP produced in culture were; cell type,
tissue origin, cell density and composition of growth medium, but
all cells secreted TSP in a linear, continuous manner. Serum, but
not TSP, appeared to be important for maintenance of adhesion and
normal morphology of endothelial cells. Production of TSP by breast
cancer cells was stimulated by sex hormones and inhibited by
corticosteroid, while insulin had a marked effect on TSP secretion.
Monoclonal antibodies generated against calcium-deplete TSP were
primarily IgM and gave unique binding patterns in immunoassays,
suggesting that they were directed against different epitopes of
TSP.
Immunocytochemical localisation of TSP showed a restricted
distribution in tissues and cells. Strong staining of infiltrating
cells in breast cancer stroma and in germinal centres of tonsil was
evidence that TSP may be involved in the immune response.
In conclusion, the results presented in this thesis support
current knowledge of TSP as an adhesive glycoprotein of platelets,
vessel walls and connective tissues. Novel studies in the breast
have revealed a marked association of TSP with cancerous tissue and
some cyst fluids, which could be due to production by vascular
endothelium and certain white blood cells. While the role of TSP in
the breast remains to be defined, its relation to disease states
may be of particular physiological significance.
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1.1 Discovery of thrombospondin
Baenziger et al (1971, 1972) first described a
thrombin-sensitive protein of human platelets which was rapidly
released upon stimulation of platelets with thrombin. This 190 kdal
glycoprotein accounted for 20 - 30% of the total protein released.
The thrombin-sensitive protein was later characterised by Lawler
et al (1977, 1978) under non-denaturing conditions. They named the
intact 450 kdal glycoprotein thrombospondin (TSP) and suggested
that each of the three constituent disulphide-linked 142 kD
polypeptide chains were equivalent to the protein of Baenziger et
al.
TSP was independently described by George (1978) as glycoprotein
G, indicating its granule origin, and has also been given the names
GP-160 or GP (McPherson et al 1981, Mosher et al 1982) and
glycoprotein Ig (Nurden et al 1982).
Other workers demonstrated that TSP was located in platelet
a-granules (Hagen 1975, Gerrard et al 1980, Gogstad et al 1982,
McLaren 1983, Wencel-Drake et al 1985) where it may account for
2 - 4% of the total platelet protein (Silverstein et al 1986).
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1.2 Isolation of TSP
The original isolation method of Baenziger et al (1972) used a
supernatant from thrombin-stimulated platelets. They separated the
components by SDS-PAGE under reducing conditions and eluted the
protein from the gel. The starting material has remained the same
in all later methods although several other separation techniques
have been employed.
Lawler et al (1978) used gel filtration on a Sepharose 4B column
in the presence of EDTA. They found that TSP could be purified
further by application of the gel-filtered protein onto a
heparin-Sepharose 4B column and eluting stepwise with buffers
containing 0.15, 0.25, 0.45 and 2.0 M NaCl (TSP eluted at 0.45 M
NaCl). In later publications by this group, 2 mM CaCl^ was
substituted for EDTA and the procedure was reversed, with heparin
affinity chromatography becoming the first step (Lawler et al 1982,
1985).
Affinity chromatography on Lens culinaris lectin-Sepharose 4B
was used by Dawes et al (1983), while Tuszynski et al (1985)
employed a fibrinogen-Sepharose column to obtain highly purified
TSP preparations. A recent method used a gelatin-Sepharose column
coupled to a heparin-Sepharose column, both equilibrated in buffer
containing 0.15 M NaCl, followed by elution of the heparin column
only with increasing NaCl concentrations, and finally gel
filtration of the TSP peak on a BioGel A-0.5m column (Santoro &
Frazier 1987).
Other methods for isolating TSP which have been reported include
barium chloride precipitation (Alexander & Detwiler 1984) and
anion-exchange chromatography on a Mono-Q column using fast protein
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liquid chromatography (Clezardin et al 1984).
1.3 Structure of TSP
The original description of the 190 kdal thrombin-sensitive
protein (Baenziger et al 1972), containing 3.9% sialic acid and
1.6% N-acetylglucosamine, with 25% acidic and 25% nonpolar amino
acids, was expanded and refined as more structural information
became available with advancing techniques.
Lawler et al (1978) reported the amino acid and carbohydrate
compositions of native TSP, noting that there was a relatively high
proportion of aspartate/asparagine, glutamate/glutamine and
cysteine residues and a relatively low proportion of leucine
residues. The glycoprotein contained 0.7% sialic acid, 1.4%
N-acetylglucosamine and 1.9% neutral sugars, had an isoelectric
point of 4.7, and exhibited a heparin-binding activity. Their early
elecron microscope images showed a filamentous structure sometimes
with nodules at the ends or occasionally along its length. Trypsin
degradation resulted in a 210 kdal core fragment and three 70 kdal
fragments.
More detailed measurements of the physical properties of TSP in
solution containing EDTA were made by Margossian et al (1981). They
concluded that the structure of TSP was largely stabilised by
disulphide linkages, since they found a relatively low proportion
of residues in ordered secondary structures yet the molecule did
not unfold greatly in 6 M guanidine hydrochloride. The same group
then compared the measurements they had made in EDTA solution with
others made in the presence of Ca^+ (Lawler et al 1982) and showed
that Ca^+ stabilised some parts of the TSP molecule. The physical
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Table 1-1. Physical properties of TSP
2mM Ca2+ ImM EDTA





Sedimentation coefficient 9.7 S 8.6 S
Intrinsic viscosity 21 ml/g 40 ml/g
Axial ratio of prolate ellipsoid model 3.3 9.3
Electron microscopic length 54 nm 63 nm












Principal high molecular weight fragments only
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data (table 1-1) were in good agreement with higher quality
electron microscope images, which were interpreted as a nodular
rod-shaped molecule containing three polypeptide chains. When Ca^+
was removed, the nodular domains were thought to unravel to some
extent, causing an increase in the length of the thin flexible
connecting regions. Concomitantly, TSP became more susceptible to
proteolysis by thrombin. The Ca^+-sensitive nature of the TSP
molecule was also demonstrated recently by ESR spin-label
techniques (Slane et al 1988).
From further electron microscopy studies and the isolation of a
30 kdal heparin-binding peptide from the amino terminus of TSP,
Coligan and Slayter (1984) proposed a crude model of the molecule.
These studies were extended by Lawler et al (1985) and Galvin et al
(1985). Both groups used information gained from proteolytic
digestion of TSP , detection of the fragments with panels of
monoclonal antibodies, and electron microscopy, to arrive at
similar schematic models of the structural and functional
organisation of the TSP molecule. They suggested that each
polypeptide chain consisted of four distinct segments having
specific binding activities for heparin, type V collagen,
fibrinogen or platelets.
In 1986, Lawler and Hynes published the complete amino acid
sequence of TSP. They used a cDNA library constructed from human
endothelial cell TSP mRNA cloned in a bacteriophage, and determined
the amino acid sequence from the nucleotide sequence of the coding
region. Their results predicted a molecular weight of 127,524
(without carbohydrate) for each of the three chains of TSP (1152
amino acids long) and were consistant with all the previously
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published structural and functional data on TSP. Three types of
repeating sequence could be identified within the chains. Type 1
repeats (57 amino acids) showed homology with circumsporozoite
proteins from Plasmodium falciparum and a cluster of type 1 repeats
were found in a region of the molecule thought to bind several
matrix proteins. Type 2 repeats (50 - 60 amino acids) had some
homology with mouse epidermal growth factor (EGF) precursor and
occurred in the central region of the molecule, next to the type 1
repeats. Other proteins, including growth factors, plasminogen
activators and coagulation factors IX and X also have a region of
EGF-like homology (Bender 1985) and some, like TSP, have binding
activities with plasminogen, fibronectin and fibrinogen (see
section 1.4). Type 3 repeats (38 amino acids) showed homology with
the calcium-binding sites of parvalbumin and calmodulin. A group of
eight type 3 repeats was found in that part of the molecule
previously thought to be sensitive to Ca^+; thus they may
constitute a series of adjacent Ca2+-binding sites in TSP. The last
of the type 3 repeats was also found to include the sequence
arg-gly-asp-ala (RGDA) and may represent the site for the
association of TSP with cells (Ruoslahti & Pierschbacher 1986),
especially platelets.
Other studies by Clezardin et al (1986a,b) have identified
subtle differences between platelet TSP and endothelial and
fibroblast TSP. We used a panel of monoclonal antibodies and a
polyclonal antibody (section 2.3) to detect trypsin- and
thermolysin-generated fragments, separated by fast protein liquid
chromatography using a Superose 6 or 12 gel filtration column. It
was also observed that TSP oligomers from the cell cultures were
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more resistant to proteolysis than oligomers of platelet TSP. Our
findings were supported by the data of Dardik and Lahav (1987).
By combining the information from primary sequence data,
electron microscopic shape and protein biochemistry studies, Lawler
and Hynes (1986) produced a more comprehensive model of the
structural and functional organisation of the TSP molecule (figure
1-1).
Most recent work, leading on from the amino acid sequence of
Lawler and Hynes (1986), has identified several homologies between
sequences in TSP and others found in the following proteins; von
Willebrand factor, procollagen, thrombomodulin, vitronectin, plasma
cell membrane glycoprotein PC-1, complement components C9, C8<x, C8S
and C7, properdin, and proteins isolated from the malaria parasite
Plasmoidium falciparum (Hunt & Barker 1987, Patthy 1988, Robson et
al 1988, Goundis & Reid 1988).
Studies of the TSP gene and messenger sequences (Donoviel et al
1988, Hennessy et al 1989) have already given an insight into its
evolutionary ancestry and the regulatory mechanisms which may
operate at the level of TSP synthesis within cells. Further studies
of this kind, together with those aimed at defining the precise
biochemical interactions of the molecule, will greatly increase the
understanding of the structure and function of TSP.
1.4 Interactions of TSP with other macromolecules
TSP is known to bind to a wide range of macromolecules involved
in the formation of extracellular matrices and in the regulation of
thrombosis and haemostasis (the fibrin clot may also be considered
as a specialised form of extracellular matrix). It has therefore
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Fig. 1-1. Schematic model of the structural and functional organisation
of the TSP molecule
(From Lawler & Hynes 1986)
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been termed a multifunctional glycoprotein (Silverstein et al 1986,
Lawl°r 1986, Asch & Nachman 1989).
1.4.1 Heparin
The interaction of TSP with heparin and related
mucopolysaccharides has been well characterised and is commonly
utilised in procedures for the purification of TSP (sections 1.2
and 2.1.2). Low molecular weight heparin binds to the 25-30 kdal
amino-terminal domain of TSP with high affinity (Dixit et al 1984a,
Raugi et al 1984, Dardik & Lahav 1987). Binding was reduced at high
ionic strength and inhibited by competition with other
mucopolysaccharides and platelet factor 4 (Slayter et al 1987).
The biological significance of the TSP-heparin interaction is
not known, but it has been proposed that the cell surface receptor
for TSP on fibroblasts and endothelial cells may be a heparin-like
molecule (Murphy-Ullrich & Mosher 1987b). Also, heparin and other
highly charged polymers are able to inhibit the complement system
via component Clq (Ecker & Pillemer 1941, Confrancesco et al 1979,
Silvestri et al 1981). It is possible that such interactions may be
important during wound healing and developmental processes, for
example at sites of vascular injury and in atherosclerosis.
1.4.2 Fibrinogen
Leung and Nachman (1982) observed the formation of a complex
between TSP and fibrinogen which was inhibited by certain amino
sugars and which was independent of the presence of calcium. There
is, however, some disagreement over the effect of calcium ions on
the TSP-fibrinogen interaction (Lawler 1986). The region of the TSP
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molecule which contains the fibrinogen-binding site has been
located to a 40 kdal fragment near the carboxy-terminus (Dixit et
al 1984b). Binding of TSP could be inhibited by antibodies directed
against the carboxy-terminus of the ot-chain of fibrinogen
(Tuszynski et al 1985) whilst Bacon-Baguley et al (1987) showed
that TSP bound to both the Aa and B3 chains but not the T-chain of
reduced fibrinogen.
1.4.3 Fibronectin and collagen
Although a specific interaction between TSP and fibronectin has
been observed (Lahav et al 1982), the properties of the binding
site are not well characterised (Leung & Nachman 1982, Lahav et al
1984). Walz et al (1987) reported that TSP bound to both chains of
reduced fibronectin but noted that progress had been hampered by
technical difficulties in handling fibronectin.
TSP was found to bind to type V collagen with high affinity
(Mumby et al 1984). Galvin et al (1987) confirmed this observation
and defined the high affinity binding site. Their studies also
revealed a low affinity site common to collagen types I-V. The
collagen-binding site of TSP has been mapped to a 70 kdal
chymotryptic fragment which represents the thin flexible connecting
region of the molecule (Galvin et al 1985).
Since fibronectin and collagen are major components of the
extracellular matrix, it is likely that interactions between TSP
and these macromolecules are important for the stability and
regulation of the matrix. Indeed, TSP has been localised by
immunocytochemical techniques in the extracellular matrix of
certain cell types where it stains in a fibrillar pattern similar
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to that of fibronectin (Raugi et al 1982, Jaffe et al 1983).
It is also of interest that the 70 kdal fragment of TSP binds
laminin, a component of basement membranes (Liotta et al 1986), in
an ELISA (Mumby et al 1984) although this has not been confirmed
using fluid-phase techniques.
1.4.4 Plasminogen and histidine-rich glycoprotein
The interactions between TSP, plasminogen, tissue-type
plasminogen activator (tPA) and histidine-rich glycoprotein (HRGP)
have been studied in detail by Silverstein and coworkers (reviewed
in Silverstein et al 1986). They have demonstrated the formation of
complexes between TSP, plasminogen and HRGP, and between TSP,
plasminogen and tPA (Silverstein et al 1985a,b).
HRGP has been shown to interact with the lysine-binding site of
plasminogen (Lijnen et al 1980) and may therefore inhibit
fibrinolysis by reducing the binding of plasminogen to fibrin. HRGP
also binds to heparin and neutralises its anticoagulant properties
(Lijnen et al 1984). Thus local binding of TSP to plasminogen and
HRGP at or near the platelet surface may regulate fibrinolysis and
coagulation.
Plasminogen activation by tPA is unfavourable in the absence of
a fibrin substrate and proceeds with optimal efficiency on the clot
surface (Hoylaerts et al 1982). However, activation was found to
occur at an intermediate rate on a TSP surface (Silverstein et al
1985b) and therefore interactions between TSP, plasminogen and tPA
may be important in extracellular proteolytic events, for example
in cell migration, tissue breakdown and repair.
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1.5 Distribution of TSP in cells and tissues
Initially TSP was thought to be a platelet-specific protein like
platelet factor 4 (PF4) and (3-thromboglobulin (BTG) which also
occur in platelet a-granules. Results of immunocytochemical
staining by McLaren (1983) suggested that platelet TSP was
synthesised in megakaryocytes, and this view was confirmed by the
35
S-methionine protein-labelling studies of Rabellino et al (1985)
using cultured megakaryocytes.
The first report of TSP synthesis by cultured endothelial cells
(McPherson et al 1981) was followed by several others for
endothelial cells derived from various human sources (Mosher et al
1982, Hunter et al 1984, Kramer et al 1985). Proteins similar to
TSP, but not identified as such, had earlier been shown to be
synthesised by hamster embryo fibroblasts (Carter & Hakomori 1978)
and HT-1080 sarcoma cells (Alitalo et al 1980). Since then, a wide
variety of cell types have been shown to produce TSP in vitro
(table 1-2) .
However, it has proved more difficult to demonstrate TSP in
tissues in vivo. Using affinity purified rabbit antibody to human
TSP, Wight et al (1985) localised TSP in the extracellular matrices
of some human tissues and specifically in the basement membranes of
others. Thus, TSP was present in the peritubular connective tissue
of kidney, at the base of glandular epithelia within skin and lung,
at the dermal-epidermal junction in skin, and in the interstitial
connective tissue of skeletal muscle. It was also observed around
small blood vessels and along the luminal surface of aorta; areas
of vessels characterised by atherosclerosis exhibited marked
immunostaining for TSP.
12
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In contrast, Murphy-Ullrich and Mosher (1987a) failed to obtain
specific staining of various adult human tissues with monoclonal or
polyclonal antibodies to human platelet TSP, but did observe
extensive staining of loose connective tissue in sections of human
foetal limb. They suggested that TSP may only be a major matrix
component during a specific period of an organ's development.
Furthermore, O'Shea and Dixit (1988) observed a unique distribution
of TSP in the extracellular matrix of the developing mouse embryo.
TSP has also been shown to be associated with wound tissue
(Raugi et al 1987) and thrombus formation (Murphy-Ullrich & Mosher
1985, Perlman et al 1987). Recent reports have identified TSP in
cartilage (Miller & McDevitt 1988) and bone (Robey et al 1989).
1.6 TSP and platelet function
Platelets play an essential role in haemostasis. Following
vascular injury, platelets adhere to the subendothelial matrix and
become activated, releasing the contents of their a-granules. The
stimulated platelets aggregate, more platelets are recruited and
eventually form a haemostatic plug (thrombus). The aggregate is
probably stabilised by interactions between the platelet membrane
glycoprotein Ilb/IIIa complex (GpIIb/IIIa), fibrinogen, TSP and
possibly other secreted glycoproteins, fibronectin and von
Willebrand factor (vWF). This model (fig.1-2) is supported by the
work of Rybak (1986) who found that GpIIb/IIIa and TSP incorporated
into liposomes formed aggregates in the presence of Ca^+ and
fibrinogen, and could also bind fibronectin and vWF.
Platelet aggregation can be described as a two-step process. In
the primary phase, stimulation with various physiological agents
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Fig. 1-2. Molecular model of platelet aggregation




clustering of Gpllb/llla complex
on platelet membrane surface
and binding of fibrinogen (Fg)
Secondary phase:
Secretion of alpha-granule contents
causes binding of TSP to the
receptor GpIV and to fibrinogen,
with stabilisation of the platelet-
platelet interaction
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(e.g. thrombin, collagen, ADP and adrenaline) causes a change in
platelet shape, clustering of the GpIIb/ITTa complex on the
membrane surface and binding of fibrinogen (Mustard et al 1978,
Bennett & Vilaire 1978, George et al 1980, Nachman and Leung 1982).
The secondary, secretion-dependent phase, is probably mediated by
the major a-granule components, resulting in the irreversible
formation of platelet aggregates (Plow et al 1984, George et al
1984).
Three main pieces of evidence support a role for TSP in the
aggregation of platelets; i) TSP can become associated with the
platelet surface, by a calcium-dependent mechanism involving
fibrinogen and GPIIb/IIIa, and by a calcium-independent mechanism
involving an, as yet, unidentified receptor (George 1978, Phillips
et al 1980, Gartner and Dockter 1984, Asch et al 1985, Hourdille et
al 1985, Plow et al 1985, Wolff et al 1986, Aiken et al 1987);
ii) TSP is thought to be the endogenous platelet lectin,
responsible for the ability of stimulated platelets to agglutinate
fixed red blood cells (reviewed by Gartner 1987); iii) anti-TSP
antibodies can inhibit platelet aggregation (Nurden et al 1983,
Agam et al 1984, Gartner et al 1984, Leung 1984, Dixit et al 1985).
Although the specific role of TSP in platelet function remains
unclear, it would seem that multiple sites on the TSP molecule are
involved in binding to the platelet membrane and to fibrinogen,
resulting in the transformation of the initial microaggregate into
an irreversible macroaggregate (Silverstein et al 1986).
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1.7 Clinical disease and TSP in the circulation
In normal individuals, TSP is present in plasma at low
concentrations detectable by radioimmunoassay (Saglio & Slayter
1982, Dawes et al 1985, Switalska et al 1985) and rises over
100-fold in serum due to its release from platelets during the
clotting process. Two clinical syndromes are known in which defects
in platelet TSP have been identified.
Grey platelet syndrome (Raccuglia 1971) is a rare inherited
bleeding disorder characterised by a lack of platelet cx-granules
and, hence, a marked deficiency of all a-granule proteins including
TSP (Nurden et al 1982). Platelets from patients with this disorder
are often large agranular cells with a distinctive grey colour, but
have a normal content of mitochondria, dense bodies, peroxisomes
and lysosomes (White 1979, Breton-Gorius et al 1981, Berndt et al
1983). Grey platelets have been shown to give decreased aggregation
in response to ADP, thrombin and collagen (Gerrard et al 1980) and
to lack the surface-bound haemagglutination activity associated
with activated platelets which is mediated by TSP (Gartner et al
1981).
Essential thrombocythemia, one of a group of myeloproliferative
disorders, is characterised by elevated platelet/megakaryocyte
elements in the circulation and frequent bleeding and thrombotic
complications (Schafer 1984). Impaired platelet function is
commonly observed in these patients (Spaet et al 1969) and is
associated with a variety of molecular defects (Bolin et al 1977,
Keenan et al 1977, Cooper et al 1978, Castaldi et al 1982, Schafer
1982). Platelet TSP has been shown to be more susceptible to
proteolysis in essential thrombocythemia (Booth et al 1984, Lawler
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et al 1986) and this may be due to its defective glycosylation
(Clezardin et al 1985).
Most interest in the measurement of circulating TSP levels has
centred on its use as a marker of platelet activation. In general,
increases in plasma TSP correlate with increases in the levels of
the specific platelet tx-granule components BTG and PF4. Although
BTG is generally the most sensitive marker of in vivo platelet
activation (Lane et al 1984, Ffrench et al 1985), measurement of
plasma TSP has been found to be useful in patients whose disease is
complicated by impaired renal function (Trzeciak et al 1985) and in
patients with vasculitis (McCrohan et al 1987). Several factors
probably explain why TSP is not always useful for monitoring in
vivo platelet activation. TSP is synthesised and secreted by a
variety of cells other than platelets, including those of the
endothelium, which may make a significant contribution to the total
plasma concentration (Dawes et al 1988). TSP may bind to the
platelet surface and to several plasma proteins, and is
incorporated into fibrin clots; mechanisms which would remove TSP
from plasma following its release from activated platelets (Booth &
Berndt 1987).
1.8 Relationship of TSP to malignant disease
During metastasis, tumour cells detach from the primary cancer,
penetrate basement membrane and endothelium, disseminate through
the circulation (avoiding host defence mechanisms), adhere to and
migrate through the endothelium again, and finally invade the
interstitial tissue to establish a secondary cancer (Poste & Fidler
1980). It has long been recognised that platelets play an important
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role in tumour cell metastasis (Gasic et al 1968), while several
lines of evidence implicate TSP in the development of malignant
disease (Asch & Nachman 1989).
Specific receptor sites for TSP have been identified on the
surface of platelets, endothelial cells and a variety of human
tumour cells (Asch et al 1987). The binding of TSP to components of
the extracellular matrix and basement membrane has already been
discussed (section 1.4.3); TSP could therefore be involved at
several points in the metastatic process through potential
interactions with extracellular matrix, endothelium or circulating
platelets.
TSP promotes the attachment and spreading of several human
tumour cells in vitro (Varani et al 1986, Roberts et al 1987,
Tuszynski et al 1987b) and a recent report showed that TSP
potentiates tumour cell metastasis in an animal model (Tuszynski et
al 1987a).
Tumour cells are known to secrete a variety of substances which
directly or indirectly may degrade components of the extracellular
matrix and basement membrane (Liotta et al 1979, Kramer et al 1982,
Laug et al 1983, Yee & Shiu 1986). In particular, plasmin(ogen)
could potentially be localised at the tumour cell surface via
binding to TSP (section 1.4.4), where its proteolytic activity
might facilitate migration of the tumour cell through extracellular
matrix and basement membrane.
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1.9 TSP and the human breast
1.9.1 Breast structure and development
The structure and development of the mammary gland has been
reviewed by Cowie (1974), Vorherr (1974) and Russo et al (1982).
The human breast is composed of glandular (parenchymal) tissue,
comprising lobules of alveoli (or acini) drained by a tree-like
duct system which opens at the nipple, embedded in supporting
tissue, which consists mainly of connective (stromal) tissue,
together with adipose tissue. The breast is supported on the chest
wall by a series of ligaments connecting the stroma with the
pectoral muscles, and by sheets of connective tissue (fascia) which
envelop the gland. The blood and nerve supply to the breast is
similar to that of the surrounding skin and this is consistant with
the cutaneous origin of the gland. However, the nipple and areolar
region are highly innervated with sensory nerve fibres, whereas
glandular structures within the breast are probably supplied by a
sympathetic nerve system only.
The breast originates from the ectoderm of the foetus. This
thickens to form the milk-lines, from which buds proliferate and
invade the surrounding mesenchyme to constitute a primordial duct
system. The development of the breast involves continuous changes
influenced by body growth from birth through to senility, with
superimposed effects due to the rhythmical hormonal stimulation of
the menstrual cycle. As a result, the gland becomes a complex and
extremely heterogeneous histological structure, due to unequal
responses of the many lobules to their local hormonal environments.
Full differentiation of the acini into milk-secreting units only
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occurs during pregnancy and lactation, when progressive hypertrophy
of the breast takes place. Even then, differentiation of acini
occurs unevenly throughout the gland, and through whole lobules.
The secretory acinus is lined by a single layer of cuboidal
epithelial cells which synthesise milk fat, protein and
carbohydrate, and is bound by a thin basement membrane in close
contact with capillaries in the surrounding tissue. It has been
suggested that the least differentiated lobules may be the most
likely targets for neoplastic transformation by carcinogens (Russo
et al 1982).
1.9.2 Breast secretions
Analysis of breast secretions, either spontaneous or collected
by nipple aspiration, has been used as a convenient and
non-invasive method for investigating breast function and disease
(Petrakis 1986, Dairkee & Hackett 1986). It is thought that the
non-lactating breast secretes and reabsorbs a wide variety of
substances, some of which may be retained, concentrated and
metabolised by breast epithelium and possibly other cells in breast
fluid such as foam cells and macrophages. Cytological analysis of
nipple aspirates may be useful in the diagnosis of breast disease;
thus a close correlation between occurence of abnormal epithelial
cell types in breast fluid and proliferative disease in
corresponding breast tissue has been shown (Sartorius et al 1977,
King et al 1983).
Colostrum and milk, the secretions produced by the lactating
breast during late pregnancy and after parturition respectively,
contain a wide range of electrolytes, carbohydrates and proteins
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(in addition to fat globules and cellular elements). The
concentration of these components change considerably around the
time of parturition (Bezkorovainy 1977, Kulski & Hartmann 1981).
TSP was previously measured in human colostrum and milk, other
breast secretions, and in goat colostrum and bovine milk (Dawes et
al 1985, 1987). Breast secretions contained high concentrations of
TSP (range = 1 - 145 ug/ml, median = 23 ug/ml) relative to those in
plasma, as did milk and colostrum. In the goat, TSP levels fell
sharply during the transition from colostrum to milk. TSP isolated
from this source showed a similar affinity for heparin-Sepharose as
did human platelet TSP, and a similar molecular weight of 450 kdal
by gel filtration chromatography. However, the colostrum protein
contained more fragments of low molecular weight and a different
fragmentation pattern after thermolysin digestion, indicating
differences in amino acid sequence between TSP isolated from goat
colostrum and other sources (Dawes et al 1987).
1.9.3 Cyst fluids
Breast cysts are a common benign lesion of Western women, and
those with cystic disease may have an increased risk of developing
breast cancer (Haagensen et al 1981). Several studies have been
done on the composition of cyst fluid and have measured proteins
(Yap et al 1984, Miller & Dawes 1985), hormones (Raju et al 1977,
Bradlow et al 1981a, Miller et al 1982), electrolytes (Gatzy et al
1979, Bradlow et al 1981b) and cells (Cowen & Benson 1979). Despite
this, the mechanism by which cyst fluid is formed is not known.
Two types of breast cyst have been identified which differ in
the nature of the epithelial lining (Dixon et al 1983) and the
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composition of the cyst fluid (Miller et al 1983a) ; group I cysts
have an apocrine epithelium and high concentrations of K+ and
DHA-sulphate; group II cysts have a flattened epithelium and high
concentrations of Na+. The levels of TSP in these two types of cyst
fluid are also different, being significantly higher in group II
(Na+) cysts (Miller & Dawes 1985). Since TSP concentrations were
low in group I (K+) cysts, which have an active apocrine lining,
this would suggest that apocrine epithelial cells are not the
source of the high TSP levels observed in some cyst fluids.
1.9.4 Breast cancer
Breast cancer is the most common form of malignancy in women
world-wide, and accounted for 18% of all new cases of female cancer
in 1980 (Parkin et al 1988). In the United States, where the
incidence of the disease is amongst the highest, 1 in 14 women are
expected to develop breast cancer sometime during their lives
(Kelsey 1979). In general, the rates of breast cancer occurrence
are low in Eastern and developing countries compared with the more
affluent populations of Europe and North America (Parkin et al
1988). The disease is relatively uncommon in young women, but
increases in frequency up to the menopause and more slowly
thereafter (De Waard 1983, Boyle & Robertson 1987). In a study of
1000 cases of invasive breast cancer, Fisher et al (1975) described
the main histological types of tumour (table 1-3). They found that
infiltrating ductal carcinoma was present in over 80% of cases,
either alone or in combination with other lesions.
A variety of genetic, environmental and hormonal factors appear
to be associated with an increased risk of developing breast cancer
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Table 1-3. Incidence of histological types of breast cancer
%
Infiltrating ductal (pure) 52.6
Infiltrating ductal with tubular 16.5











From Fisher et al 1975
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(table 1-4). The involvement of hormones, particularly the ovarian
steroids (oestrogens), in the development of the normal and
malignant breast is well established. However, only about one third
of breast cancers respond to oestrogen deprivation therapy
(Henderson & Canellos 1980), such as oophorectomy in premenopausal
women, or administration of drugs which inhibit oestrogen
biosynthesis (e.g. aminoglutethimide) or block oestrogen action
(e.g. tamoxifen) (Miller 1987).
The responsiveness of breast tumour cells to oestrogens is
thought to depend upon the presence of specific intracellular
receptor proteins (Edelman 1975, Lippman & Allegra 1978). Thus,
tumours containing measurable amounts of oestrogen receptors (ER)
have a 50% chance of responding to endocrine therapy while ER
negative tumours generally show response rates of less than 10%
(Hawkins 1985). Presence of both ER and progesterone receptor (PR)
may give an even better prognosis (Leclercq et al 1983) and
probably indicates that the tumour has maintained its sensitivity
to oestrogen, since PR synthesis is itself induced by oestrogen
(Horwitz & McGuire 1978).
25
Table 1-4. Factors associated with increased risk of breast cancer
Genetic Family history of breast cancer
Environmental Domicile Western Europe and North America




Hormonal Long menstrual life
(early menarche, late menopause)
Anovulatory menstrual cycles
Nulliparity
Late age at first pregnancy
Prolonged high dose oestrogen therapy
Disease Previous history of benign breast disease
(epithelial hyperplasia)




Unless stated specifically, chemicals and solvents were
generally obtained from Sigma Chemical Co. Ltd., Poole, Dorset, BDH
Chemicals Ltd., Poole, Dorset, or Fisons pic, Loughborough, Leics.
2.1 Isolation of TSP from human platelets
Unless stated otherwise, the TSP used in assays and experiments
described later was isolated from fresh human platelets after
stimulation by thrombin, followed by affinity chromatography,
ion-exchange chromatography and gel filtration chromatography.
2.1.1 Preparation of a supernatant from thrombin—stimulated













Freshly prepared platelet concentrates from 4-6 units of human
blood were obtained from the Scottish National Blood Transfusion
Service, Edinburgh and used within 1 h.
Platelet concentrates were pooled into plastic 250 ml bottles
and centrifuged at 100 g (750 rpm) in a Sorvall RC-5B centrifuge
with type HS-4 rotor (Du Pont Instruments, Stevenage, Herts) for 15
min to remove red cells. Platelet-rich plasma was decanted into
universal containers and centrifuged at 600 g (2000 rpm; Sorvall
RC-5B/HS-4 rotor) for 15 min to pellet platelets. Platelet-poor
plasma was removed and the pellets resuspended in pH 6.5 buffer and
centrifuged again. Washed platelets were resuspended in a suitable
volume of pH 7.6 buffer in 50 ml flat-bottomed plastic containers
and incubated for 5-10 min at 37°C. In most preparations the
volume of pH 7.6 buffer used was 30 ml (2 x 15 ml) but it was
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preferable to adjust the volume to give approximately 2 x 10
cells/ml since too high a platelet count may result in subsequent
loss of TSP through precipitation from concentrated solution.
Human thrombin (Sigma product no. T6759) was added at 1
NIH unit/ml with gentle stirring, and after 2 min further
stimulation was inhibited by the addition of 40 uM leupeptin, 10 uM
D-phenylalanyl- L-prolyl-L-arginine chloromethyl ketone (PPACK;
Calbiochem, Cambridge Bioscience, Cambridge) and 1 mM
phenylmethylsulphonyl fluoride (PMSF). Ethylenediaminetetra-acetic
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acid (EDTA) was added at a final concentration of 5 mM to
dissociate platelet-bound TSP, and the aggregated platelets were
allowed to settle at 0°C.
The supernatant from thrombin stimulated platelets was decanted
into plastic tubes and centrifuged at 40000 g (18000 rpm; Sorvall
RC-5B/SS-34 rotor) for 60 - 120 min at 4°C to remove cells and
particulate material. The resulting supernatant was decanted into a
clean plastic tube and processed further without delay.
2.1.2 Affinity chromatography of thrombin-stimulated platelet
supernatant on heparin-Sepharose CL-6B (Lawler et al 1978)
A glass column (2 x 24 cm) was packed with 10 g
heparin-Sepharose CL-6B freeze-dried powder (Pharmacia Ltd., Milton
Keynes, Bucks) which had been pre-swollen and washed according to
the manufacturer's instructions and equilibrated in 15 mM Tris-HCl,
0.15 M NaCl, 0.02% NaN3, pH 7.4.
Supernatant from thrombin-stimulated platelets was applied to
the column and eluted at a flow rate of 0.4 ml/min with Tris-HCl
buffer containing successively higher NaCl concentrations (0.15 M,
0.25 M, 0.55 M and 2.0 M). Fractions of volume 4 ml, collected
during sample application and elution, were assayed for protein by
a dye-binding method (see section 2.2). The TSP peak eluting at
0.55 M NaCl was stored at 4°C in the presence of 1 mM PMSF. In some
experiments this material was purified further by anion-exchange
chromatography and gel filtration chromatography.
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2.1.3 Purification of TSP by anion-exchange chromatography on a
Mono—Q column (Clezardin et al 1984)
The TSP peak from the heparin column was concentrated in an
ultrafiltration cell with a PM10 membrane (Amicon Ltd., Woking,
Surrey) and diluted 1:3 - 1:4 in start buffer (20 mM
triethanolamine, pH 7.4). This solution was applied, via a 50 ml
Superloop, to a Mono-Q HR 5/5 anion-exchange column connected to a
Fast Protein Liquid Chromatography (FPLC) system (all from
Pharmacia) at a flow rate of 0.5 ml/min. The column was washed with
start buffer until the absorbance of the eluate at 280 nm returned
to zero, then eluted with a 0 - 1 M NaCl gradient generated over
30 min. The final buffer was 20 mM triethanolamine, 1 M NaCl, pH
7.4. Fractions containing the TSP peak, identified by
radioimmunoassay, were pooled and concentrated by ultrafiltration
as before.
2.1.4 Purification of TSP by gel filtration on a Superose 6
column (Clezardin et al 1986a)
The TSP solution was injected (500 ul, flow rate 0.5 ml/min)
onto a Superose 6 HR 10/30 gel filtration column (Pharmacia)
connected to an FPLC system and eluted with 20 mM triethanolamine,
0.35 M NaCl, pH 7.4 buffer. Fractions containing the TSP peak,
identified by radioimmunoassay, were pooled and stored at 4°C in
the presence of 0.02% w/v NaN^.
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2.2 Protein assay
Samples were assayed for total protein by the Bio-Rad protein
assay, based on the method of Bradford (1976). In some experiments
the assay was performed according to the manufacturer's
instructions (Bio-Rad Laboratories Ltd., Watford, Herts) but in
others, especially where many samples were involved, a modified
procedure was used as follows:
Samples (50 ul) and diluted (20% v/v) dye reagent (2.5 ml) were
mixed in plastic tubes. After incubation at 20°C for 15 - 60 min,
aliquots (200 ul) were transferred to the wells of a 96-flat bottom
well microtitre plate (Sterilin Ltd., Feltham, Middlesex). The
absorbance of each well at 620 nm was measured in a Titertek
Multiskan MCC/340 photometer (Flow Laboratories Ltd., Irvine,
Ayreshire) against a reagent blank. For each assay, a standard
curve was constructed using bovine serum albumin (BSA) solutions
from 0.2 - 1.4 mg/ml.
2.3 TSP radioimmunoassay
The method used was that of Dawes et al (1983) with minor
modifications.
2.3.1 Iodination of TSP
TSP isolated from human platelets was iodinated in early
experiments by the chloramine T method and in later experiments by
an Iodogen coated tube method. Iodination using Iodogen was
advantageous in that (i) a more dilute solution of TSP could be
used, (ii) tracer of lower specific radioactivity could be produced
which had better stability and retention of binding activities, and
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(iii) the procedure was simpler to perform.
2.3.1.1 Chloramine T method (Greenwood et al 1963)
The following reagents were dispensed into a plastic tube as
separate drops;
125 -
5 ul I (100 mCi/ml, I in NaOH; Amersham International pic,
Amersham, Bucks)
5-20 ul antigen (at least 500 ug/ml in aqueous solution)
10 ul chloramine T (5 mg/ml in 0.25 M phosphate buffer, pH 7.5)
The tube was mixed manually for 5 sec and the reaction stopped
by the addition of 0.86 ml NaoSo0r (160 ug/ml in 0.05 M phosphate2 2 5
buffer, pH 7.5) and 100 ul KI (10 mg/ml in 0.05 M phosphate buffer,
125
pH 7.5). Protein was separated from unreacted I by gel
filtration on a 1 x 10 cm glass column packed with Sephadex G-50
Fine (Pharmacia), equilibrated and eluted with 0.05 M phosphate
buffer, 2.0% horse serum (Wellcome Diagnostics, Dartford), 1.0%
Tween 20, pH 7.5. A specific activity of about 1100 KBq/ug was
routinely obtained.
2.3.1.2 Iodogen coated tube method (Salacinski et al 1981)
Plastic micro-reaction tubes were coated internally with 20 ug
Iodogen (1,3,4,6-tetrachloro-3ot,6ot-diphenylglycouril; Pierce and
Warriner (UK) Ltd., Chester, Cheshire) by evaporation under
nitrogen from a methylene chloride solution (200 ug/ml). The
Iodogen coated tubes were stable for several months at -40°C. TSP
(5 - 20 ug) in aqueous solution was mixed in the tube with buffer
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(0.05 M phosphate buffer, 0.01% Tween 20, pH 7.5) up to a total
125 -
volume of 100 ul, and 1 - 5 ul I (100 mCi/ml, I in NaOH;
Amersham). After 5 min the reaction was terminated by transfer of
the solution to a clean plastic tube. After a further 10 min,
125
protein was separated from unreacted I by gel filtration as
before. Specific activities of 100 - 2000 KBq/ug were obtained,
125
depending on the ratio of TSP to I used.
2.3.2 Production of primary antibody
Polyclonal rabbit anti-TSP was provided by Dr G.0. Gogstad,
Research Institute for Internal Medicine, University of Oslo,
Norway and had been produced as follows. TSP from human platelets
stimulated with polystyrene latex particles (Dow Chemical Co.,
Midland, USA) and purified by gel filtration on a Sephacryl S-300
column followed by affinity chromatography on a Lens culinaris
lectin-Sepharose 4B column, was used as immunogen. A 1:1 v/v
solution of TSP and Freunds incomplete adjuvant (Gibco Ltd.,
Paisley, Renfrewshire) was injected subcutaneously into rabbits.
Four injections of 60 ug TSP/rabbit were given at 2-weekly
intervals, followed by 30 ug at 4-weekly intervals. Blood was
collected 10 and 20 days after each of these injections. The pooled
antiserum from 3 rabbits was adsorbed with platelet membranes. It
was monospecific for TSP and did not crossreact with BTG, PF4,
fibrinogen, fibronectin or vWF.
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2.3.3 Preparation of solid-phase secondary antibody
Donkey anti-rabbit IgG (Scottish Antibody Production Unit,
Carluke, Lanarkshire) was coupled to Sepharose 4B (Pharmacia) by
the method of Hunter and Budd (1981). Briefly, 80 g pre-swollen
Sepharose 4B was reacted with 8 g CNBr at pH 10 - 11. After
extensive washing with 0.1 M NaHCO^ followed by 0.1 M citric acid,
pH 6, the activated gel was mixed with 20 ml antiserum by inversion
overnight at 20°C. Glycine (final concentration 0.2 M) was added
and mixed a further 2 h. The coupled gel was washed extensively
with 0.1 M citric acid, pH 6 followed by 50 mM phosphate buffer, pH
7.5 and 50 mM phosphate buffer, 1% Tween 20, pH 7.5. The product
was stored at 4°C as a 1:1 v/v solution in the final wash buffer.
The working dilution in the assay was optimised for each batch but
was usually 1:5 v/v.
2.3.4 Assay procedure
The assay was carried out in 50 mM sodium phosphate, 2% horse
serum (Wellcome), 1% Tween 20, pH 7.5. Duplicate plastic tubes were
set up for each test containing 50 ul standard or sample, 50 ul
125
primary antibody (1/800 dilution) and 50 ul I-TSP (10 ng/ml) in
a final volume of 200 ul. Tubes containing only tracer and buffer
gave the level of non-specific binding (generally 1 - 5%) while the
binding of tracer to antibody in the absence of added TSP was also
routinely assessed (generally 25 - 60%). After incubation overnight
at 20°C, 50 ul Sepharose 4B-coupled donkey anti-rabbit IgG solution
was added and the tubes incubated with shaking for 45 min at 20°C.
The solid and liquid phases were separated by sedimentation of the
Sepharose-bound material through assay buffer containing 10% w/v
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sucrose and removal of the supernatant by aspiration (Hunter 1977).
Radioactivity was measured in a model NE1600 gamma counter (Nuclear
Enterprises Ltd., Edinburgh). The tubes were measured until 50 ul
tracer gave 10000 counts. Values of TSP in samples were read from a
standard curve which was constructed using doubling dilutions of a
human platelet TSP solution covering an approximate range of
1 - 400 ng/ml.
2.4 Radioimmunoassays for vWF and BTG
vWF and BTG were measured by Ms 0. Drummond and Ms S. Maguire,
Blood Components Assay Group, Edinburgh, by the radioimmunoassays
described elsewhere (McArthur et al 1986 and Bolton et al 1976).
2.5 Radioimmunoassay for epidermal growth factor (EGF)
EGF in breast cyst fluid was measured by Dr K. Smith, Division
of Oncology, University of Newcastle Upon Tyne, using the
radioimmunoassay described below.
Purified recombinant human B-urogastrone (a gift from
Dr H. Gregory, ICI Ltd., Macclesfield, Cheshire) was used as
standard and iodinated by the Iodogen method for use as tracer.
Primary antibody was monoclonal mouse anti-human urogastrone
(G.D.Searle, High Wycombe, Bucks) which had been desalted over a
Sephadex G-50 Fine column (2.2 x 39 cm) using 0.04 M sodium
phosphate, 0.15 M NaCl, 0.01 M EDTA, 0.5% BSA, 0.1% thiomersal, pH
7.2 (buffer A).
Assays were performed in triplicate in Eppendorf tubes in 400 ml
buffer A containing 100 ul primary antibody (1:9000 dilution),
100 ul 125I-urogastrone (80 - 120 uCi/ug; approximately 10000 cpm)
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and either unlabelled urogastrone or varying amounts of breast cyst
fluid. After incubation for 24 h at 4°C, 100 ul SAC-CEL (donkey
anti-mouse) was added, the tubes vortexed, 900 ul distilled water
added and left for 45 min at 20°C. The contents were centrifuged at
14000 g for 6 min at 4°C, supernatants discarded and the tips of
the Eppendorf tubes cut off and counted in an LKB Wallac 1272-
Clinigamma-Spectrometer.
2.6 Collection of plasma samples for assays of TSP and BTG
Plasma samples were obtained routinely by collection of venous
blood (2.7 ml) into 0.3 ml of ice-cold platelet release inhibitor
solution (ETP) containing 78 mM EDTA, 10 mM theophylline and
0.33 ug/ml prostaglandin E^, as described by Ludlam and Cash
(1976) .







Breast tissue from patients attending the Edinburgh Breast
Clinic, obtained at the time of mastectomy or biopsy, was dissected
free from surrounding fat and connective tissue, and stored at
-70°C. The following procedures were carried out on ice or at 4°C.
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Cytosols were prepared in the Department of Clinical Surgery,
Edinburgh. A piece (100 - 200 mg) of frozen tissue was placed in a
centrifuge tube, diced with scissors, and buffer added at a ratio
of 1:5 or 1:10 w/v. Tissue was homogenised using a mixer/emulsifier
(Silverson Machines Ltd., Chesham, Bucks) at full speed for 20 sec.
The homogenate was centrifuged at 105000 g for 1 h at 4°C and the
supernatant (cytosol) stored at -20°C.
2.8 Anti-TSP enzyme-linked immunosorbant assay (ELISA)
An ELISA was developed to detect murine antibodies against TSP,
which was used to screen and monitor the production of monoclonal
antibodies by hybridoma cultures.
Wash buffer;















in 100 mM sodium acetate/citrate buffer, pH 6.0
Flat-bottomed 96-well polystyrene microtitre plates (M29AR;
Sterilin) were coated overnight at 4°C with 100 ul/well of human
platelet TSP (5 - 10 ug/ml in 50 mM phosphate buffer, 0.15 M NaCl,
pH 7.4) purified by heparin-Sepharose affinity chromatography. Only
the central 60 wells were used to avoid the high non-specific
binding which could occur in the edge wells of some plates.
Coated plates were washed 4 x with 250 ul/well wash buffer and
incubated with 200 ul/well blocking buffer in a humid chamber for
2 h at 20°C. The plates were washed once with 250 ul/well wash
buffer.
Assay buffer (100 ul/well) was added to all wells in the first
row (negative control) and duplicate samples (100 ul/well) added to
the remaining wells. The plates were incubated in a humid chamber
at 20°C overnight.
The plates were washed 4 x as before and incubated with 200
ul/well peroxidase-conjugated rabbit anti-mouse immunoglobulins
(DAK0 Ltd., High Wycombe, Bucks) diluted 1/500 in assay buffer
containing 0.1% BSA, in a humid chamber for 1 h at 37°C.
The plates were washed 4 x as before and then incubated with
200 ul/well TMB substrate solution for 10 min at 20°C, with
shaking. The reaction was stopped by the addition of 50 ul/well
2.5 M H2S0^ and shaking continued for a few seconds.
The absorbance of the wells at 450 nm was measured using a
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Titertek Multiskan MCC/340 photometer (Flow) which had been blanked
on air, and the results expressed as absorbance units after
subtraction of the mean negative control value.
2.9 Slot-immunobinding assay (SIBA)
Immobilon PVDF transfer membrane (Millipore (UK) Ltd., Harrow,
Middlesex) was cut to size (3.8 x 12.4 cm), wet in methanol for
1-2 sec and soaked in deionised water. It was placed in a
Hybri-Slot manifold (Gibco Ltd., Uxbridge, Middlesex) connected to
a vacuum source.
Antigen solutions were applied into the sample wells and
filtered under negative pressure. The membrane was removed from the
manifold and washed in deionised water before incubation in 20 mM
Tris-HCl, 0.9% NaCl, 5% BSA, pH 7.4 (5% BSA-TBS) for 1 h at 37°C to
block excess protein-binding sites.
After washing in 0.1% BSA-TBS (3 changes of 5 min each), the
membrane was incubated in 1st antibody solution (murine monoclonal
anti-TSP diluted in 1% BSA-0.05% Tween 20-TBS) for 2 h at 20°C.
The membrane was washed in 0.1% BSA-TBS (3 x 5 min) and
incubated in 2nd antibody solution (peroxidase-conjugated rabbit
anti-mouse immunoglobulins (DAKO) diluted 1/400 in 1% BSA-0.05%
Tween 20-TBS) for 2 h at 20°C.
After washing again, bound antibody was visualised by incubating
the membrane in 0.02% 3-amino-9-ethylcarbazole, 0.03% H-pO^
0.05M acetate buffer, pH 5.0 (prepared and filtered immediately
before use) for 15 min at 20°C. The membrane was rinsed in
deionised water, fixed in 3.7% formaldehyde in 0.1 M phosphate
buffer, pH 7.5 for 5 min, rinsed again and air dried.
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2.10 Immunocytochemical techniques
2.10.1 Indirect immunoperoxidase (Nakane and Pierce 1966)
Pre-fixed paraffin-embedded sections were de-waxed in 3 changes
of CNP 30 and brought to water through graded alcohols (100%, 90%,
70% ethanol). Fresh cryostat sections were air dried or post-fixed
in acetone (20 min).
Endogenous peroxidase was blocked by immersing slides in 3% H^O^
in methanol for 30 min followed by washing in 0.05 M Tris-HCl,
0.85% NaCl, pH 7.6 (TBS) for 5 min.
Possible background reaction was blocked by incubating sections
with a layer of normal rabbit serum diluted 1/5 in TBS (NRS-TBS),
in a humid chamber for 10 - 15 min at 20°C. The serum was drained
off and the slides wiped dry except for areas of section.
Sections were incubated with 1st layer antibody (e.g. murine
monoclonal anti-TSP) diluted in NRS-TBS, in a humid chamber for
30 - 60 min at 20°C or overnight at 4°C. Slides were washed in TBS
(3x5 min) and then dried except for the areas of section.
Sections were incubated with peroxidase-conjugated rabbit
anti-mouse immunoglobulins (DAK0) diluted 1/20 in NRS-TBS, in a
humid chamber for 30 min at 20°C. Slides were washed in TBS
(3x5 min) and in 0.05 M Tris-HCl, pH 7.6 (5 min).
Localisation of peroxidase was carried out by incubating slides
in 0.05 M Tris-HCl, pH 7.6 containing 0.025% 3,3'-diaminobenzidine
tetrahydrochloride (DAB; Aldrich Chemical Co. Ltd., Gillingham,
Dorset) and 0.03% H^O^ for 5-20 min (Graham and Karnovsky, 1966).
Development of the stain was checked microscopically and optimal-
staining (dark brown against a light background) was produced after
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5-20 min.
The reaction was stopped by rinsing slides in deionised water.
They were then counterstained lightly with haematoxylin, dehydrated
through graded alcohols, cleared in CNP 30 and mounted in DPX.
2.10.2 Indirect peroxidase anti—peroxidase (PAP) (Sternberger
1979)
Sections were processed as for the indirect immunoperoxidase
method up to and including blocking of endogenous peroxidase.
Slides were then washed in 2% normal swine serum diluted in TBS (3
x 5 min).
Possible background reaction was blocked by incubating sections
with a layer of normal swine serum (1/5 in TBS) in a humid chamber
for 30 min at 20°C. Slides were drained and wiped dry except for
the areas of section.
Sections were incubated with 1st layer antibody (e.g. rabbit
anti-TSP) diluted in 2% NSS-TBS, in a humid chamber for 30 min at
20°C or overnight at 4°C. They were washed in 2% NSS-TBS
(3x5 min) and wiped dry except for the areas of section.
Sections were incubated with 2nd layer antibody (swine
anti-rabbit immunoglobulins; DAK0) diluted 1/30 in 2% NSS-TBS, in a
humid chamber for 30 min at 20°C. They were washed in 2% NSS-TBS
(3x5 min) and wiped dry except for the areas of section.
Sections were incubated with peroxidase-rabbit anti-peroxidase
(DAK0) diluted 1/100 in 2% NSS-TBS, in a humid chamber for 30 min
at 20°C. They were washed in 2% NSS-TBS (3x5 min) and in
0.05 M Tris-HCl, pH 7.6 (5 min).
PAP was localised by incubating the slides in DAB solution as
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for the indirect immunoperoxidase method. Optimal staining was
obtained within 1-5 min, after which the slides were rinsed,
counterstained, dehydrated, cleared and mounted as before.
2.11 Cell culture






2.0% v/v human serum
2 mM L-glutamine
0.4 g/1 NaHC03
0.15 g/1 endothelial cell growth supplement
(ECGS; Maciag et al 1979)
100 U/ml penicillin
100 mg/ml streptomycin
2.5 ug/ml Fungizone (Flow)
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Endothelial cells were isolated from human umbilical cords
obtained from the Maternity Wards of the Western General Hospital,
Edinburgh or the Simpson Maternity Pavilion, Edinburgh. The cords
were placed in glass bottles containing 50 ml Medium 199 (Flow),
200 U/ml penicillin-G potassium salt, 200 ug/ml streptomycin
sulphate and stored at 20°C for up to 12 h after delivery.
Damaged or overdistended portions of the cord were excised and
the required vessel was cannulated. For human umbilical vein
endothelial cells (HUVEC) the umbilical vein was cannulated using a
16 gauge catheter, while for human umbilical artery endothelial
cells (HUAEC) one umbilical artery was cannulated using a 1 mm
rounded-end capillary tube. In either case the cannula was secured
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with silk thread.
The vessel was perfused with 20 - 50 ml Earle's buffered salt
solution (Flow) to remove blood and clots, then with a 1 mg/ml
solution of collagenase, type IA (Sigma) in Medium 199 (for the
artery, 10 ug/ml Trapidil , a potent vasodilator, was added to both
solutions). The effluent end was tied off, more enzyme solution
infused to fill the vessel, the affluent end tied off and the cord
wrapped in aluminium foil. After incubation at 37°C for up to
15 min, the cord was massaged gently to aid dislogement of cells
from the vessel lumen. The vessel was perfused with 20 ml Medium
199, the effluent collected and centrifuged at 200 g for 10 min at
15°C. The pellet was resuspended in 5 ml complete medium
2
(containing 30% v/v human serum) and transferred into a 25 cm
2
tissue culture flask which had been pre-coated with 10 ug/cm human
fibronectin (Scottish National Blood Transfusion Service Protein
Fractionation Centre).
After 4 h the medium was replaced with complete medium (30% v/v
human serum) and replaced every 48 h thereafter with complete
medium (20% v/v human serum) until the cells reached confluence.
2.11.1.2 Subcultuning
At confluence, the cells were subcultured with a 1:4 split ratio
as follows. The monolayer was washed with buffered salt solution to
2
remove serum components and incubated with 2 ml/25 cm of a
solution containing 0.025% trypsin (Flow) and 0.020% EDTA in
phosphate buffered salts, Dulbecco's formula (modified) without Ca
and Mg, using agitation to release the cells (usually complete
within 5 min). An equal volume of complete medium was added to
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inhibit trypsinisation and the cell suspension transferred into
sterile universal containers for centrifugation at 200 g for 5 min.
The supernatant was decanted, the container flicked vigorously to
disperse the pellet and the cells resuspended in a suitable volume
of fresh complete medium for transfer into a pre-coated flask, or
in freezing medium for preservation.
2.11.1.3 Preservation
To the dispersed cell pellet from a trypsinised culture, 1 ml
cold freezing medium (90% v/v complete medium / 10% v/v dimethyl
sulphoxide, DMSO) was added dropwise with gentle shaking. The
resulting cell suspension was transferred aseptically into a
sterile screw-top plastic vial and cooled at l°C/min in the vapour
phase of liquid nitrogen for at least 1 h. Frozen cells were stored
in the vapour phase of a liquid nitrogen container.
For recovery of frozen cells, a vial was thawed in a water bath
at 37°C. The outside of the vial was sterilised with alcohol and
the contents transferred aseptically to a pre-coated flask
containing fresh complete medium (the DMSO should be diluted at
least 10-fold). Medium was replaced after 24 h, the flask













Human oral fibroblasts (H0F) or human skin fibroblasts (HSF)
(generous gifts from Dr Y. Barlow and Dr G.C. Priestley, Department
of Dermatology, Royal Infirmary, Edinburgh) were cultured
essentially as described for human endothelial cells.
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2.11.3 MCF-7 Human breast cancer cells
Growth medium (complete);
Eagle's Minimal Essential Medium
with Hank's salts (Flow)
20 mM HEPES
10% v/v foetal calf serum (Gibco)
NEAA
2.0 mM L-glutamine












100 ng/ml prostaglandin F
7.5 ug/ml fibronectin
Freezing medium;
95% v/v complete medium / 5% v/v DMS0
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MCF-7 Human breast cancer cells were obtained from
Professor S.C. Brooks, Michigan Cancer Foundation, Detroit, USA.
This cell line was derived from a pleural effusion from a patient
with breast adenocarcinoma, and retains several characteristics of
differentiated mammary epithelium (Soule et al 1973). Cells were
maintained in routine culture as recommended, and for some
experiments they were transferred into serum-free culture (Barnes
and Sato 1979).
2.11.4 Detection of mycoplasma (Chen et al 1977)
Mcllvaine's buffer (pH 5.5);
11.37 ml 0.2 M Na^HPO,2 4
8.62 ml 0.1 M citric acid
Glass coverslips were seeded with cells which had been grown in
the absence of antibiotics. The cells were fed 24 h prior to
fixation in 3 ml methanol: acetic acid (3:1 v/v) added dropwise to
the complete medium, and left for at least 1 min. This was
aspirated and replaced with 5 ml fresh fixative solution and
incubated a further 5 min. After washing with fixative and drying
in air, the cells were incubated with 5 ml 0.05 ug/ml bisbenzimide
(Hoechst 33258) in phosphate buffered salt solution (containing Ca
and Mg) for 10 min. The cells were washed twice with distilled
water and the coverslips mounted in Mcllvaine's buffer and sealed.
The stain was visualised under a fluorescent microscope.
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2.12 Production of monoclonal antibodies against TSP
2.12.1 Immunisation
Mice (female Balb/c, 12 - 15 weeks old; bred in the Medical
Faculty Animal Facility, Edinburgh from stock originally obtained
from the Laboratory Animal Centre, Carshalton) were primed by
intraperitoneal injection of a 1:1 v/v mixture of human platelet
TSP (50 ug/mouse) and Freund's complete adjuvant, then boosted
after 6-9 weeks with 50 ug TSP in aluminium hydroxide gel
(Superfos Speciality Chemicals a/s, Vedbaek, Denmark) and after
19 - 30 weeks with 50 - 100 ug TSP in Dulbecco 'A' saline.
Mice were bled from the tail 10 - 14 days post-boosting and the
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sera tested for antibodies binding I-TSP in a modified
radioimmunoassay. Briefly, tubes containing 50 ul each of serum
(doubling dilutions from 1/100 - 1/3200), assay buffer and tracer
were incubated overnight, and then with 50 ul Sepharose 4B-sheep
anti-mouse immunoglobulins (1:1 v/v;; prepared according to section
2.3.3 using antiserum from the Scottish Antibody Production Unit)
for 45 min with shaking. The bound and free tracer were separated
by sedimentation through 10% sucrose. Mice which showed a positive
antigen-binding curve were sacrificed and their spleens removed.
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15% foetal calf serum
2.0 mM L-glutamine










Spleen cells were fused with NS-0 mouse plasmacytoma cells
(Galfre and Milstein 1981) in a 1:1 cell ratio using 50% PEG 4000
at pH 8.5 - 9.0 (Kennett et al 1978). Fused cells were seeded in
Costar 96-well tissue culture clusters (Northumbria Biologicals,
5
Cramlington, Northumberland) at 2 x 10 cells/well in 0.1 ml HAT
medium/well and incubated at 37°C in 5% CO^/air. The wells had
previously been charged with 0.1 ml mixed-thymocyte conditioned
medium (MTM) diluted 1:2 v/v with HAT medium. When sufficiently
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well grown, hybrids were tested for antibody secretion by ELISA
(section 2.8), and those which were positive were then transferred
to 24-well plates.
2.12.3 Cloning by limiting dilution (Micklem et al 1987)
Cells were diluted in 10% MTM in RPMI-15FCS and plated at
0.1 ml/well in 96-well plates to give (theoretically) 2 rows at
5 cells/well, 2 rows at 1 cell/well and 2 rows at 0.5 cells/well.
After incubation for 7 days, the number of clones per well was
recorded and 3 drops of RPMI-15FCS were added to each well. Clones
were tested for antibody secretion by ELISA when sufficiently well
grown. Those which were positive were re-cloned as necessary until
a stable cell line (i.e. one which gave 100% positive clones) was
achieved in each case.
2.12.4 Bulk production
Monoclonal antibodies were produced in bulk by culture of cloned
cell lines in vitro and by growth as ascitic fluid in vivo.
2
Cells were generally grown up in 150 cm tissue culture flasks
(Corning, New York, USA) in RPMI 1640 supplemented with 5% foetal
calf serum and the antibody-rich medium harvested at cell death.
One cell line (producing antibody ESTs8) was grown up in a CelliGen
cell culture system (New Brunswick Scientific (UK) Ltd., Watford,
Herts) in RPMI 1640 with 10% foetal calf serum, pH 7.2, dissolved
oxygen 30%, stirring rate 30 rpm, at 37°C.
Ascitic fluid was produced as follows. Mice (male Balb/c) were
primed with two injections of 0.5 ml Pristane (2,6,10,14-tetra-
methyl-pentadecane) at an interval of 7 days, up to 14 weeks before
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inoculation of cells. The mice were inoculated intraperitoneally
5
with 3 - 5 x 10 cells in Dulbecco 'A' saline. Ascitic fluid was
tapped at intervals up to 4 weeks after inoculation.
2.12.5 Determination of antibody type
Monoclonal antibodies were typed by radial immunodiffusion (RID)
employing specific anti-mouse Ig subclass antibodies (Monoclonal
Antibody Typing Kit RK008; The Binding Site Ltd., Birmingham).
Samples of bulk culture supernatants and specific antisera were
applied to the wells of the RID plates as directed. After
incubation for 24 - 48 h, the plates were observed for
precipitation lines which indicated the subclass of the antibodies.
2.12.6 Purification of monoclonal IgG antibodies by affinity
chromatography on protein A
2.12.6.1 Preparation of a protein A-Sepharose 4B column
Coupling buffer (pH 8.3);
0.1 M NaHC03
0.5 M NaCl
A suspension of 7 g CNBR-activated Sepharose 4B (Pharmacia) in
1 mM HC1 was washed with 1.4 1 1 mM HC1 in a 100 ml glass conical
flask using a filter tube with sintered glass end (Pyrex) connected
to a vacuum line. A solution of 250 mg protein A (Fermentech,
Edinburgh) in 35 ml coupling buffer was added to the washed gel,
the flask stoppered and mixed by inversion overnight at 4°C.
52
The coupled gel was washed in the flask as before with 400 ml
coupling buffer and suspended in 30 ml 1 M et.hanolamine, pH 9.
After rotation for 2 h at 20°C, the product was washed with 3
cycles of alternating pH. Each cycle consisted of 300 ml 0.1 M
acetate buffer, 0.5 M NaCl, pH 4, followed by 300 ml 0.1 M
Tris-HCl, 0.5 M NaCl, pH 8.
The product was adjusted to an approximate 75% v/v gel solution
in pH 8 buffer and poured into a K26/40 column fitted with two A26
flow adapters (Pharmacia).
2.12.6.2 Elution of monoclonal IgG on protein A-Sepharose 4B
High pH buffer (pH 8.5);
0.1 M Na^HPO,2 4
0.1 M trisodium citrate
2.0 M NaCl
Low pH buffer (pH 2.0);
0.1 M citric acid
Dialysis buffer (pH 6.0);
50 mM NaH^PO,2 4
50 mM trisodium citrate
Bulk culture supernatant was concentrated 20 x by
ultrafiltration (Amicon), passed through a pre-filter (type AP20;
Millipore), NaCl added to a final concentration of 2.0 M and the pH
adjusted to 8.5 with 1 M NaOH. Ascites fluid was centrifuged at
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15000 g to remove particulate material, NaCl added and the pH
adjusted as above.
The column was equilibrated in high pH buffer and the sample
loaded at 0.8 - 0.9 ml/min using a peristaltic pump P—1
(Pharmacia), followed by washing with high pH buffer and monitoring
the absorbance of the eluate at 280 nm. When the baseline had
returned to zero, the column was eluted with a linear gradient
formed from 120 ml high pH buffer and 120 ml low pH buffer using a
gradient mixer GM-1 (Pharmacia) and collecting 80 x 3 ml fractions
in a fraction collector FRAC-100 (Pharmacia).
Each fraction was assayed for protein (ODggg). pH and mouse IgG
(by radial immunodiffusion, section 2.12.5); fractions which were
positive by 0D and RID were pooled, neutralised and dialysed£LO0
overnight. The sample was filtered (0.2 urn) and concentrated, if
necessary, until the reached 1.4 - 1.5. Maltose was added
(10% w/v) and the sample stored in aliquots at -20°C or
lyophilised.
2.12.7 Detection of monoclonal IgG by radial immunodiffusion
Aronson and Grunwall buffer, pH 8.9;
100 mM Tris
4 mM EDTA, free acid
15 mM boric acid
Radial immunodiffusion plates were prepared as follows. Agarose
(1 g; Miles Laboratories Ltd., Slough, Berks) was boiled in 100 ml
Aronson and Gronwall buffer until clear, and cooled to 56°C. Sheep
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anti-mouse IgG (1 ml; Scottish Antibody Production Unit) was mixed
2
with ?r ml agarose solution, poured into a 10 cm plastic petri
dish (Sterilin) on a level table and allowed to set. Wells were
made with a 2 mm well cutter (10 mm apart, 81 wells/plate), samples
applied (10 ul/well) and the plate incubated overnight at 20°C.
Observation of precipitate rings indicated the presence of mouse
IgG antibody in the sample.
2.12.8 Purification of monoclonal IgM antibodies by gel
filtration on Sephacryl S-300
Bulk culture supernatant (1000 ml) was concentrated 100 x by
ultrafiltration (Amicon) and glucose added (1% w/v) to increase the
sample density. The sample was applied under the eluent onto a
2.5 x 78 cm Sephacryl S-300 gel filtration column (Pharmacia) which
was equilibrated and eluted with 0.4% w/v trisodium citrate,
0.15 M NaCl, pH 7 buffer. The flow rate was 0.8 - 0.9 ml/min using
a P-l pump (Pharmacia) and 90 x 8 ml fractions were collected in a
FRAC-100 fraction collector (Pharmacia).
Each fraction was assayed for protein (by absorbance at 280 nm)
and the presence of anti-TSP antibody (by ELISA). Those fractions
which were positive by ELISA were pooled and concentrated to 50 ml
as before. Maltose (10% w/v) was added, and the sample filtered
through a AP20 pre-filter (Millipore) and through a Sterivex-GS




THROMBOSPONDIN IN PLASMA AND SERUM
Studies of TSP in plasma and serum were done on three groups of
patients (general surgery, Christmas disease and thrombocytopenic)
and in an animal model (dogs receiving infusions of blood
products). The aim of this work was to investigate the factors
which influence circulating TSP levels, as far as was possible
within the confines of these larger clinically-orientated studies.
Measurements of BTG and vWF were sometimes made alongside those of
TSP, as indicators of specific cx-granule release and of possible
endothelial cell activation respectively.
3.1 Patients undergoing general surgery
Plasma samples were taken from 20 patients; age (mean + SD) = 39
+ 7.4 y, range = 24 - 51 y; having general surgical procedures,
before anaesthesia and at 30 min, 60 min, 24 h and 96 h intervals
post-operatively.
3.1.1 Comparison of pre—operative levels of TSP, BTG and vWF
with those in normal plasma
Table 3-1 shows the plasma levels of TSP, BTG and vWF measured
before anaesthesia, compared with those in normal individuals
prevously measured in this laboratory (Dawes et al 1983). No
statistically discernible differences were observed in the plasma
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Table 3-1. Comparison of pre-operative plasma levels of TSP, BTG
and vWF with those in normal plasma
Pre-op Normal
TSP mean + SD 111.3 + 123.9 105.0 + 31.0
range 28 - 600 57.5 - 215.6
N 20 27
BTG mean + SD 59.6 + 58.6 37.2 + 10.9
range 12.8 - 237.5 20.1 - 68.5
N 20 27
vWF mean + SD 1.37 + 0.48 no data
range 0.53 - 2.40
N 20
Results expressed in ng/ml (TSP and BTG) and iu/ml (vWF).
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concentrations of TSP or BTG in the two groups (Student's t test).
No data was available for vWF in normal individuals.
3.1.2 Comparison of pre and post-operative plasma levels of TSP,
BTG and vWF
Plasma levels of TSP, BTG and vWF measured before anaesthesia
and at intervals post-operatively are shown in fig. 3—1. No
statistically discernible differences (Student's t test) were
observed between the pre and post-operative concentrations of TSP
nor BTG, which were both relatively constant.
However, for vWF the plasma content was observed to increase
after surgery in all the patients studied. The highest levels
occured at either 24 h or 96 h post-operatively, when they became
statistically discernible from the level before anaesthesia
(P < 0.001, Student's t test).
3.1.3 Relationships between plasma TSP, BTG and vWF levels
The relationship between TSP and BTG for all plasma samples
taken before and after surgery is shown in fig.3-2. A positive
correlation (r = 0.81) which was statistically discernible
(P< 0.005) was observed between the two.
The relationship between TSP and vWF for the same samples is
shown in fig. 3-3. A lack of correlation between the two was
apparent (r = 0.16) and this was confirmed by statistical testing
(P > 0.05).
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Fig. 3-1. Plasma TSP, BTG and vWF levels after general surgery
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Ig. 3-2. Relationship between plasma TSP and BTG in general surgery patients
TSP (ng/ml)
60
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3.1.4 Comparison of plasma TSP, BTG and vWF levels after general
or epidural anaesthesia
Plasma TSP, BTG and vWF were measured as before in two groups of
patients undergoing general surgical procedures. One group (n = 5,
age = 38 + 5.6 y, range = 33 - 47 y) had a general anaesthetic,
while the other (n = 8, age = 38 + 8.8 y, range = 22 - 51 y) had an
epidural anaesthetic. The results are summarised in table 3-2.
Statistical comparisons (Student's t test) between the two groups
of patients did not reveal any discernible differences in the
plasma levels of TSP, BTG or vWF in samples taken at corresponding
times. In both groups, vWF increased similarly with time after
surgery, and the differences compared with the corresponding levels
before anaesthesia became statistically discernible at 24 h and
96 h.
3.2 Christmas disease patients and TSP in human factor IX
concentrate
Plasma levels of TSP were studied in three patients with
Christmas disease, an hereditary deficiency of clotting factor IX,
during treatment by intravenous infusion of factor IX concentrate.
Samples were taken anticubitally by separate venepuncture before
infusion was commenced and at intervals of 15 min, 2 h, 5 h, 7 h
and 24 h after its completion. Details of the patients and
infusions are given in table 3-3, and their plasma TSP levels and
factor IX activities are shown in fig.3-4.
In all three patients, the initial plasma TSP concentrations
were normal and increased to high levels (5 - 9 times normal)
immediately post-infusion. The plasma TSP levels fell rapidly
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Table 3-2. Plasma TSP, BTG and vWF levels after general or epidural
anaesthesia
TSP BTG vWF
GENERAL (N = 5)
Pre 85.5 + 39.9 38.0 + 16.4 1.50 + 0.47
Post 30 min 40.4 + 9.6 28.9 + 6.7 1.52 + 0.50
60 min 61.8 + 27.4 39.7 + 12.7 2.27 + 0.89
24 h 80.8 + 47.1 45.8 + 26.8 2.87 + 0.85a
96 h 77.4 + 41.4 26.5 + 6.8 3.04 + 1.23b
EPIDURAL (N = 8)
Pre 64.4 + 21.0 53.6 + 55.7 1.28 + 0.40
Post 30 min 46.1 + 19.4 38.0 + 26.0 1.10 + 0.19
60 min 90.7 + 44.7 36.4 + 23.0 1.96 + 0.79
24 h 104.1 + 16.5 50.2 + 38.7 2.54 + 0.79C
96 h 81.0 + 17.5 32.5 + 8.0 2.61 + 0.53d
Results expressed in ng/ml (TSP and BTG) and iu/ml (vWF).
a
P< 0.02 (statistically discernible from pre-anaesthesia level).
P < 0.05 (ditto).
C
P < 0.005 (ditto).
d
P < 0.001 (ditto).
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Table 3-3. Christmas disease patients receiving factor IX infusions
*
Patient Body Plasma Infusion Plasma TSP Recovery
weight volume volume increment of TSP








Recovery of TSP = plasma vol x increment x 100
infusion vol x 110,000
where 110,000 ng/ml = TSP concentration of factor IX infusion
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during the first 15 min, then in an approximately exponential
manner up to 5 h post-infusion, when, in two of the patients (B and
C) normal levels had been reached, and in the other patient (A) the
level was still elevated but falling gradually. The half-life of
TSP in plasma during the exponential phase of clearance (15 min -
5 h) was 148 + 55 min (mean + SD).
In contrast, the plasma factor IX activities in these patients
(data provided by Dr C. Prowse, Scottish National Blood Transfusion
Service, Edinburgh) reached their highest levels at 15 min
post-infusion and then decreased in an approximately linear manner
to 24 h, when they were still markedly above those measured prior
to infusion of factor IX concentrates (fig.3-5).
The TSP content of lyophilised human factor IX concentrate
(Scottish National Blood Transfusion Service Protein Fractionation
Centre) was analysed by affinity chromatography using a 2 x 24 cm
heparin-Sepharose CL-6B column (Pharmacia). When reconstituted with
20 ml distilled water, the factor IX concentrate contained
8.6 mg/ml protein and 42 ug/ml TSP (0.5% total protein).
Fig.3-6 shows the heparin affinity elution profile obtained from
16 ml factor IX concentrate loaded onto the column (equilibrated in
15 mM Tris-HCl, 0.35 M NaCl, 0.02% NaN^, pH 7.4) and eluted using a
stepwise gradient of 0.35 M, 0.55 M and 2.0 M NaCl. Measurement of
TSP concentrations in the fractions showed that most of the antigen
was contained in the peak eluted with 0.55 M NaCl (fractions 57-60,
mean TSP = 38 ug/ml), but some TSP was also detected in the other
peaks (e.g. fraction 8, 0.4 ug TSP/ml; fraction 12, 7.4 ug TSP/ml,
fractions 70-72, 2.6 ug TSP/ml).
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TSP and BTG were measured in plasma and serum samples from 20
patients with profound marrow hypoplasia, usually following
chemotherapy (table 3-4). In all cases, chemotherapy caused severe
peripheral pancytopenia attributable to the marrow hypoplasia.
Individual samples were taken prior to any platelet transfusion. In
addition, serial samples were taken from three of these patients
during recovery from severe bone marrow depression.
3.3.1 Plasma and serum levels of TSP and BTG in severe
peripheral pancytopenia
Platelet count, plasma and serum levels of TSP and BTG in 19
patients with severe peripheral pancytopenia are shown in fig.3-7.
In every case the platelet count and serum levels of TSP and BTG
were less than 10% of normal.
The plasma TSP level was normal or elevated in 17 of the 19
patients (89%), whereas the plasma BTG concentration was below
normal in 11/19 (58%) of cases (in 7 of these it was undetectable
by the radioimmunoassay).
No statistically discernible relationship was observed between
plasma levels of TSP and BTG in patients with severe peripheral
pancytopenia (r = 0.25; P> 0.10), but there was a positive
correlation between their serum TSP and BTG concentrations which
was statistically discernible (r = 0.75; P < 0.0005) (fig. 3-8).
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Table 3-4. Plasma samples from thrombocytopenic patients
Patient Age Sex Sample time (days from
termination of chemotherapy)
SINGLE SAMPLES
1 38 M + 10
2 16 F + 12
3 25 F + 9
4 38 M no chemotherapy
5 46 F + 11
6 78 M no chemotherapy
7 32 F + 3
8 63 M + 30
9 32 M + 19
10 88 F no chemotherapy
11 79 F + 12
12 53 M + 18
14 62 F + 13
15 57 F + 14
16 64 M + 24
17 29 M + 12
18 74 F + 27
19 62 F + 7
20 76 M + 41
SERIAL SAMPLES
9 32 M + 11 to + 24
13 49 F - 6 to + 41
14 62 F 0 to + 28
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Fig. 3-8a. Relationship between plasma TSP and BTG In thrombocytopenic patients
TSP (ng/ml)
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;ig. 3-8b. Relationship between serum TSP and BTG In thrombocytopenic patients
TSP (ng/ml)
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3.3.2 Plasma and serum levels of TSP and BTG during recovery
from severe bone marrow depression
Platelet count, plasma and serum levels of TSP and BTG in serial
samples taken from three patients during recovery from bone marrow
hypoplasia are shown in fig.3-9. Serum concentrations of the two
proteins rose and fell in tandem with the platelet count, down to a
minimum level which reflected that of plasma.
Similarly, the plasma content of BTG tended to follow the
platelet count, though measurement of low values was limited by the
sensitivity of the assay (5 ng/ml). While there was some variation
in the plasma TSP level which did reflect changes in platelet
count, the relationship between the two was not as close as was
apparent for BTG. Moreover, the fluctuations in the plasma TSP
concentration were superimposed upon a basal level of approximately
50 ng/ml.
3.3.3 Relationships between platelet count, plasma and serum
levels of TSP and BTG in thrombocytopenic patients
The relationships between platelet count and the plasma contents
of TSP and BTG for all samples from the thrombocytopenic patients
are shown in fig.3-10. No statistically discernible correlation was
observed between platelet count and plasma TSP (r = -0.09;
P > 0.25), nor between platelet count and plasma BTG (r = 0.21;
P > 0.05).
Fig.3-11 shows the relationships between platelet count and the
serum TSP and BTG concentrations. Both TSP (r = 0.97; P < 0.0005)
and BTG (r = 0.85; P < 0.0005) in serum correlated well with
platelet count.
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3-1Oa. Relationship between plasma TSP and platelet count In thrombocytopenic
patients
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3.4 Plasma TSP in dogs receiving infusions of blood products
The animal model used to test the thrombogenicity of human blood
products has been described by Littlewood et al (1987). Briefly,
greyhounds (25 - 30 kg) were anaesthetised and catheterised,
isotonic saline was infused via the femoral vein from 0-30 min,
followed by the test infusion (maximum 140 ml) from 30 - 60 min.
Blood samples were taken by separate venepuncture from superficial
limb or jugular veins, at 0, 15, 30, 45, 60, 75, 90, 120, 150 and
180 min, into ETP anticoagulant/inhibitor. Test infusions were
bovine thrombin (Parke-Davis, New Jersey, USA), human albumin,
human factor IX (Scottish National Blood Transfusion Service
Protein Fractionation Centre), human factor VII or human factor XI
(Churchill Hospital Plasma Fractionation Centre, Oxford).
3.4.1 Infusion of albumin and thrombin
Plasma levels of TSP in dogs infused with human albumin (250 -
300 mg/kg) or bovine thrombin (150 U/kg) are shown in fig.3-12.
Each result represents the mean of six experiments. When albumin
was infused, the plasma TSP content remained steady at its normal
basal level (approximately 70 ng/ml).
In contrast, infusion of thrombin caused a large and rapid rise
in plasma TSP concentration, to approximately 7 times normal at 60
min, which remained at an elevated level for the duration of the
experiment. A wide variation in peak plasma TSP concentration was
observed between individual animals and ranged from a 3- to a
24-fold increase above the pre-infusion level.
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Fig. 3-12. Plasma TSP in dogs infused with albumin or thrombin
87
3.4.2 Infusion of varying amounts of factor IX
Plasma levels of TSP in dogs infused with human factor IX
concentrate (50, 100 or 200 iu/kg) are shown in fig.3-13. Each
result represents the mean + SD of three experiments. Infusion of
factor IX caused a rapid rise in plasma TSP concentration, which
peaked at 60 min, then fell sharply after the infusion was stopped.
The peak level of TSP was approximately proportional to the dose of
factor IX given. After infusion of 50 iu/kg factor IX, the plasma
TSP concentration returned to a normal level by 150 min, but for
increasing doses it remained elevated for the duration of the
experiment.
3.4.3 Infusion of untreated and heat—treated factor IX
Plasma levels of TSP in dogs infused with a different batch of
human factor IX concentrate (100 iu/kg) which had been left
untreated, heated for 72 h at 96°C or heated in the presence of
antithrombin III (to inhibit generation of thrombin) are shown in
fig.3-14. Each result represents the mean of two (heated) or three
(unheated, heated + AT III) experiments. Infusion of unheated or
heat-treated factor IX produced similar effects on the plasma TSP
level. As observed before, the TSP concentration rose rapidly
during infusion and fell sharply upon its completion, remaining
elevated to the end of the experiment. A similar pattern was
obtained for factor IX prepared in the presence of antithrombin
III, except that the peak value was reduced, and the TSP
concentration had returned to a near-normal level by 180 min.
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Fig. 3-13. Plasma TSP in dogs Infused with varying amounts of factor IX
Time (mln)
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3.4.4 Infusion of factor VII and factor XI
Plasma levels of TSP in dogs infused with human factor VII
(heated, 100 iu/kg) or human factor XI (heated, 150 iu/kg)
concentrates are shown in fig.3-15. Each result represents the mean
of three (factor VII) or two (factor XI) experiments. Infusion of
factor VII did not cause any change in the plasma TSP level during
the experimental period. Infusion of factor XI resulted in a
gradual rise in the TSP content of plasma which continued to the
end of the experiment. The increase in TSP concentration became
statistically discernible from the control (albumin infusion) after
150 min (P < 0.05, Wilcoxon-Mann-Whitney test).
3.5 Discussion
Levels of TSP in plasma from normal individuals have been
reported by several groups (Saglio & Slayter 1982, Dawes et al
1983, Lane et al 1984, Ffrench et al 1985, Switalska et al 1985,
Trzeciak et al 1985, McCrohan et al 1987), showing a relatively
large variation (table 3-5). Different assays have varying
sensitivities due to the use of different antibodies and
methodologies. An important factor is the procedure used for
venepuncture and plasma collection; it is vital to prevent in vivo
and ex vivo platelet activation which would otherwise falsely
elevate the levels of TSP and other a-granule components. Good
sampling technique and the use of an inhibitor cocktail such as ETP
(section 2.6) are therefore essential.
Patients undergoing general surgery had similar pre-operative
levels of TSP to those in normal plasma, which was expected since
there was no evidence of haematological disorders in this group of
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:ig. 3-15. Plasma TSP in dogs infused with factor VII or factor XI
Time (min)
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patients. However, it was important to demonstrate that the
radioimmunoassay, in this operator's hands, produced results which
were consistant with those obtained previously and by other groups
(table 3-5). Normal plasma BTG concentrations confirmed the absence
of excess platelet activation prior to anaesthesia.
Neither general/epidural anaesthesia nor surgery appeared to be
thrombogenic, since the plasma levels of TSP and BTG remained
steady following surgery. The rise in post-operative plasma vWF
concentrations, which was independent of the type of anaesthesia
given, could be explained by an increase in endothelial activity
involved in the trauma of surgery and the initiation of healing
processes by the vessel wall.
The strong positive correlation observed between plasma TSP and
BTG in general surgery patients is evidence that the release of
platelet ot-granules is a major factor which determines the level of
circulating TSP. The lack of correlation between TSP and vWF
suggests that different mechanisms influence the plasma content of
these glycoproteins. Although endothelial cells synthesise and
secrete both TSP and vWF, their intracellular location and control
of release are separate (Reinders et al 1985). Therefore activation
of the endothelium following surgery could cause an increase in
plasma vWF without a concomitant rise in TSP levels.
Studies of Christmas disease patients receiving factor IX
infusions revealed that TSP co-purified with factor IX during the
production of this plasma fraction. High plasma TSP concentrations
found in these patients immediately post-infusion were due to the
presence of TSP in factor IX concentrate, and not to any
thrombogenicity associated with the infusion material. This was
93
Table 3-5. Levels of TSP in normal plasma
TSP (mean + sd, ng/ml) n Anticoagulant Ref.
163 + 103 21 Thrombotecta (1)
226 + 100 25 Thrombotect (1)
132 + 72 11 Thrombotect (1)
107 + 71 11 acdb (1)
209 + 141 11 edta-k3 (1)
105 + 31 27 etpc (2)
211 + 31 21 etp (3)
264 + 53 9 etp (3)
54 + 16 33 etp (4)
61 + 11 6 acd + prostaglandin e^ (5)
97 + 31 6 etp (5)
98 + 12 6 etfd (5)
146 + 56 6 edta + theophylline (5)
56 + 12 28 etp (6)
61 + 6 16 edta (7)




EDTA + theophylline + prostaglandin E
EDTA + theophylline + forskolin
References:
1) Saglio & Slayter 1982
2) Dawes et al 1983
3) Lane et al 1984
4) Ffrench et al 1985
5) Switalska et al 1985
6) Treciak et al 1985
7) McCrohan et al 1987
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confirmed by analysis of human factor IX concentrate, of which TSP
constituted 0.5% of the total protein. Most of the TSP retained its
normal heparin-binding activity, although a minor fraction, which
may have been partially degraded or bound to other components in
factor IX concentrate, did not.
Clearance of TSP from the plasma of Christmas disease patients
occurred in a similar manner to that reported previously for a
normal individual (Dawes et al 1983) and in rabbits (Switalska et
al 1985). Thus there was rapid initial redistribution followed by a
phase of much slower, approximately exponential, loss of TSP from
plasma. The routes by which TSP leaves the plasma are not well
understood. It is likely that the rapid elimination observed may be
due to binding of TSP to platelets and other sites within the
vasculature (fibrinogen, fibronectin, plasminogen, HRGP and
endothelium) while the slower component could reflect catabolism of
this glycoprotein by the liver. Renal clearance is unlikely to be
an important route for the catabolism of TSP (Lane et al 1984). In
contrast, factor IX was lost from plasma in a much slower,
approximately linear manner, such that over 50% of the maximum
plasma level achieved following infusion remained after 24 h.
The contribution of platelets to plasma and serum concentrations
of TSP was studied in thrombocytopenic patients by relating TSP and
BTG levels to their platelet counts. Throughout these studies, the
serum content of TSP and BTG correlated closely with the platelet
count, and with each other. Since these two glycoproteins are
released from platelet a-granules during clotting, their serum
levels simply reflect the number of platelets present.
The relationship between plasma concentrations of the two
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glycoproteins and platelet count is, however, more complex. The
lack of correlation between plasma BTG and platelet count, and the
observation that 42% of individual plasma samples had normal or
raised BTG concentrations, despite platelet counts being 10% of
normal or less, was unexpected. These results cannot be accounted
for by abnormally high platelet BTG contents, since serum levels
were those expected from the platelet counts. However, they could
reflect release from defective megakaryocytes, which appears to
occur in the grey platelet syndrome (Gerrard et al 1980). It should
also be emphasised that the kinetics of production and clearance of
TSP, BTG and platelets differ and are almost certainly altered in
these severely ill patients.
No relationship was demonstrable between plasma TSP
concentration and platelet count, nor between the plasma contents
of TSP and BTG (in contrast to the case for general surgery
patients, where there was a positive correlation between the two).
Furthermore, normal levels of TSP were frequently found in plasma
in the absence of detectable amounts of BTG, clearly indicating
that much of the TSP in plasma can originate from sources other
than platelets.
During consecu tive sampling of three patients recovering from
severe bone marrow depression, the plasma TSP content of both TSP
and BTG tended to mirror the platelet count. However, for TSP this
pattern was superimposed upon a basal level of approximately 50
ng/ml. The most likely source of this background plasma TSP
content, which was independent of the platelet count, is the
vascular endothelium.
The response of plasma TSP concentrations in dogs to the
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infusion of blood products, can be described in terms of two
independent mechanisms which can occur alone or in combination.
Firstly, the sharp rise and fall in TSP levels following factor
IX infusion, is due to the presence of human TSP in the infusion
material and its rapid clearance from plasma. The animal model gave
very similar results to those seen in Christmas disease patients,
in that peak levels of TSP following infusion of factor IX
concentrate, and the rates of clearance of TSP, were comparable in
dogs and humans. Secondly, the prolonged increase in plasma TSP
content after thrombin or factor XI infusion, is caused by
activation of platelets and release of TSP in the circulation.
Although factor IX concentrate was non-thrombogenic at low dose,
there was evidence of platelet activation and prolonged release of
TSP when larger amounts were infused. Heat treatment of factor IX
did not appear to increase its thrombogenicity, but there was some
evidence to suggest that addition of antithrombin III to the




SURFACE-ASSOCIATED THROMBOSPONDIN OF HUMAN PLATELETS
A preliminary study of the surface-associated TSP of human
platelets was done in collaboration with Prof N. Crawford and
Dr M. Crook, Department of Biochemistry, Royal College of Surgeons
of England, London. The feasibility of measuring TSP on
formol-fixed platelets in various anticoagulants was investigated,
and levels of surface-associated TSP were related to the
electrophoretic properties of platelets.
4.1 Comparison of MgCl^ and CPD-adenine-1 anticoagulants
Platelet-associated TSP was measured by radioimmunoassay in
suspensions of human platelets prepared by Dr M. Crook, Department
of Biochemistry, Royal College of Surgeons of England, London using
a method similar to that of George et al (1986). This involved
fixation of platelets with formaldehyde (0.4% v/v final
concentration) in whole blood anticoagulated with either MgCl^
(30 mM final concentration) or CPD-adenine-1 (Zuck et al 1977).
When MgCl^ was used as anticoagulant, the platelet-associated
TSP concentration was 4.29 + 2.06 ng/10 cells (mean + SD, n = 7).
Assuming that one TSP molecule bound one antibody molecule in the
radioimmunoassay, and a molecular weight for TSP of 450 kD, then
this was equivalent to 5720 molecules/platelet. However, since TSP
is a trimeric glycoprotein, antibody binding may have overestimated
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the number of molecules associated with the platelet surface.
Similarly, the platelet-associated TSP in CPD-adenine-1
0
anticoagulant was 2.26 + 0.42 ng/10 cells, equivalent to 3010
molecules/platelet. The difference between MgCl^ and CPD-adenine-1
anticoagulants was statistically discernible (P < 0.05, Student's t
test).
4.2 Platelet subpopulations separated by continuous flow
electrophoresis
Platelet-associated TSP was studied in surface charge-dependent
subpopulations of human platelets separated by continuous flow
electrophoresis (Crook and Crawford 1988). Briefly, platelets
isolated from MgCl^-anticoagulated blood were fixed with
formaldehyde (0.4% v/v final concentration) and applied into the
cathodal side of the chamber of a Bender & Holbein VAP5 continuous
flow electrophoresis apparatus. Platelets were separated into 20 -
25 fractions on the anodal side of the chamber according to
increasing electrophoretic mobility. Fractions were assayed for TSP
and subdivided into population pools A , B and C of decreasing
electronegativity (table 4-1). No statistically discernible
difference was observed in the surface TSP of the platelet
subpopulations (P > 0.05 for A/B, A/C and B/C comparisons,
Student's t test).
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Table 4-1. Surface-associated TSP of platelet subpopulations
Whole pool Subpopulation
'0' A B C
TSP (ng/10 cells) 6.1 + 1.9 5.8 + 1.4 5.2 + 2.6 5.8 + 1.2
Results expressed as mean + SD from four experiments.
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4.3 Discussion
In many clinical situations there is a need for assessment of in
vivo platelet activation, and although measurements of plasma
levels of oc-granule proteins may be useful, they are not always
reliable (section 1.7).
Following activation of platelets, TSP is released along with
other oc-granule components and may bind to the platelet surface
(section 1.6). Dawes et al (1983) estimated that approximately 50%
of the TSP secreted by platelets becomes associated with the
platelet aggregate during the clotting process. Thus, measurements
of surface-associated TSP may provide a more reliable indication of
the extent of platelet activation than those of a-granule proteins
in plasma.
Levels of platelet-associated TSP detected in unstimulated,
formol-fixed preparations were higher than those reported by George
et al (1986). They observed 1763 molecules TSP/platelet when the
cells were prepared in 5 mM EDTA, compared with 5720
molecules/platelet in 30 mM MgCl^ and 3010 molecules/platelet in
CPD-adenine-1 for the present study. It is well established that
TSP can bind to platelets by a Ca2+-dependent mechanism (section
1.6) and Ca^+-chelating anticoagulants, such as EDTA, may cause a
proportion of the bound TSP to dissociate from the platelet
surface. It has been shown that the use of MgCl^ as anticoagulant
causes no loss of platelet-bound TSP (George et al 1986) and is
thought to maintain the surface-associated "halo" of
electrostatically- and Ca^+-linked proteins around the platelet
(Crawford et al 1987). This would explain the higher
surface-associated TSP concentration found in "Mg^+-platelets"
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compared with those in EDTA or CPD-adenine-1 anticoagulant.
Measurement of surface-associated TSP in platelet subpopulations
separated by continuous flow electrophoresis showed that the
binding of TSP was not dependent on the overall platelet surface
charge (electronegativity). The latter has been shown to correlate
positively with cell volume, electrophoretic mobility and surface
sialic acid, but inversely with membrane -SH group status (Crook &
Crawford 1988).
Thus, the surface-associated TSP of human platelets appears to
be independent of the size, charge and other intrinsic properties
of these cells, but has been shown by George et al (1986) to be
increased by thrombin stimulation and in patients with adult
respiratory distress syndrome (a clinical condition with increased
platelet activation and secretion). It is suggested therefore, that
measurement of surface-associated TSP may be a sensitive and
specific marker of in vivo platelet activation.
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CHAPTER FIVE
THROMBOSPONDIN IN BREAST SECRETIONS
The present studies of TSP in breast secretions, and those
published previously (Dawes et al 1985, Miller & Dawes 1985, Dawes
et al 1987), sought to investigate the source of TSP and the
mechanisms controlling its production in the mammary gland. Thus,
TSP levels in breast cysts were related to concentrations of other
fluid constituents and to the type of lining epithelium, while in
human and animal milk the production of TSP was examined during
various stages of the reproductive cycle.
Breast cyst fluids were provided by Mr W.N. Scott, University
Department of Clinical Surgery, Edinburgh and samples of animal
milk by Dr R. Nowak, AFRC Institute of Animal Physiology and
Genetics Research, Cambridge.
5.1 Human breast cyst fluids
Platelet-associated proteins have been studied previously in
human breast cyst fluids in this laboratory (Miller and Dawes
1985). TSP levels in 50 cyst fluids were 65 - 55000 ng/ml (median =
2500 ng/ml) and 92% were above the normal plasma range. When fluids
were classified according to their electrolyte composition, group
II (Na+) cysts (Na+:K+> 3) had significantly higher levels of TSP
than group I (K+) cysts (Na+:K+ < 3).
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5.1.1 Relationship between TSP, EGF and type of cyst fluid
TSP was measured in 37 breast cyst fluids from 31 women, which
had been assayed for EGF by radioimmunoassay (section 2.5) and the
results published elsewhere (Smith et al 1989). TSP levels were 92
- 48000 ng/ml (median = 580 ng/ml) and 29/37 (78%) were above the
normal plasma range. A negative correlation which was statistically
discernible was observed between TSP and EGF in breast cyst fluids
(r = -0.44, P< 0.005, Spearman rank correlation test) (fig.5-1).
When the fluids were classified as above, group II (Na+) cysts
had a higher TSP content (n = 15, median = 1100 ng/ml, range = 140
- 5800 ng/ml) than group I (K+) cysts (n = 20, median = 385, range
= 92 - 48000) and the difference was statistically discernible
(P < 0.005, Wilcoxon-Mann-Whitney test) (fig.5-2). Conversely, the
EGF concentration in group I (K+) fluids (n = 20, median = 799.5
ng/ml, range = 307.6 - 1599.0 ng/ml) was higher than that in group
II fluids (n = 15, median = 312.6, range = 7.9 - 1158.9) and the
difference was also statistically discernible (P < 0.001)
(fig.5-3).
5.1.2 Analysis of cyst fluid by heparin—Sepharose affinity
chromatography
A single group II (Na+) cyst fluid (volume = 13 ml, TSP content
= 2800 ng/ml) was centrifuged at 40000 g (18000 rpm) in a Sorvall
RC-5B centrifuge with type HS-4 rotor (DuPont Instruments) for
60 min at 4°C in the presence of the protease inhibitors PMSF
(100 mM) and leupeptin (6 mM). The supernatant was filtered (AP20
prefilter and GS 0.22 urn membrane filter; Millipore) and 5 ml was
applied to a heparin-Sepharose CL-6B column (2 x 24 cm, Pharmacia)
104
Fig. 5-1. Relationship between TSP and EGF In human breast cyst fluids
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equilibrated in 15 mM Tris-HCl, 0.15 M NaCl, 0.02% NaN^, pH 7.4, at
a flow rate of 0.4 ml/min. The column was eluted stepwise with
buffers of increasing NaCl concentration, and fractions (4 ml) were
collected. Each fraction was measured for protein (0D„o^) and TSP
<±oU
content, and the elution profile is shown in fig.5-4.
All of the protein in cyst fluid which was detectable by
absorbance measurement at 2.80 nm was eluted by 0.15 M NaCl. The
TSP-like antigenicity of cyst fluid was separated into three peaks
eluted by 0.15 M, 0.25 M and 0.55 M NaCl.
5.2 TSP in milk
It was previously shown that TSP was a component of the aqueous
phase of bovine milk, that the gel filtered protein isolated from
goat colostrum had a major peak at 450 kdal together with fragments
of low molecular weight, and that TSP from goat colostrum displayed
a different proteolytic fragmentation pattern compared with TSP
isolated from human platelets, endothelial cells and fibroblasts
(Dawes et al 1987).
5.2.1 Cow and goat milk
Fresh animal milk samples were stored at -20°C until assayed for
TSP and total protein. Daily milk samples were taken from two cows
and one goat during their normal oestrous cycles. There was
considerable variation in milk TSP content, both within and between
animals. No pattern in TSP or total protein levels was observed
which corresponded with the oestrous cycle, as shown by the example
in fig.5-5.
Milk samples were also taken on successive days from a goat
108





Fig. 5-6. Daily levels of TSP and protein in goat milk before and after mating




around the time of mating, and from a cow during pregnancy. Goat
milk TSP concentrations tended to increase at the onset of
pregnancy (fig.5-6), while in the cow a relatively high level of
TSP was maintained despite a gradual fall in the total milk protein
content as pregnancy progressed (fig.5-7).
5.2.2 Human milk
The concentrations of TSP and protein in mammary secretions of
one woman during the period from 17 days prepartum to 5 days
postpartum are shown in fig.5-8. Colostrum contained as much as 70
- 80 ug/ml TSP, and this dropped to 4 ug/ml as lactation became
established. Total protein levels also fell during the peripartum
period but the ratio of TSP to protein declined almost tenfold from
2 to 0.25 ug TSP/mg protein (fig.5-9).
A sample of milk from another lactating woman was assayed for
TSP and several other related proteins, and the results are shown
in table 5-1. All the proteins were measured in this laboratory by
routine radioimmunoassays, except fibrinogen and fibronectin, which
were assayed by rocket immunoelectrophoresis. The platelet-specific
proteins BTG and PF4 were not detectable in human milk, as was the
case for fibrinogen (although the assay for this protein was rather
less sensitive). Fibronectin was present at a similar concentration
to TSP, while vWF and granulocyte elastase were detectable at low
levels.
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Fig. 5-8. TSP and protein in human mammary secretions during the peripartum period
Time from parturition (d)
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g. 5-9. Relative TSP levels In human mammary secretions during the perlpartum period
Time from parturition (d)
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Table 5-1. Levels of platelet-related and adhesive proteins in
human milk












In their study of platelet-associated proteins in breast cyst
fluids, Miller & Dawes (1985) ruled out platelets as the source of
the remarkably high levels of TSP in group II (Na+) cysts since BTG
was not simultaneously elevated above normal plasma concentrations.
Group II (Na+) cysts also contain wholly or predominantly the 7S
non-secretory form of IgA, high concentrations of Na+, IgG and
albumin and low levels of K+ and DHA-sulphate (Miller et al 1983a,
Yap et al 1984); findings which are consistant with the hypothesis
that these fluids may be formed by accumulation from plasma. In
contrast, group I (K+) cysts contain the 11S secretory form of IgA,
low concentrations of Na+, IgG and albumin and high levels of K+
and DHA-sulphate; suggesting that these fluids may reflect the
synthetic activity of the apocrine epithelium. These concepts of
fluid generation are supported by comparison of the epithelial
lining of cysts; group I (K+) cysts are characterised by active
apocrine epithelium, whereas group II (Na+) cysts possess thin,
attenuated (flattened) epithelial cells (Dixon et al 1983). Since
TSP concentrations are highest in group II (Na+) cysts, it seems
very unlikely that these levels represent synthesis by apocrine
cells. Alternatively, TSP may be actively accumulated or produced
locally by other cells associated with breast cysts.
The present data confirm the finding by Miller & Dawes (1985) of
high levels of TSP in human breast cyst fluids, particularly those
of group II. Furthermore, an inverse relationship has been shown to
exist between TSP and EGF concentrations in cyst fluids. This
negative correlation is probably due to differences in fluid
composition between the two groups of cysts, since EGF levels were
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lower in group II fluids, as has recently been reported (Smith et
al 1989). EGF has been detected in cyst fluid by several others
(Jaspar & Franchimont 1985, Collette et al 1986, Boccardo et al
1988) and also in milk (Starkey & Orth 1977) and in nipple
aspirates (Rose 1986).
The higher concentrations of EGF in group I fluids may reflect
the active nature of the apocrine epithelium surrounding these
cysts. Alternatively, the differences in EGF content may be
responsible for the varying epithelial activities of group I and
group II cyst walls. EGF has been shown to have potent mitogenic
effects on breast epithelial cells (Osborne et al 1980, Imai et al
1982), while Dickson and coworkers (1985) have reported the
secretion of EGF-like peptides by breast cancer cell lines.
Although there is no direct evidence that breast cyst epithelium
produces EGF, mammary epithelium can secrete EGF in vivo which has
been administered systemically (Brown et al 1986). Taken together,
the above data could imply that EGF in breast cyst fluids is
produced by the lining epithelium and may potentially modulate the
activity of these cells by autocrine/paracrine mechanisms. TSP
levels, on the other hand, were found to correlate inversely with
EGF in breast cysts, and it may be that mammary epithelial cells
are not the major source of TSP in these secretions.
Separation of a group II (Na+) cyst fluid by heparin affinity
chromatography showed that although some of the TSP detected by
radioimmunoassay retained a heparin-binding affinity similar to
that of platelet TSP (eluting with 0.55 M NaCl), most was eluted in
the initial column flow-through together with the measurable cyst
fluid protein content, plus another peak of reduced heparin-binding
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affinity (eluting with 0.25 M NaCl). The loss of heparin-binding
affinity may be due to partial degradation of TSP by proteases, or
to the association of TSP with other molecules in cyst fluid.
TSP was found in high concentrations in the aqueous phase of
milk (constituting 0.2% and 0.02% of the total protein of colostrum
and mature milk respectively) compared with plasma (where it
accounts for only 0.00015% of the total protein). Data from animal
models suggested that the relative TSP content of milk tended to
increase with time during pregnancy, when the mammary gland becomes
fully developed, i.e. hypertrophy of the glandular epithelium and
differentiation of acini into milk-secreting units occurs.
However, the pattern of TSP secretion by the human breast
observed during the initiation of lactation was the inverse of that
described for the specific milk proteins a-lactalbumin and
lactoferrin (Kulski & Hartmann 1981). Thus, compared to the total
protein content, the relative TSP concentration decreased tenfold
during the transition from colostrum to mature milk, whereas the
relative levels of a-lactalbumin and lactoferrin increase over this
period. a-Lactalbumin is synthesised by differentiated mammary
epithelial cells (Hill & Brew 1975) and while lactoferrin is
probably synthesised in situ by the breast, additional amounts may
be produced by white blood cells which invade its interstitial
tissues (Rumke et al 1971).
It is of considerable interest that the pattern of TSP secretion
in early milk closely resembled that of IgA, the major
immunoglobulin of milk. IgA also shows a dramatic fall in
concentration during the first few days after parturition (Ammann &
0
Stiehm 1966). Human milk contains around 1 - 4 x 10 white blood
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cells/ml during the first two weeks following delivery and slightly
fewer thereafter (Hanson & Winberg 1972). These white cells include
lymphocytes (which secrete IgA), macrophages and neutrophils, and
have also been described in nipple aspirate fluid (Petrakis 1986).
In the present study, granulocyte elastase (a product of
neutrophils) was found in human milk along with TSP, but the
platelet-specific proteins BTG and PF4 could not be detected. It is
apparent that the composition of milk and other breast secretions
may be influenced by cells other than those of the mammary
epithelium. Since TSP is known to be secreted by macrophages (Jaffe
et al 1975) , there is a strong possibility that the high levels of
TSP in breast secretions may originate from these and/or other
cells which infiltrate the mammary gland, and not from platelets or
the glandular epithelium itself.
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CHAPTER SIX
THROMBOSPONDIN IN MALIGNANT AND NON-MALIGNANT BREAST TISSUE
TSP was found in high concentrations in secretions of the breast
(chapter 5) and therefore it was interesting to study its levels in
breast tissue, with the aim of investigating further the origin and
production of TSP in the mammary gland. Measurements of TSP were
made in two sets of breast tissue cytosols. Firstly, TSP
concentrations were compared within benign and malignant breast
tissue, with the corresponding contents of BTG and vWF, and with
various indicators of hormonal status. Secondly, levels of TSP were
related to the site of the tissue with respect to the tumour mass,
and to the concentration of tissue plasminogen activator (tPA), an
oestradiol-inducible enzyme. The results of these studies have been
published (Pratt et al 1989).
Breast tissue cytosols (101 breast carcinoma, nine benign
mammary dysplasia, five fibroadenoma, one gynaecomastia, one
normal) were provided by Miss J. Telford, University Department of
Clinical Surgery, Edinburgh, and had been prepared as described in
section 2.7. Nineteen breast tissue cytosols from eight patients
with breast cancer, which were classified according to whether the
tissue had been taken from the centre of the tumour (n = 7), the
edge of the tumour (n = 3), or the surrounding non-malignant tissue
(n = 9), were provided by Dr G. Savidge, Department of Haematology,
St.Thomas' Hospital, London. They had been obtained by
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snap-freezing of washed tissue samples taken at mastectomy,
followed by cryofragmentation using a mechanical dismembrator, and
preparation of a supernatant from the tissue extract resuspended in
buffered saline.
6.1 TSP, vWF and BTG in breast cytosols
A wide range of TSP levels was found in breast cytosols
(fig.6-1). Highest levels were observed in breast cancers (n = 101,
median = 317 ug TSP/g cytosol protein, range = 17.4 - 23400 ug
TSP/g cytosol protein) and lowest in benign breast (n = 15, median
= 21.7, range = 1.78-155). The difference between cancer and benign
samples was highly discernible (P < 10 Wilcoxon-Mann-Whitney
test). TSP in fibroadenomas (n = 5, median = 21.7, range = 5.93 -
155) was not statistically discernible from that in benign mammary
displasia and gynaecomastia (n = 10, median = 19.7, range = 1.78 -
47.6) and therefore all benigns were considered as a single group.
Measurement of vWF in breast cytosols revealed a narrower range
of concentrations compared with TSP (fig.6-2), but higher levels
were also found in cancers (n = 101, median = 40.8 ug vWF/g cytosol
protein, range = undetectable - 392 ug vWF/g cytosol protein) than
in benigns (n = 15, median = 14.0, range = undetectable - 46.0).
The difference was statistically discernible (P < 10 4) although
less marked than for TSP. A plot of TSP against vWF (fig.6-3)
showed that there was a positive correlation between the two which
was statistically discernible (n = 116, r^ = 0.484; P< 0.001,
Spearman rank correlation test).
BTG was measured together with TSP in 20 breast cytosols (18
cancer, one benign, one normal) and no statistically discernible
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Fig. 6-3. Relationship between TSP and vWF In breast tissue
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correlation was observed between the two (r = -0.365; P > 0.10)
s
(fig.6-4).
6.2 TSP and indicators of hormonal status in breast cancer
cytosols
Breast cancer cytosol TSP levels were compared in a group of 92
patients classified according to menopausal status (fig.6-5). TSP
in breast cancer cytosols from pre-menopausal women (n = 32, median
= 213.5 ug TSP/g cytosol protein, range = 17.4 - 23400 ug TSP/g
cytosol protein) was slightly lower than that in cancers from
post-menopausal women (n = 60, median = 367, range = 41.8 - 12800),
the difference was just statistically discernible (P = 0.043).
TSP did not correlate with oestrogen receptor (ER) concentration
in breast cancers (fig.6-6), measured in the University Department
of Clinical Surgery, Edinburgh using a method described by Hawkins
et al 1981 (n = 98, rg = -0.0075; P > 0.20) nor with progesterone
receptor (PR) concentration (fig.6-7), measured by the method of
Miller et al 1983b (n = 33, r = -0.146; P > 0.20).
s
6.3 TSP and tissue plasminogen activator (tPA) in cytosols of
tissue taken from different locations within cancerous breast
Nineteen breast tissue cytosols from eight patients with breast
cancer were measured for their TSP and tPA content (results from
the tPA enzyme-linked immunosorbant assay, as described by Rijken
et al 1984, have been published by Layer et al 1987). The tissue
had been classified according to whether it was taken from the
centre of the tumour mass ('centre' ), from the edge of the tumour
('interface') or from the surrounding non-malignant tissue
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Fig. 6-7. Relationship between TSP and PR In breast cancer tisuue
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('surround').
A weak negative correlation which was not statistically
discernible was observed between TSP and tPA in breast tissue
(n = 19, r = -0.356; P > 0.10) (fig.6-8).
However, comparison of the TSP concentration in samples from the
centre of the tumour mass and from the surrounding non-malignant
tissue (fig.6-9) showed that the centre (n = 7, median = 1080 ug
TSP/g cytosol protein, range = 31.8 - 4480 ug TSP/g cytosol
protein) contained much higher levels than the surround (n = 9,
median = 53.0, range = 17.0 - 324). The difference between the two
groups was statistically discernible (P < 0.01), and in three out
of four patients where samples from both locations were available,
TSP was higher in the malignant tissue.
Conversely, tPA concentrations were lower in the centre (n = 7,
median = 3.19 ug tPA/g cytosol protein, range = 1.30 - 4.39 ug
tPA/g cytosol protein) than in the surround (n = 9, median = 5.42,
range = 2.50 - 11.99) (fig.6-10). The difference between the two
groups was statistically discernible (P < 0.005), and in all four
patients where samples from both locations were available, tPA was
lower in the malignant tissue.
6.4 Discussion
The elevated levels of TSP and vWF in malignant breast, and the
correlation observed between the two suggest that they may have a
common site of synthesis within the breast which is stimulated in
malignant disease. Whilst vWF is not known to be associated with
cancer, TSP has been implicated previously in tumour cell
metastasis (section 1.8).
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Fig. 6-8. Relationship between TSP and tPA In breast tissue
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Fig. 6-10. tPA In breast tissue from different locations within cancerous breast
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vWF is synthesised by endothelial cells and megakaryocytes and
is contained in platelet oc-granules. vWF functions as a carrier
protein for coagulation factor VIII in plasma and is thought to be
involved in platelet-vessel wall interactions (Girma et al 1987).
Indeed, vWF is incorporated into the extracellular matrix of
cultured endothelial cells (Hormia et al 1983) where it may
function as an adhesive protein. Although not specific for
endothelial cells, vWF has been used as a marker of endothelial
cell perturbation in vitro (Mannucci et al 1975, Levine et al 1982,
Loesberg et al 1983) and as a criterion for endothelial cell
identification (Jaffe et al 1973).
TSP is also synthesised by endothelial cells and megakaryocytes,
and is stored in platelet oc.-granules, but has also been described
in a wide range of other cell types (section 1.5). Since the
platelet oc-granule protein BTG was not simultaneously raised with
TSP in breast cytosols, it is very unlikely that platelets are the
source of the high levels of TSP and vWF in malignant breast.
Increased vascularity and/or stimulation of the endothelium could
explain the higher TSP and vWF content of cancer tissue despite the
finding that the difference between cancer and benign samples was
much greater for TSP than for vWF (the median cytosolic vWF of
malignant breast was three times higher than non-malignant breast,
whereas for TSP it was 15 times higher). TSP and vWF have been
shown to be located in different subcellular compartments in
endothelial cells where their secretion is separately controlled
(Reinders et al 1985). However, it is possible that another source
within the breast , in addition to the endothelium, may be
contributing to the very high level of TSP observed in some breast
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cancers.
It has been said that breast cancer is hormonally mediated and
that oestrogens are the prime agents in tumour expression (Miller &
Bulbrook 1980). Approximately 30% of breast cancers respond to
oestrogen deprivation therapy and most of these are ER positive
(Edwards et al 1979). Since oestrogens are so closely implicated in
breast cancer, it was of interest to investigate whether the high
levels of TSP in malignant breast were related to any of the known
indicators of hormonal status. A slight difference was observed in
the TSP content of breast cancers from pre- and post-menopausal
women, but no correlation was observed between TSP and ER or PR,
and therefore it seems unlikely that synthesis of TSP by the
malignant epithelium regulated by oestrogens is involved in causing
the high levels found in breast cancer.
Further evidence for the specific elevation of TSP in malignant
breast came from the measurement of TSP in tissue taken from
different sites within the cancerous breasts of a group of
patients. Very high levels of TSP (> 500 ug/g cytosol protein) were
only seen in tissue from the centre of the tumour mass; levels in
tissue from elsewhere within the same breast were comparable to
those found in benign breast.
It was interesting that measurement of tPA in these samples
showed the opposite trend. tPA is the major plasminogen activator
(PA) in human milk where it shows a similar pattern of secretion
during early lactation as does TSP (Marshall et al 1986, section
5.2.2). While elevated PA levels have been reported in breast
cancer (Dano et al 1985), some tumours contain predominantly
urokinase-type plasminogen activator (uPA) and others predominantly
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tPA (0'Grady et al 1985) which makes early studies in which only
total PA was measured difficult to interpret. However, it has been
established that tPA, rather than uPA, correlates with ER and PR in
breast tumour cytosols (Duffy et al 1986) and tPA secretion by
mammary epithelial cells in culture is preferentially induced by
oestradiol and glucocorticoids (Ryan et al 1984, Busso et al 1986).
The finding that TSP and tPA were inversely related in tissue from
different sites within cancerous breasts suggests that they are not
coordinately expressed by the malignant epithelium.
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CHAPTER SEVEN
THROMBOSPONDIN IN CULTURED CELLS
In vitro culture of cells grown on plastic surfaces in media of
defined composition was used as a model system in which to study
the production of TSP by cells derived from various human tissues.
Three main types of human cells were investigated; endothelial
cells, fibroblasts and an established breast cancer cell line
(MCF-7) of epithelial origin. Secretion of TSP into the
extracellular medium was quantitated with respect to time for each
cell type, and comparisons were made between endothelial cells and
fibroblasts from various tissue sources. Factors which may
potentially influence the production of TSP by endothelial and
MCF-7 cells were also studied.
In the following experiments, unless stated otherwise, cells
were grown in 6-well Costar culture clusters (Northumbria
Biologicals) using complete medium (2 ml per well) as described in
section 2.11. At confluence, the monolayer was washed with buffered
salt solution to remove residual serum components, and incubated
with serum-free medium (SFM) for the experimental time period.
Supernatants, prepared by aspiration of the serum-free conditioned
medium (SFCM) and centrifugation to remove cell debris, were stored
at -40°C prior to assay. Cell numbers were measured using a
haemocytometer following trypsinisation of the monolayer. Some of
the experiments were performed in collaboration with
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Dr N.R. Hunter, Scottish National Blood Transfusion Service
Headquarters Unit Laboratory, Edinburgh.
7.1 Endothelial cells
7.1.1 Secretion of TSP by endothelial cells derived from human
umbilical vein (HUVEC) and adult saphenous vein (HSVEC)
The secretion of TSP by HUVEC and HSVEC has been measured in
this laboratory and the results described by Hunter et al (1984).
HUVEC and HSVEC both secreted TSP into the culture medium in a
linear time-dependent manner with no apparent feedback control.
After 24 and 48 h, HUVEC were found to produce about 5 times as
much TSP as HSVEC (approximately 6 ug TSP/10 cells compared with
1.2 ug TSP/106 cells at 24 h).
7.1.2 Secretion of TSP by human umbilical artery endothelial
cells (HUAEC)
An endothelial cell line was isolated from human umbilical cord
artery as described in section 2.11.1.1. SFCM was removed at 4, 12
and 24 h (8 wells for each time point) for measurement of TSP, as
shown in fig.7-1. HUAEC were found to secrete almost twice the
0
amount of TSP as their venous counterparts (10.4 ug TSP/10
cells/24 h).
7.1.3 Effect of cell density on TSP secretion by HUVEC
A HUVEC line was plated at 25, 50, 75 and 100% confluent density
(6 wells for each density) and incubated for 2 h in complete
medium. The monolayer was washed, the cells incubated in SFM for
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Fig. 7-1. TSP secretion by human umbilical artery endothelial cells (HUAEC)
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12 h, and the supernatants assayed for TSP as before. Cell numbers
were measured in 4 wells at each density, except for the 25%
confluence group for which an accurate cell count could not be
determined because of the low cell number. Fig.7-2 illustrates the
secretion of TSP measured in the same HUVEC line plated at
different cell densities. Results have been expressed (i) as the
0
amount secreted per 10 cells and (ii) corrected for plating
density to 100%. The results showed that the secretion of TSP by
HUVEC decreased at higher cell densities.
7.1.4 Effect of anti-TSP on HUVEC
In order to investigate the role of TSP in the adhesion of
endothelial cells to substratum, a HUVEC line was plated at 25%
confluent density in the presence of growth medium (3 ml per well)
as follows;
medium A: SFM without EGF
medium B: medium A + 1% normal rabbit serum
medium C: medium A + 1% rabbit anti-TSP antiserum
The monolayers were observed by light microscopy for
morphological differences and duplicate supernatants were prepared
at 24, 50 and 76 h for measurement of TSP as shown in fig.7-3.
After incubation for 24 h, there were no visible morphological
differences; each monolayer consisted of cells which were attached
and spread. The cell viability in all wells approached 100% (as
observed by the ability of cells to exclude the dye Trypan blue).
At 50 h, a minority of the cells in medium A were detached from the
plate and rounded in shape, whereas the monolayers in media B and C
were indistinguishable, with nearly all cells remaining attached
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Fig. 7-2. Effect of cell density on TSP secretion by human umbilical vein endothelial
cells (HUVEC)
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error bars = 5D
and spread. At 76 h, many cells in medium A were detached and
rounded, while most of the cells in media B and C were still
attached and spread, with no apparent difference between the two.
The concentration of TSP measured in wells containing 1% normal
rabbit serum was twice that in wells containing SFM alone. Addition
of 1% rabbit anti-TSP antiserum was sufficient to bind virtually
all the TSP in solution, as shown by the very low level of TSP
which could be detected by the radioimmunoassay (10 - 20 ng/ml).
7.2 Fibroblasts
7.2.1 Secretion of TSP by human skin fibroblasts (HSF)
A normal HSF cell line was incubated in SFM for 6, 12 and 24 h
(6 wells for each time point) and measurements of secreted TSP are
shown in fig. 7-4. Levels of TSP in SFCM increased in a linear
time-dependent manner and were similar to those previously reported
by Hunter et al (1984) for human forearm skin fibroblasts
g
(approximately 3 ug TSP/10 cells at 24 h).
7.2.2 Secretion of TSP by human oral fibroblasts (HOF)
HOF were incubated in SFM and supernatants removed from
duplicate wells at 6, 12 and 24 h for TSP assay. Fig.7-5 shows the
secretion of TSP by HOF during this period, which was also linear
with time but higher than that observed for HSF (5.5 ug TSP/10^
cells/24 h for HOF compared with 3.0 ug TSP/10^ cells/24 h for
HSF).
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Fig.7-4. TSP secretion by human skin fibroblasts (HSF)
Tim* (h)
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Fig. 7-5. TSP secretion by human oral fibroblasts (HOF)
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7.3 MCF-7 Human breast cancer cells
7.3.1 Effect of oestradiol and other hormones on TSP secretion
by MCF-7 cells
MCF-7 cells were incubated with SFM containing 0.1% ethanol
—8
(control) or 17 -oestradiol (10 M) which had been added from a
stock ethanolic solution (final ethanol concentration 0.1%).
Supernatants were removed from triplicate wells at 24, 51, 76 and
97 h for TSP assay and the results are shown in fig.7-6. The amount
of TSP secreted in both cases was relatively low compared with the
other cell types previously tested, but also increased in a linear
time-dependent manner. Addition of oestradiol caused a small but
consistant increase in the secretion of TSP (the difference was
only statistically discernible at 97 h).
In another experiment, MCF-7 cells were incubated with a variety
of hormones; supernatants were removed from triplicate wells at 24
and 48 h and at the same time the cells were harvested by
trypsinisation, washed and resuspended in buffered salt solution
for the preparation of cell homogenates using a Microson MS-25
ultrasonic disintegrator (Heat Systems-Ultrasonics Inc., New York,
USA). Measurements of TSP in supernatants (secreted TSP) and in
homogenates (cell-associated TSP) are shown in fig.7-7. Oestradiol
and the two androgens, testosterone and 5a-dihydrotestosterone,
caused small increases in the amounts of secreted and
cell-associated TSP. Cortisol caused a decrease in both the
secreted and cell-associated TSP after 48 h. The effect of insulin
was unusual and quite marked in comparison with the other hormones
tested; at both time points a decrease in the amount of TSP
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Fig. 7-6. Effect of oestradlol on TSP secretion by MCF-7 human breast cancer cells
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Fig. 7-7a. Effect of hormones on TSP production by MCF-7 human breast cancer cells
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Fig. 7-7b. Effect of hormones on TSP production by MCF-7 human breast cancer cells
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secreted was observed, while the corresponding levels in cell
homogenates were much higher than in the controls.
7.3.2 Effect of EGF on TSP secretion by MCF-7 cells
MCF-7 cells were incubated in SFM containing 0, 1, or 10 ng/ml
EGF. Triplicate supernatants and cell homogenates were prepared at
24 and 48 h as before, and assayed for their TSP content. The
results (fig.7-8) showed that addition of EGF had no effect on the
production of TSP by MCF-7 cells.
In another experiment, SFM (5 ml) without EGF was replaced every
24 h in triplicate wells over a period of 10 days, followed by SFM
containing 10 ng/ml EGF for a further 4 days. The daily production
of TSP and cumulative levels are shown in fig.7-9, which clearly
illustrates that TSP was secreted , in relatively low amounts, in a
linear time-dependent manner, unaffected by the presence of EGF.
7.3.3 Comparison of anti-TSP binding curves for MCF-7 SFCM and
human platelet TSP
The binding of TSP-like antigen from MCF-7 cells to polyclonal
rabbit anti-TSP was compared with that of human platelet TSP by
radioimmunoassay (as described in section 2.3). Antigen dilution
curves were obtained for a supernatant from MCF-7 cells grown in
SFM and for TSP purified from human platelets. The binding curves
for both are compared in fig. 7-10. Since the two curves were
superimposable, it was concluded that TSP-like antigen in MCF-7
SFCM was indistinguishable from human platelet TSP by the specific
rabbit anti-TSP antiserum used in the radioimmunoassay.
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The production of TSP has been demonstrated in a variety of
human cells cultured under serum-free conditions. Thus, TSP could
be detected by radioimmunoassay in the extracellular medium of
cells, irrespective of their type or the tissue source from which
they were derived. This is in concordance with the observations of
other investigators which show that TSP is synthesised and secreted
by a wide range of cells in vitro (section 1.5). Using a panel of
monoclonal antibodies, we have previously shown that platelet,
endothelial cell and fibroblast TSPs are immunologically identical
(Clezardin et al 1986b) and furthermore, evidence presented here
suggests that TSP produced by MCF-7 breast cancer cells is also
indistinguishable from platelet TSP using a specific polyclonal
antibody. Although TSPs from endothelial cells and fibroblasts
appear to be structurally similar, the conformational properties of
these forms of TSP may be different from those of platelet TSP
(Clezardin et al 1986b).
The growth conditions (section 2.11) were optimised so that
cells could be subcultured over extended periods while still
retaining morphological and biochemical properties characteristic
of those in the original tissue; for example endothelial cells
assumed a "cobblestone" appearance at confluence and synthesised
vWF, fibroblasts remained elongated and irregular in shape, MCF-7
cells expressed measurable levels of ER. It is suggested therefore,
that in vitro culture of cells may be a useful model system in
which to study the contribution of various components of tissues to
the overall production of TSP in vivo, and the factors which might
influence such production.
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Although TSP was found in all the cell cultures under study,
quantitative differences were observed between each cell type. In
general, high levels of TSP were secreted by endothelial cells and
fibroblasts whereas much lower levels were measured in the
extracellular medium of MCF-7 cells. In all cases however, the
secretion of TSP occurred in a continuous, almost linear manner
under the serum-free culture conditions.
The production of TSP has been most extensively studied in
endothelial cells; the data presented here are comparable with the
findings of other groups, and fall within the range of levels of
secreted TSP which have been reported previously (table 7-1). The
relatively large variation in the amounts of TSP detected in
endothelial cell cultures probably reflects the different species
and tissues from which they have been derived, the varying
composition of the growth media used, and the different
sensitivities and specificities of the TSP assays.
It is clear that several factors influence the amounts of TSP
detected; of importance is the presence of serum which contains
variable levels of proteins (including TSP and immunoglobulins)
which may interfere with TSP assays, and growth factors and
hormones which can have potent effects on the growth and metabolism
of cells. Unlike most of the studies reported by others, the
present investigations have been performed using chemically defined
serum-free media in order to eliminate unknown variables in the
growth conditions due to serum and to allow comparisons to be made
between different cell types cultured under standardised
conditions.
Although other groups have studied endothelial cells isolated
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Table 7-1. Secretion of TSP by endothelial cells
Tissue source Growth medium Secreted TSP Ref.
Bovine aorta Weymouth1s + 1.0 ug/106 cells/18 h (1)
1% porcine serum
Human umbilical Medium 199 + 49 ug/106 cells/24 h (2)
cord vein 20% rabbit serum
Human umbilical MEM + 21 ug/106 cells/24 h (3)
cord vein 20% rabbit serum
Human umbilical Serum-free 8.7 ug/106 cells/24 h (4)
cord vein conditioning medium
References:
1) Raugi et al 1982
2) Mosher et al 1982
3) Jaffe et al 1983
4) Hunter et al 1984
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from foetal and adult tissue, and from arteries and veins, no
direct comparisons between the secretion of TSP by these cells were
made. It is therefore of interest that differences have been found
in the levels of TSP secreted by human endothelial cells derived
from foetal (HUVEC) and adult (HSVEC) veins, and between those from
umbilical cord artery (HUAEC) and vein (HUVEC). While it is not
clear to what extent these findings might reflect the situation in
vivo, it may be concluded that the differences observed are due to
characteristics of the cells themselves, since each cell type was
grown under identical conditions. The higher levels of TSP found in
the extracellular medium of HUVEC compared with HSVEC might be
evidence that the expression of TSP varies according to the stage
of development of a tissue. Kramer et al (1985) showed that TSP was
a significant component of the subendothelial matrix of neonatal
microvascular endothelial cells whereas those cultured from adult
skin produced a matrix containing negligable amounts of TSP, while
Murphy-Ullrich et al (1987a) observed an extensive distribution of
TSP in sections of human foetal limb using immunohistochemical
techniques but were unable to localise TSP in various human adult
tissues. Taken together, these results may support the hypothesis
that the production of TSP by cells, and its incorporation into
their extracellular matrices, is higher during certain stages of
development when TSP may be involved in tissue reorganisation and
cell migration (section 1.4.4).
Endothelial cells form a smooth, non-thrombogenic lining of both
arteries and veins, but the structures of these two types of vessel
are markedly different. Arteries have a thick wall containing
elastic and collagen fibres and smooth muscle, which enables them
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to withstand the pulsed flow of blood under high pressure from the
heart. On the other hand, veins carry blood at low pressure and
possess relatively thin, non-elastic walls. The finding that HUAEC
produce approximately twice as much TSP in culture as their venous
counterparts is interesting and could relate to the structural and
functional differences of arteries and veins, since TSP has been
localised around small blood vessels and along the luminal surface
of aorta in situ (Wight et al 1985).
Increasing cell density caused a marked reduction in the
secretion of TSP by endothelial cells. This is in agreement with
the studies of Mumby et al (1984) who observed that the production
of TSP by endothelial cells, fibroblasts and smooth muscle cells
was density-dependent. They concluded that the higher level of TSP
in the extracellular medium of low-density cells was due to
increased secretion rather than decreased degradation or its
incorporation into matrix. In contrast, cell density did not
modulate the secretion of two other matrix proteins, fibronectin
and collagen, by fibroblasts (Mumby et al 1984). In endothelial
cells, TSP and fibronectin secretion rates appear to depend solely
on the rate of de novo protein synthesis, unlike another adhesive
protein, vWF, which is stored in secretory organelles (Reinders et
al 1985). Thus, the synthesis and secretion of different matrix
components may be under separate control mechanisms. The increased
production of TSP by cells at low density may be evidence of a role
for TSP at sites of injury and wound healing where cell-cell
contacts are reduced, since this protein has been found to be
specifically associated with clots formed in situ (Murphy-Ullrich
et al 1985) and atherosclerotic plaques (Wight et al 1985).
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Adhesion of endothelial cells to fibronectin-coated plastic was
not visibly affected by the presence of anti-TSP antiserum in
sufficient quantity to bind all the TSP secreted into the
extracellular medium by these cells. Although TSP has been shown to
promote the cell-substratum adhesion of a variety of human cells
(Lawler et al 1988, Tuszynski et al 1987b, Varani et al 1986,
Roberts et al 1987, Roberts et al 1985), there is conflicting
evidence concerning the effect of TSP on endothelial cell adhesion
(Lahav 1988, Murphy-Ullrich & Hook 1989). In reports where TSP has
been shown to mediate cell adhesion, this activity could be blocked
by synthetic peptides containing the RGD sequence and by certain
anti-TSP antibodies, suggesting that one or more specific domains
of TSP may be involved in cell-substratum interactions. The lack of
inhibition of endothelial cell adhesion by the rabbit polyclonal
antibody used here could indicate that TSP is not important for the
attachment and spreading of endothelial cells on fibronectin, or
that this antibody is not specifically directed against the region
of the TSP molecule which is active in cell adhesion. There was
evidence to suggest that a serum factor other than TSP was
necessary for the maintenance of adhesion and normal morphology,
since most cells plated in SFM alone became rounded and detached
from the substratum after 76 h, whereas those plated in the
presence of 1% serum remained attached and spread.
Like endothelial cells, fibroblasts synthesise and secrete
relatively large amounts of TSP and the data presented here are
comparable with those reported by others (table 7-2). The variation
in amounts of fibroblast-secreted TSP which have been detected is
probably mainly due to differences in the culture conditions and
160
Table 7-2. Secretion of TSP by fibroblasts
Tissue source Growth medium Secreted TSP Ref.
0
Human foreskin Weymouth's + 2.5 ug/10 cells/18 h (1)
1% porcine serum
Human foreskin MEM + 15.7 ug/10 cells/24 h (2)
20% rabbit serum
Human foetal lung MEM + 5.8 ug/10 cells/24 h (2)
20% rabbit serum
Human foreskin DMEM + 0.36 ug/10 cells/24 h (3)
5% rabbit serum
0
Human foreskin Weymouth's + 3.0 ug/10 cells/24 h (3)
5% rabbit serum
References:
1) Raugi et al 1982
2) Jaffe et al 1983
3) Mumby et al 1984
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assay procedures employed, although the present results show that
the tissue source may also be a factor which determines the
quantity of TSP produced.
MCF-7 breast cancer cells produced much smaller but measurable
amounts of TSP in a continuous, linear manner. Cumulative secretion
over a period of 14 days in serum-free culture confirmed that the
TSP detected in extracellular medium was of MCF-7 cell origin
rather than due to leaching of any TSP adsorbed from the foetal
calf serum used in the initial growth medium. These results
represent the first quantitation of TSP secretion by cells of
epithelial origin and therefore indicate that the production of TSP
is more ubiquitous than has previously been known. Such secretion
is unlikely to fully account for the high levels of TSP found in
breast cancer (section 6.1) but may at least contribute to the TSP
content of that tissue.
Since the growth and metabolism of MCF-7 cells is known to be
modulated by hormones and other factors through binding to specific
cellular receptors, it was of interest to investigate the effects
of these agents on TSP production by MCF-7 cells. Given that the
secretion of TSP by endothelial cells appears to depend solely on
the rate of de novo protein synthesis (Reinders et al 1985), it
might be expected that agents which modulate the latter should also
affect the rate of TSP production in these and perhaps other cell
types. The steroid hormones oestradiol, testosterone and
dihydrotestosterone all caused small increases in TSP secretion by
MCF-7 cells at concentrations which have previously been shown to
stimulate macromolecular synthesis and proliferation of these cells
(Lippman et al 1976a,b). Similarly, the reduction in TSP secretion
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observed in the presence of Cortisol was consistant with previously
reported inhibitory effects of glucocorticoids on the growth of
MCF-7 cells (Lippman et al 1976c). MCF-7 cells have been shown to
be strikingly sensitive to insulin (Osborne et al 1978) and,
indeed, insulin had a marked effect on TSP production. While the
amount of secreted TSP was much lower in the presence of insulin,
that which was associated with the cells themselves increased
considerably, suggesting that insulin may inhibit the transport of
TSP into the extracellular medium by MCF-7 cells.
It has been reported that breast cancer cells produce, and
possess receptors for, several growth factors including EGF, which
may stimulate their growth and mediate some of the effects of
hormones in an autocrine or paracrine manner (Lippman et al 1986).
The present studies showed that EGF had no effect on TSP production
by MCF-7 cells. The modulation of the latter by oestradiol and
other hormones which has been observed was therefore either a
direct hormone effect or was mediated by factors other than EGF.
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CHAPTER EIGHT
PRODUCTION OF MONOCLONAL ANTIBODIES AGAINST THROMBOSPONDIN
In order to facilitate studies of TSP, monoclonal antibodies
(MAbs) were raised to this macromolecule which would potentially be
more powerful research tools than the existing polyclonal rabbit
anti-TSP antiserum. Purified human platelet TSP was used as
immunogen for the generation of murine MAbs in an attempt to
produce a panel of antibodies having a range of TSP-binding
specificities, which could be used to investigate the activities of
this multifunctional glycoprotein. Methods for bulk production and
purification of murine anti-TSP MAbs were developed, and a
preliminary study of the binding activities of the resulting
antibody panel was done using two different assay systems, ELISA
(section 2.8) and SIBA (section 2.9).
The production of monoclonal antibodies against human platelet
TSP was carried out in collaboration with Dr L. Micklem, Department
of Surgery, Edinburgh (see section 2.12 for methods).
8.1 Immunisation of mice with TSP, hybridisation and
production of monoclonal antibodies
Immunisations of mice were carried out on three separate
occasions as follows. Five mice were immunised with human platelet
TSP prepared in the presence of Ca^+ and 6+5 mice immunised with
TSP prepared in the presence of EDTA. None (0%) of the mice which
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received Ca^+-replete TSP produced a detectable antibody response,
whereas six (55%) of those which received Ca^+-deplete TSP showed
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positive responses when their sera were tested for I-TSP binding
in a modified RIA.
Spleen cells from three responding mice were used in
hybridisations and yielded 10 hybridoma cell lines which were
positive for antibody secretion by anti-TSP screening ELISA, from a
total of 329 clones tested. The isotypes and titres of the
monoclonal antibodies produced in bulk by these cell lines are
shown in table 8-1.
8.2 Bulk production of mouse monoclonal anti-TSP antibody by
continuous stirred culture
One clone of cells producing anti-TSP IgM antibodies was grown
in a CelliGen cell culture system. The cell growth curve and
anti-TSP levels over 11 days of continuous stirred culture are
shown in fig.8-1. Production of anti-TSP antibody closely followed
cell growth. During a period of accidentally-induced anoxia in the
middle of the 11-day period, production of anti-TSP activity was
seen to level off. This was then followed by a sharp decrease in
cell viability and anti-TSP activity.
8.3 Purification of mouse monoclonal IgG by affinity
chromatography on protein A
The elution profile for a mouse monoclonal IgG^ anti-TSP
antibody is shown in fig.8-2. Concentrated bulk culture supernatant
was loaded onto a protein A-Sepharose 4B column and eluted as
described in section 2.12.6. Antibody which bound to the column,
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Table 8-1. Murine monoclonal antibodies produced against human
platelet TSP
* *
Antibody Type Titre of bulk Titre of
culture medium ascitic fluid
ESTs3 IgM 10° 103
ESTs4 IgM 10° 104
ESTs6 IgM 10° 103
ESTs8 IgM 10° io4




F189/20.4 IgM 10° 104
F189/53.2 IgG. > io4 > io5
F189/58.1 IgM 10° 103
F189/76.2 IgM 10° 105
*
Highest dilution factor which gave a positive result by ELISA
(section 2.8)
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Fig. 8-1. Production of murine monoclonal antibody (ESTs8) by hybridoma cells
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Fig. 8-2. Purification of murine monoclonal IgG anti-TSP antibody (F189/53.2)
by affinity chromatography on protein A-Sepharose 4B
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and which was separated from other proteins in the culture
supernatant at high pH, was eluted in a peak between pH 6.5 - 5.5.
8.4 Purification of mouse monoclonal IgM by gel filtration on
Sephacryl S-300
The elution profile for a mouse monoclonal IgM anti-TSP antibody
is shown in fig.8-3. Concentrated bulk culture supernatant was
loaded onto a Sephacryl S-300 column and eluted as described in
section 2.12.8. The high molecular weight IgM antibody was
separated from smaller proteins in the culture supernatant, and was
eluted close to the void volume of the column.
8.5 Binding patterns of mouse monoclonal anti-TSP antibodies
to platelet proteins in an enzyme-linked immunosorbant assay
(ELISA)
The ELISA (section 2.8) which was used in the screening of
clones for anti-TSP production, was modified by substituting other
peaks from the separation of thrombin-stimulated platelet
supernatant using heparin affinity chromatography, for TSP in the
coating step. Thus, the ELISA coating solutions A - D corresponded
to the peaks A - D in the elution profile shown in fig.8-4. Each
peak was diluted in 15 mM Tris-HCl, 2 mM CaCl^, 0.02% NaN^, pH 7.6,
to a protein concentration of 10 ug/ml before use.
The following mouse monoclonal anti-TSP antibodies were tested
using this ELISA; ESTs3, ESTs4, ESTs6, ESTs8, F189/2.1, F189/12.3,
F189/20.4, F189/53.2, F189/58.1, F189/76.2 (all as undiluted
culture supernatants), MA-I and MA-II (1/500 dilutions of purified
antibody solutions, 6.3 mg/ml and 7.7 mg/ml respectively; generous
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Fig. 8-3. Purification of murine monoclonal IgM antUSP antibody (F189/20.4)





















gifts from Dr J. Lawler, Boston, USA). Antibodies MA-1 and MA-II
have already been well characterised (Lawler et al 1985).
Results of binding of the monoclonal anti-TSP antibodies to the
various platelet protein peaks in the ELISA are summarised in
table 8-2. In general, antibodies of the IgG^ subclass (F189/12.3,
F189/53.2, MA-I and MA-II) showed much higher binding to TSP than
those of the IgM type, two of which (ESTs3 and ESTs8) were
negative. An exception to this was F189/76.2 (IgM-type) which gave
the strongest binding to all the platelet protein peaks. A wide
range of binding patterns to coating solutions A - D was observed,
each of which was characteristic of the particular antibody used.
8.6 Binding of mouse monoclonal anti—TSP antibodies to human
platelet TSP, proteins from breast cyst fluid, cultured cells and a
variety of animal sera in a slot-immunobinding assay (SIBA)
The following mouse monoclonal anti-TSP antibodies were tested
for binding various antigens in a SIBA (section 2.9); ESTs3, ESTs4,
ESTs6, ESTs8, F189/2.1, F189/20.4, F189/58.1, F189/76.2 (all 1/100
dilutions of ascites), F189/12.3, F189/53.2 (1/1000 dilutions of
antibody solutions, approximately 1 mg/ml, purified from culture
supernatants) MA-I, MA-II (1/1000 dilutions of purified antibody
solutions, 6.3 mg/ml and 7.7 mg/ml respectively), FTI 10, FTI 52,
FTI 53 (1/1000 dilutions of ascites; produced in collaboration with
Prof N. Crawford, Royal College of Surgeons, London).
The antigen preparations (100 ul/slot) used were; human platelet
TSP (diluted 1/20 - 1/20000 in TBS; 320 - 0.32 ng TSP by RIA),
human breast cyst fluid (1/100, 48 ng TSP), normal human serum
(1/100, 17 ng TSP), various animal sera (all at 1/100), serum-free
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Table 8-2. Binding patterns of monoclonal anti-TSP antibodies








ESTs3 — ++ +++ +
ESTs4 + + + + —
ESTs6 + + + - -
ESTs8 - + + + -
2.1 + - +++ +++ -
12.3 +++ - - - ++
20.4 + - - - -
53.2 +++ + +++ +++ +++
58.1 + - - ++ -
76.2 +++ +++ +++ +++ +++
MA-I +++ + ++ +++ +++
MA—II +++ - - - -
Data from several experiments.
Key: - = < 0.2 (0D units; 450nm)
+ = 0.2 - 0.8
++ = 0.8 - 1.4
+++ = > 1.4
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conditioned media from human umbilical artery endothelial cells
(1/2, 70 ng TSP; HUAEC SFCM), human oral fibroblasts (undiluted,
81 ng TSP; HOF SFCM) and MCF-7 human breast cancer cells
(undiluted, 1 ng TSP; MCF-7 SFCM).
Results of the SIBA are shown in figs.8-5a - 8-5g. Again, a wide
range of binding patterns was observed as was the case by ELISA
(section 8.5).
Antibodies which bound strongly to TSP in the ELISA (MA-I,
MA-II, F189/12.3, F189/53.2, F189/76.2) also showed high affinities
for TSP in the SIBA, whilst those which did not bind TSP in the
ELISA (ESTs3 and ESTs8) were also negative by SIBA, even at the
highest TSP loading. It was interesting that ESTs3 and ESTs8 caused
high non-specific binding to the Immobilon PVDF membrane and this
was not observed with any of the other antibodies tested. ESTs6 was
the only antibody which showed a marked difference in TSP-binding
in the SIBA (strong) compared with the ELISA (weak).
Only 4 of the 15 antibodies tested recognised a 1/100 dilution
of a human breast cyst fluid which contained 48 ng TSP/lOOul as
measured by RIA using a rabbit polyclonal antibody (section 2.3).
These antibodies (MA-I, ESTs6, F189/53.2 and F189/76.2) also gave
the strongest binding to platelet TSP (positive with 0.32 ng
TSP/slot) and to serum-free conditioned medium from HUAEC, HOF and
MCF-7 cells.
Of the antibodies which showed appreciable binding to platelet
TSP, only ESTs6 cross-reacted with all the animal sera tested. This
was the only antibody which recognised turkey and chicken sera; the
other animal sera were recognised variably by the remaining
antibodies. An exception to this was goat serum which strongly
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8-5a. Binding patterns of monoclonal anti-TSP antibodies
(MA-I. MA-II) to various antigens in a SIBA
MA—I MA-II
TSP (320 ng) FOETAL CALF
SERUM
(1/100)







TSP (32 ng) DONKEY
SERUM
(1/100)
TSP (3.2 ng) OX
SERUM
(1/100)
TSP (3.2 ng) OX
SERUM
(1/100) Li-
TSP (0.32 ng) SHEEP
SERUM
(1/100)




























































































8-5b. Binding patterns of monoclonal anti-TSP antibodies
(ESTs3, ESTs4) to various antigens in a SIBA
ESTs3
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8-5c. Binding patterns of monoclonal anti-TSP antibodies












































































































































8-5d. Binding patterns of monoclonal anti-TSP antibodies
(F189/12.3, F189/53.2) to various antigens in a SIBA
F189/12.3 F189/53.2
TSP (320 ng) FOETAL CALF
SERUM
(1/100)







TSP (32 ng) DONKEY
SERUM
(1/100)
TSP (3.2 ng) OX
SERUM
(1/100)
TSP (3.2 ng) OX
SERUM
(1/100)
TSP (0.32 ng) SHEEP
SERUM
(1/100)


































































































8-5e. Binding patterns of monoclonal anti-TSP antibodies




































































8-5f. Binding patterns of monoclonal
(F189/58.1, F189/76.2) to various
anti-TSP antibodies
antigens in a SIBA
F189/58.1
TSP (320 ng) FOETAL CALF
SERUM
(1/100)
TSP (32 ng) DONKEY
SERUM
(1/100)
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Fig. 8-5g. Binding patterns of monoclonal
(FTI 10, FTI 52, FTI 53) to various
anti-TSP antibodies





































































































































































bound all the antibodies tested, including those which did not bind
to purified human platelet TSP.
Antibodies which bound to TSP at a loading of 32 ng/slot or less
also bound to HUAEC SFCM (which contained 70 ng TSP/slot) whereas
MCF-7 SFCM (approximately 1 ng TSP/slot) was only recognised by
antibodies with the highest affinities for TSP (positive at a
loading of 3.2 ng/slot or less). An exception to this was antibody
F189/58.1 which did not bind appreciably to purified human platelet
TSP but recognised both HUAEC and MCF-7 SFCM. Although HOF SFCM
contained a comparable amount of TSP (measured by RIA using a
polyclonal antibody) as did that from HUAEC, it was not recognised
by four of the antibodies which bound to the latter (MA-II,
F189/12.3, F189/58.1 and FTI 10).
8.7 Discussion
It was interesting that native TSP, purified in the presence of
Ca2+, did not appear to be immunogenic in mice whereas that
prepared in the absence of Ca2+ produced a detectable antibody
response in over half the animals tested. TSP has been described as
a nodular rod-shaped molecule with certain regions stabilised by
Ca2+ (section 1.5). Removal of Ca2+ may cause these parts of the
polypeptide chains to unravel, producing a more filamentous
structure. The greater immunogenicity of Ca2+-deplete TSP may
therefore be due to such a physical change, allowing some epitopes
(which would not be accessible in the more tightly folded
Ca2+-replete form) to be presented to the host's immune system.
In order to screen for anti-TSP antibodies in the culture medium
of hybridoma cells, it was necessary to develop a solid-phase
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binding assay since the presence of foetal calf serum interfered
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with the binding of I-TSP in the modified RIA. The ELISA
technique has several advantages over RIA which may allow for the
more sensitive detection of antigen-antibody binding:
1) Adsorption of antigen onto solid phase may create a high local
concentration where antibody can bind favourably despite the
presence of free antigen in solution.
2) Solid-phase antigen is not chemically modified (unlike the
iodinated TSP used in RIA) and may fully retain its immunological
characteristics.
3) Use of an enzyme-labelled secondary antibody greatly amplifies
the binding signal.
Despite the advantages of the screening ELISA, the presence of
foetal calf serum could still attenuate the binding of anti-TSP
antibodies which cross-react with bovine TSP (results not shown).
The high proportion of IgM antibodies which were evoked by TSP
(8 out of 10 of the final MAb panel) was an unusual immune
response. This finding was unlikely to have been due to the
selection procedure since a standard immunisation schedule was used
and the screening ELISA was at least as sensitive in the detection
of IgG as IgM. Indeed, the two IgG^ MAbs which were obtained had
the highest titres of all the antibodies, a finding which was
consistant with the general observation that IgG antibodies usually
bind antigens with higher affinities than those of the IgM class.
The preponderance of IgM antibodies might suggest that the immune
response to TSP occurred without the involvement of helper T-cells,
since T-independent antigens evoke primarily IgM antibodies (Roitt
et al 1985). Furthermore, the few known T-independent antigens are
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all large polymeric molecules with repeating antigenic
determinants, and TSP is a trimer of identical subunits which has a
tendency to self-aggregate into large molecular weight oligomers
(Booth et al 1985, Clezardin et al 1986b).
Results from the CelliGen cell culture system suggested that
continuous stirred culture was a suitable alternative to flat-bed
culture for the bulk production of MAb. It was evident that the
duration of culture was an important factor in determining the
maximum antibody titre. This was optimal shortly after the number
of viable cells reached its peak. As cells began to die, the
anti-TSP activity decreased, possibly due to degradation of the
relatively unstable IgM molecule by released enzymes and the
increasingly acidic conditions.
Two different characteristics of IgG and IgM antibodies were
utilised for their purification from bulk culture supernatants.
IgG^ (and other IgG subclasses) binds specifically to protein A, a
42 kdal polypeptide of the cell wall of Staphylococcus aureus
(Harlow & Lane 1988). Using an immobilised form of protein A,
murine anti-TSP MAbs of this subclass were separated from other
constituents of the culture supernatant by affinity chromatography.
Thus, IgG^ molecules were specifically adsorbed onto a protein
A-Sepharose 4B column at pH 8 and then desorbed by reducing the pH
after non-adsorbed proteins had been washed through.
IgM antibodies do not bind to protein A but, because of their
large size (molecular weight approximately 900,000), could be
separated from most other proteins by gel filtration chromatography
using a Sephacryl S-300 column. The IgM molecules were excluded by
the Sephacryl beads and eluted close to the void volume, while
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smaller proteins were retained for longer on this column.
All the anti-TSP MAbs, except ESTs3 and ESTs8, were able to
recognise purified human platelet TSP adsorbed either onto
polystyrene (ELISA) or onto a polyvinylidene difluoride membrane
(SIBA). The well-characterised antibodies MA-I and MA-II showed
unique binding patterns in the ELISA and SIBA, as did the other
MAbs tested. MA-I has been shown to bind to a portion of the
connecting region of TSP near the C-terminal globular domain while
the epitope of MA-II is located in the N-terminal globular domain
(Lawler et al 1985). It was interesting that in the ELISA, MA-II
bound only to TSP which had a normal heparin-binding affinity and
is directed against the heparin-binding domain of TSP, whereas MA-I
recognised all the peaks from a thrombin-stimulated platelet
releasate separated by heparin-affinity chromatography. It may be
concluded that peaks A - D used in the ELISA contained TSP (as
demonstrated by RIA and MA-I binding) but which had altered
heparin-binding affinities, possibly due to partial degradation
causing loss of the N-terminal globular domain, or to complex
formation with other platelet cx-granule components. The unique
binding patterns observed for each MAb in both assay systems may be
evidence that they are directed against different epitopes of the
TSP molecule, as has been shown for MA-I and MA-II. Without further
studies however, the possibility cannot be excluded that at least
some of the MAbs could be directed against other proteins which
might have been present in small amounts in the TSP preparations
used as immunogens.
The results from the SIBA are considered to be the first
demonstration of binding of murine anti-TSP MAbs to TSP from
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various sources using this technique. The order of their
TSP-binding affinities was generally comparable to thu?~ observed
by ELISA, with the exception of ESTs6, which had the highest
affinity for human platelet TSP in the SIBA but one of the lowest
by ELISA. This could indicate that TSP bound to polyvinylidene
difluoride has a different conformation to that adsorbed onto
polystyrene.
The binding patterns of the MAbs to the various antigens tested
in the SIBA may be explained in part by their different affinities
for platelet TSP. Thus, only those MAbs which showed the highest
affinities for TSP also recognised a human breast cyst fluid and
serum-free conditioned media from three different cell types.
Although it would be interesting to speculate more, further
conclusions cannot be drawn from the data without full
characterisation of the MAbs.
MAbs, by nature of their single-epitope specificity, are
potentially more useful than polyclonal antisera in studies of the
structure and function of TSP. Given that separate domains of the
TSP molecule appear to be responsible for its various activities
(sections 1.3 and 1.4), it should be possible to produce MAbs
against specific domains which block the functions of TSP mediated
by those domains. Indeed, several such MAbs have already been
described (Galvin et al 1985, Dixit et al 1985, Roberts et al 1987)
and it remains to be seen whether the MAbs described here will be




IMMUNOCYTOCHEMICAL LOCALISATION OF THROMBOSPONDIN
In order to investigate and define the cell types responsible
for the production of TSP in vivo, particularly in the breast,
sections of various different tissues and cytospin preparations of
isolated cells were used for immunocytochemical studies with
antibodies to human platelet TSP.
Formalin fixed, paraffin embedded sections of human breast
cancer and lactating goat mammary gland were provided by
Dr D. Harrison, Department of Pathology, University of Edinburgh.
Cytospin preparations of human skin mast cells were provided by
Dr M. Church, Clinical Pharmacology Group, University of
Southampton. Studies of tonsil, umbilical cord and HUVEC cytospin
preparations were done in collaboration with Dr N.R. Hunter,
Scottish National Blood Transfusion Service Headquarters Unit
Laboratory, Edinburgh.
9.1 Human breast cancer
TSP was localised in human breast cancer by the PAP technique
(section 2.10.2) using a specific polyclonal rabbit anti-TSP
antiserum (diluted 1/10). A negative control was performed by
substituting normal rabbit serum (diluted 1/10) for the 1st layer
antibody. Figs. 9-1 and 9-2 show, at low magnification, a group of
lobules from the control and test slides respectively. The negative
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Fig. 9-1. Human breast cancer: PAP technique, negative control
total magnification 170x
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Fig. 9-2. Human breast cancer: PAP technique, anti-TSP
total magnification 170x
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control had light background staining only, while the anti-TSP
antiserum gave intense staining of isolated mononuclear cells
scattered variably throughout the interlobular stroma, which itself
was more heavily stained than in the control. Fig. 9-3 illustrates
a region of the test slide at high magnification, showing intense
cytoplasmic staining of one of the cells in the interlobular
stroma, lighter staining of the stromal material, and absence of
staining of the lobules.
TSP was also localised in other sections of the same tissue by
the indirect immunoperoxidase technique (section 2.10.1) using
murine monoclonal anti-TSP antibody F189/53.2 (purified from
culture supernatant, diluted 1/100). Results were similar to those
obtained with the specific polyclonal antiserum, and fig. 9-4
shows, at high magnification, a group of intensely stained cells in
the interlobular stroma.
Human breast cancer was also stained with toluidine blue, a
basic dye which turns a characteristic purple colour upon
interaction with acid mucopolysaccharides (e.g. heparin). Fig. 9-5
shows, at high magnification, three cells in the stroma which have
intense cytoplasmic metachromatic staining. This distribution of
staining by toluidine blue was indistinguishable from that observed
during the localisation of TSP in human breast cancer by
immunocytochemical techniques.
9.2 Goat mammary gland
Mammary gland tissue from a normal, primiparous, lactating goat
was provided by Dr R. Nowak, AFRC Institute of Animal Physiol gy
and Genetics Research, Cambridge. TSP was localised in goat mammary
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Fig. 9-3. Human breast cancer: PAP technique, anti-TSP
total magnification 700x
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Fig. 9-4. Human breast cancer: Indirect immunoperoxidase, anti-TSP
total magnification 700x
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Fig. 9-5. Human breast cancer: Toluidine blue
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gland by the indirect immunoperoxidase technique using murine
monoclonal antibody F189/53.2 (purified from culture supernatant,
diluted 1/1000). A negative control was performed by substituting
normal mouse serum (diluted 1/100) for the 1st layer antibody.
Figs. 9-6 and 9-7 show, at low magnification, areas of mammary
gland from the control and test slides respectively. The negative
control had light background staining of the interlobular stroma
only, while antibody F189/53.2 gave strong staining throughout the
interlobular stroma and absence of staining of the lobules.
Fig. 9-8 illustrates a region of the test slide at high
magnification, showing strong staining of the stromal material and
an absence of stained cells, either in the stroma or the lobules.
9.3 Other tissues and cells
Murine monoclonal anti-TSP antibodies were used to localise TSP
in other human tissues and cells (results not shown).
In tonsil, there was strong staining of venous and arterial
endothelium, of cellular elements in the germinal centres (possibly
macrophages), variable staining of connective tissue and possible
staining of T-lymphocytes.
In umbilical cord, TSP was localised in venous and arterial
endothelium.
Cytospin preparations of HUVEC showed granular staining of the
cytoplasm, while those of mast cells isolated from human foreskin
were negative.
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It is surprising that, given its synthesis and secretion by a
wide variety of cultured cells (section 1.5), TS? does not appear
to be prevalent in tissues in vivo. Wight et al (1985) used
immunofluorescence techniques to demonstrate the presence of TSP in
human peritubular connective tissue, basement membranes at
dermal-epidermal junctions and beneath glandular epithelium in skin
and lung, skeletal muscle interstitial connective tissue and in
small blood vessels and aorta. They concluded that TSP was a
component of the extracellular matrix of some tissues while
confined to basement membrane regions of others, and suggested that
TSP may be a general constituent of loose connective tissues. In
contrast, Murphy-Ullrich & Mosher (1987) were unable to obtain
specific staining of various human adult tissues using antibodies
to platelet TSP. However, they did observe extensive staining of
loose connective tissue in human foetal limb, indicating that TSP
may be a major component of extracellular matrix only during
certain periods of development or a cell's life span.
Alternatively, TSP could be present in adult tissues but not
detected because of a lack in assay sensitivity, the masking of an
epitope, or conformational differences which cause the antigen to
be unrecognisable by the antibodies used. Indeed, evidence for such
a polymorphism between platelet, endothelial cell and fibroblast
TSPs has been reported (Clezardin et al 1986b).
In the present study, a restricted distribution of TSP was also
observed in several different tissues and cells. Immunoperoxidase
staining of tonsil and umbilical cord using specific polyclonal >r
monoclonal antibodies to human platelet TSP showed the presence of
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TSP in connective tissue and in blood vessel endothelium, similar
to the results obtained by Wight et al (1985) in other tissues.
Localisation of TSP within the endothelium was supported by
positive staining of cytospin preparations of cultured HUVEC.
TSP was also strongly immunolocalised throughout the stromal
connective tissue of normal lactating goat mammary gland, but only
weakly in the stromal material of human breast cancer. Comparisons
of non-lactating/lactating and of normal/malignant breast were not
possible due to the unavailability of non-diseased breast tissue.
Nevertheless, the abundance of TSP in the stroma of lactating goat
mammary gland is interesting considering the high levels of TSP
which have been found in goat and human milk, particularly during
the initiation of lactation (Dawes et al 1987, section 5.2). The
lack of staining of lobules in both normal and malignant mammary
gland indicates that mammary epithelial cells are probably not a
major source of TSP in these tissues, and is consistant with the
low production of TSP by cultured breast cancer cells which has
been observed (section 7.3).
The stroma of human breast cancer, but not that of normal goat
mammary gland, contained variable numbers of intensely staining
mononuclear cells. A similar distribution of stained cells was
obtained using toluidine blue, which reacts with heparin (and other
acid mucopolysaccharides) in mast cell granules. However, cytospin
preparations of human skin mast cells were negative for TSP,
suggesting that the intensely staining cells of breast cancer
stroma may be a different type of infiltrating cell. Studies of
tonsil showed that TSP could be localised in cells (possibly
macrophages) in the germinal centres. Also, TSP is known to be
199
synthesised and secreted by macrophages and monocytes (Jaffe et al
1985). Furthermore, solid human tumours (such as breast cancer) are
sometimes characterised by a marked mononuclear cell infiltrate,
frequently consisting of macrophages and various types of
lymphocyte as well as minority populations of plasma cells and mast
cells (Roitt et al 1985). This infiltration may vary from florid to
none at all, and rarely follows a consistant or predictable
pattern. Thus, if such cells are a major source of TSP in breast
cancer, then the large variation in extent of infiltration may
account for the wide range of TSP levels which have been found in
malignant breast tissue (section 6.1). The question would then
arise as to the possible role of TSP in macrophage function and the




When this project was commenced in 1985, the physiological role
of TSP was ill-defined, and though its involvement in platelet
aggregation is well recognised, many questions regarding the
function of TSP remain unanswered. By studying the production and
distribution of TSP in a broad range of cells, tissues and body
fluids it was hoped that some clues would emerge as to the wider
importance of this glycoprotein.
The studies described in this thesis were dependent to a large
extent on a regular supply of freshly prepared human platelet
concentrates as the source from which TSP could be purified for use
in various immunoassays, in structural studies, and as an immunogen
for the generation of MAbs. No commercial TSP preparation was, nor
at the present time is, available as an alternative. Since TSP is
relatively labile towards proteolysis, and the yield from
purification procedures is low, the availability of a suitable
source of TSP may become a limiting factor in research studies.
When platelet function is normal, stimulation of these cells by
thrombogenic agents and the subsequent release of oc-granule
constituents is the major factor which determines the level of TSP
in the circulation. However, extra-platelet sources such as
endothelial cells and white blood cells may contribute
substantially to basal plasma TSP levels as has been demonstrated
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in thrombocytopenic patients, and it is not known to what extent
these sources may be stimulated in various pathophysiological
situations. For example vWF, an endothelial cell adhesive protein,
was elevated in the plasma of patients following general surgery,
possibly due to increased endothelial cell activity during wound
healing, while TSP has been localised to vessel walls and is
particularly abundant in atherosclerotic lesions (Wight et al
1985).
The long half-life of TSP in the circulation is probably related
to its high molecular weight (making TSP too large to be filtered
at the glomerulus). TSP catabolism most likely occurs in the liver,
but little is known of this excretory pathway; further studies to
define the mechanisms involved would be helpful in understanding
the control of circulating TSP levels and the role of TSP in
haemostasis and thrombosis.
Measurement of plasma levels of a-granule proteins is not a
reliable indicator of the extent of in vivo platelet activation in
clinical situations where rates of catabolism and clearance are
modulated by disease. The potential use of surface-associated TSP
measurements on fixed, isolated platelets as an alternative to
plasma concentrations for assessing platelet activation is worthy
of further study and may find clinical use in many conditions
including thrombosis, vascular disease, myeloproliferative
disorders, leukaemia and diabetes.
Novel studies of TSP in the breast have increased the breadth of
knowledge regarding its occurrence and significance in biological
fluids and tissues. The remarkably high levels of TSP in type II
cyst fluids, early milk, other breast secretions and malignant
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breast tissue suggest that TSP may have an important function in
the mammary gland, although no physiological role has yet been
identified. However, the data may point to an involvememt of TSP in
the activity of certain white blood cells (possibly macrophages)
which infiltrate the interstitial connective tissues of the breast,
particularly during the peripartum period and in breast cancer. It
may be that TSP has a role in macrophage function which is of equal
physiological importance as that which has long been recognised in
platelets. Further work aimed at defining such a role for TSP and
its possible involvement in the interactions of macrophages, the
immune system and malignant cells may prove to be most interesting.
Cultured cell systems, similar to those described in chapter 8,
will continue to be useful models for studying the synthesis and
secretion of TSP and its role in cell-cell and cell-matrix
interactions. The increasing availability of MAbs which can inhibit
specific functions of TSP will allow the molecular mechanisms
underlying such interactions to be investigated.
To date, little is known of the functional importance of the
carbohydrate moiety of TSP. Although the full amino acid sequence
of TSP has now been determined, knowledge of the structural
organisation of its sugar residues remains incomplete. The
possibility exists for variation in the carbohydrate moiety between
TSPs produced by different cell types, which could give rise to
altered functional properties. Research along these lines may lead
to a greater understanding of how TSP could be involved in such
apparently diverse physiological processes as platelet aggregation,
fibrinolysis, cell-matrix interactions, tissue development, wound
healing, immune responses and malignant disease.
203
In summary, the results presented in this thesis support current
knowledge of TSP as an adhesive glycoprotein of platelets, vessel
walls and connective tissues, but indicate that TSP is more
ubiquitous than previously thought. While platelets are the major
source of TSP in the circulation, different cell types appear to be
responsible for the production of this glycoprotein in other body
fluids and in tissues. Novel studies in the breast have revealed a
marked association of TSP with cancerous tissue and some cyst
fluids which could be due to production by vascular endothelium and
certain white blood cells. While the role of TSP in the breast
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Thrombospondin is a 450-kDa glycoprotein secreted by a variety of cells including endothelial cells, fibroblasts
and platelets. The aim of this study was to compare the structural and immunological properties of human
endothelial, fibroblast and platelet thrombospondins. All three thrombospondins were purified, digested with
thermolysin, and the subsequent thermolysin-generated fragments isolated on a Superose 12 gel-permeation
column using non-denaturating conditions. Each isolated proteolytic fragment of thrombospondins was then
detected using either a radioimmunoassay with a polyclonal antibody or an enzyme-linked immunosorbent assay
with three monoclonal antibodies (P10, MA-I, MA-II) directed against different epitopes of whole platelet
thrombospondin. The fragmentation pattern of human endothelial thrombospondin consists of six major
thermolysin-generated fragments (135 — 110, 98 — 82, 54— 47, 25 — 20, 18—f5 and 10 kDa) having molecular
masses very similar to those observed with human fibroblast thrombospondin (115 — 100, 92— 80, 54 — 49, 27 —
21, 17— 13 and 12—10 kDa). Treatment of platelet thrombospondin with thermolysin only generated four
proteolytic fragments having molecular masses of 110, 50, 25 and 12/10 kDa respectively. All these proteolytic
fragments of endothelial, fibroblast and platelet thrombospondins were recognized by a polyclonal antibody.
Monoclonal antibodies MA-I and P10 essentially recognized two proteolytic fragments (135—110,-98 — 82 kDa)
of endothelial and fibroblast (115 — 100, 92 —80 kDa) thrombospondins, and the 110-kDa fragment of platelet
thrombospondin. Monoclonal antibody MA-II recognized three proteolytic fragments (54— 47, 25 — 20, 18 —
15 kDa) of endothelial and fibroblast (54— 49, 27 — 21, 17—13 kDa) thrombospondins, and two fragments (50,
25 kDa) of platelet thrombospondin, different from those detected by P10 an MA-I. The results clearly demon¬
strate that, under non-denaturating conditions, endothelial and fibroblast thrombospondins are structurally
different from platelet thrombospondin since two fragments of endothelial thrombospondin (98 — 82, 18 —
15 kDa), equivalent to those of fibroblast thrombospondin (92 — 80, 17— 13 kDa), are not released from platelet
thrombospondin after thermolysin treatment. These three forms of thrombospondin are, however,
immunologically indistinguishable. To investigate further the structural differences observed between platelet and
the two other forms of thrombospondin, their degree of polymerization was compared. Prior to thermolysin
treatment, the three forms of thrombospondin were separated into several oligomers ranging from 450 kDa to
3300 kDa when injected onto a Superose 6 gel-permeation column. In the presence of thermolysin, platelet
thrombospondin oligomers were all digested whereas the 3300 kDa oligomer of endothelial or fibroblast thrombo¬
spondin was unaffected. All these oligomers were recognized by a polyclonal antibody and three monoclonal
antibodies directed against platelet thrombospondin. Such a resistance to proteolysis of endothelial and fibroblast
thrombospondins does explain the structural differences observed in this study, and therefore suggests that the
conformational properties of these two forms of thrombospondin are different from those of platelet
thrombospondin.
Correspondence to P. Clezardin, INSERM U63, Laboratoire
d'Hemobiologie, Faculte de Medecine Alexis Carrel, Rue Guillaume
Paradin, F-69372 Lyon Cedex 02, France
Abbreviations. HUVEC, Human umbilical cord vein endothelial
cells; HUAEC, human umbilical cord artery endothelial cells;
HSVEC, human saphenous vein endothelial cells; HOP", human oral
fibroblasts; HFF, human foreskin fibroblasts; HSF, human forearm
skin fibroblasts; FPLC, fast protein liquid chromatography; SDS,
sodium dodecyl sulfate; TMB, 3,3',5,5'-tetramethylbenzidine.
Enzymes. Thermolysin (EC 3.4.24.4); horseradish peroxidase (EC
1.11.1.7).
Thrombospondin is secreted from human blood platelet
a-granules following stimulation [1] and binds to the surface
of activated platelets in the presence of physiological concen¬
trations of calcium [2], This molecule is also secreted and
incorporated into the extracellular matrix by a variety of
cultured cells including endothelial cells [3, 4], fibroblasts [5,
6], smooth muscle cells [5], monocytes [7] and some macro¬
phages [7, 8],
Thrombospondin, in its native state, is a glycoprotein
composed of four globular regions stabilized with calcium,
570
vhich are unravelled in the presence of EDTA [9], This
inravelling results in an increased susceptibility of thrombo-
pondin to protease attack [9], Thrombospondin has a molec-
ilar mass of 450 kDa [9] and forms oligomers ranging from a
timer to a 40000-kDa polymer when released from stimulated
ilatelets [10], The native monomeric form of thrombospondin
s composed of three equivalent disulphide-linked chains of
50—160 kDa [9]. Each thrombospondin chain is made up
>f several protease-resistant domains, which differ in their
liological activities [11 — 19]. Some of these functional
lomains have been separated by limited proteolysis and sub-
equent affinity chromatography using different ligands [12,
9-22],
Following isolation of trypsin-generated and thermolysin-
;enerated fragments of thrombospondin by gel-permeation
ast protein liquid chromatography (FPLC), and immuno-
letection of each isolated proteolytic fragment by a panel
if polyclonal [23] and monoclonal antibodies [24] specific
or platelet thrombospondin, we recently reported a poly-
lorphism between human thrombospondins purified from
ilatelets and foetal vein endothelial cells cultivated at con-
luence [25], However, since changes in the glycosylation of
lycoproteins take place in human endothelial cells as they
pproach confluence in culture [26], we could not exclude
rom our preliminary study [25] the possibility that such
hanges occurred in the carbohydrate moiety of endothelial
hrombospondin when purified from confluent cells, thus
ccounting for the structural differences previously observed
etween the two forms of thrombospondin. In addition,
ualitative and quantitative differences occur in the secretory
henotypes of foetal and adult endothelial cells [27— 29]. For
hese reasons, we are reporting in this study the comparison
f the structural and immunological properties of human
hrombospondins isolated from platelets and from
^upernatants of foetal and adult endothelial cells cultivated
at subconfluence and confluence. In addition we have ex¬
tended our study to the structural and immunological
characterization of human thrombospondin isolated from
adult fibroblasts cultivated at confluence and subconfluence.
The thermolysin fragmentation patterns of platelet,
endothelial and fibroblast thrombospondins as well as their
degree of polymerization were compared by gel-permeation
fast liquid chromatography under non-denaturating con¬
ditions, followed by the immunological characterization of
each isolated proteolytic fragment using a polyclonal [23] and
three monoclonal antibodies (P10, MA-I, MA-11), two of
them (P10 and MA-II) directed against functional domains
of platelet thrombospondin [30, 31], The results indicate that,
whatever the foetal or adult origin of the cells may be,
endothelial and fibroblast thrombospondins are structurally
different from platelet thrombospondin.
EXPERIMENTAL PROCEDURE
FPLC separations were either performed on a Superose
12 HR 10/30 or a Superose 6 HR 10/30 gel-filtration column
(300 x 10 mm) (Pharmacia, Uppsala, Sweden). The Superose
12 and 6 columns separate proteins ranging from 1 kDa to
500 kDa and 5 kDa to 5000 kDa respectively. Thermolysin
was from Sigma (St Louis, MO, USA). Materials and
chemicals, unless stated otherwise, were as previously in¬
dicated [24, 25,31,32],
Cell culture
Human foetal and adult endothelial cells from eight
donors were obtained from the following sources: H7, Hll,
H24, H32 and H55 were foetal endothelial cells isolated from
the human umbilical cord vein; H56 was foetal endothelial
cells isolated from the human umbilical cord artery; LAY2
and SAP2 were adult endothelial cells isolated from the
human saphenous vein. Human adult fibroblasts from four
donors were obtained from the following sources: F34 was
fibroblasts isolated from the normal human foreskin (a gener¬
ous gift of Dr G. Priestley, Edinburgh); F5 and F22 were
fibroblasts isolated from the normal human forearm skin (a
generous gift of Dr G. Priestley); CI was normal human oral
fibroblasts (a generous gift of Dr Y. Barlow, Edinburgh).
Human endothelial cells and fibroblasts were cultured using
methods and materials previously described [29]. Cell super-
natants were harvested at subconfluence and confluence.
Purification ofhuman thrombospondins from platelets,
endothelial cells andfibroblasts
Thrombospondins secreted from thrombin-stimulated
platelets and into the culture medium of human endothelial
cells and fibroblasts were purified by a modification of the
methods of Lawler et al. [9] and Clezardin et al. [32], Brief¬
ly the culture medium (50—100ml) from both endothelial
cells and fibroblasts or the supernatant (15 —30 ml) from
thrombin-stimulated platelets were loaded onto a heparin-
Sepharose column (120 x 20 mm) equilibrated in 20 mM Tris
buffer, pH 7.4, containing 0.35 M NaCl (buffer A). The
column was washed successively with 0.35 M, 0.55 M and
2 M NaCl in buffer A. The thrombospondin peak eluting at
0.55 M NaCl was then applied to a gelatin-Sepharose column
previously equilibrated in buffer A containing 0.55 M NaCl.
The flow-through material from the gelatin-Sepharose column
was then concentrated (0.5 — 0.7 ml) and gel-filtered through
a Superose 12 column connected to a FPLC system and
equilibrated with 20 mM triethanolamine buffer, pH 7.4,
containing 0.35 M NaCl. The thrombospondin peak (2 ml)
eluted from the Superose 12 column at a molecular mass of
450 kDa. Some thrombospondin preparations were further
purified on a Mono Q anion-exchange column connected to
a FPLC system following a previously described method [32].
Thermolysin digestion ofpurified thrombospondins
Thermolysin digestion was performed using purified
thrombospondin prepared in the presence of 20 mM tri¬
ethanolamine (pH 7.4) and 0.35 M NaCl. The protease to
thrombospondin ratio was 1:20 (w/w) at 37°C. After 90 min
of incubation the digestion of thrombospondin was ter¬
minated by addition of 10 mM EDTA. In some experiments
a negative control was included by incubating purified
thrombospondin with 10 mM EDTA prior to thermolysin
treatment. Under such experimental conditions no proteolytic
degradation of thrombospondin occurred, indicating a total
inhibition of the enzymatic activity of thermolysin by EDTA
as reported by Clezardin et al. [33].
Isolation of thrombospondin proteolytic fragments
by gel-permeation chromatography
The Superose 12 and 6 HR 10/30 gel-permeation columns
were used to compare the thermolysin fragmentation patterns
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platelet, endothelial an fibroblast thrombospondins. Prior
chromatography the Superose 12 and 6 columns were
uilibrated with 20 mM triethanolamine buffer (pH 7.4)
ntaining 0.35 M NaCl. Samples of thronrbospondin digests
5 — 0.7 ml) were directly injected onto the column at a flow
:e of 0.5 ml/min.
\munodelection of thrombospondin proteolytic fragments
!ng a radioimmunoassay with a polyclonal antibody
ected against platelet thrombospondin
Using a polyclonal antibody the isolated proteolytic
gments of thrombospondins were immunodetected by
mpetitive radioimmunoassay following a method pre-
>usly described by Dawes et al. [23]. Briefly, 50 pi of each
lated proteolytic fragment were mixed with I25I-labelled
itelet thrombospondin (50 pi 10 ng/ml) and a rabbit
lyclonal antibody (50 pi, 1:1200 dilution) directed against
iole platelet thrombospondin. After incubation overnight
4°C, 50 pi buffer containing 8.3 pi Sepharose-4B-coupled
nkey anti-(rabbit IgG) were added, and the tubes were
:ubated with shaking for 45 min at 20 °C. Sepharose-bound
iterial was separated from that remaining in the liquid phase
sedimentation of the solid phase through assay buffer
naming 10% (w/v) sucrose and removal of the supernatant
aspiration.
munodetection of thrombospondin proteolytic fragments
ng an enzyme-linked immunosorbent assay
It three monoclonal antibodies directed
linst different epitopes ofwhole platelet thrombospondin
The mouse monoclonal antibodies used had been pre¬
viously characterized [30, 31]. Mouse monoclonal antibodies
MA-11 [30] and P10 [31] were directed against epitopes located
within the heparin-binding domain and near the hemag¬
glutinin activity domain respectively. MA-1 [30] was directed
against a 47-kDa tryptic fragment of platelet thrombospondin
as judged by sodium dodecyl sulphate (SDS)/polyacrylamide
gel electrophoresis. When assayed in a radioimmunoassay it
was observed that the buffer used to equilibrate the Superose
12 and 6 columns affected the binding ofmonoclonal antibody
P10 to the isolated thrombospondin proteolytic fragments
whereas the binding of the polyclonal antibody was not
affected. Such an observation has also been reported by
Dawes et al. [34] using different monoclonal antibodies
directed against human a-thrombin. The unusual behaviour
of P10 explains the immunological differences previously ob¬
served between platelet and foetal endothelial thrombo¬
spondins [25], For this reason the proteolytic frag¬
ments of thrombospondins were immunodetected by an
enzyme-linked immunosorbent assay following modifications
of the method described by Bos et al. [35]. Briefly, 100 pi of
each isolated proteolytic fragment were added in duplicate to
96 microtitre plates with fiat-bottom wells (Linbro/Titertek,
Flow Laboratories Inc.) and incubated 48 h at room tempera¬
ture. Negative and positive controls were phosphate-buffered
saline instead of proteolytic fragments (negative control) and
purified thrombospondin (positive control). After incubation,
the wells were washed four times with 250 pi/well phosphate-
buffered saline containing 0.1% Tween 20 (v/v) (washing
buffer). The last wash was left for 30 min at room tem¬
perature. After removing the washing buffer, 100 pi anti-
thrombospondin mouse IgG monoclonal antibody (diluted to
1/10000) were added to each well for 1 h incubation at 37°C.
At this stage a mouse IgG monoclonal antibody not directed
against thrombospondin was used at a dilution of 1/10000 as
a second negative control. After incubation, the contents of
the wells were aspirated and rinsed four times with the washing
buffer. 100 pi goat anti-(mouse IgG) conjugated with
horseradish peroxidase (diluted to 1/3000) (Bio-Rad Labora¬
tories) were added to each well for an additional 1 h incuba¬
tion at 37°C. The contents of the wells were then aspirated
and rinsed four times with the washing buffer. 100 pi
dimethylsulfoxide containing 42 mM 3,3',5,5'-tetramethyl-
benzidine (TMB) were mixed with 10 ml 0.1 M sodium/
acetate/citric acid buffer, pH 6.0 (TMB solution). Just
before use, the substrate solution was constituted by adding
100 pi 1.3 mM hydrogen peroxide to the TMB solution.
Finally 100 pl/well of this substrate solution were added and
the enzyme reaction was allowed to proceed for 10 min in the
dark at room temperature. The reaction was then stopped
with 100 pl/well 2.5 M sulphuric acid. The absorbance was




of thrombospondin purifiedfrom human umbilical cord vein
endothelial cells (HUVEC) cultivated at subconfluence
and confluence
Thrombospondin purified from the confluent foetal vein
endothelial cells (HUVEC line HI 1 P9) showed a single peak
at 450 kDa when injected on a Superose 12 gel-permeation
column (Fig.lA). Thermolysin digestion of Hll P9 endo¬
thelial thrombospondin from confluent cells generated six
major peaks, two of which eluted after the total volume of the
column (Fig. 1 B). The proteolytic fragments corresponding
to these peaks had molecular masses (120, 95, 53, 24, 15
and 10 kDa) (Table 1) very similar to those observed after
thermolysin digestion of endothelial thrombospondin purified
from the same foetal cell line (Hll P9) cultivated at sub-
confluence (Fig. 1C and Table 1). In addition the thermolysin
digestion of thrombospondin purified from four other
confluent foetal vein endothelial cell lines (H24, H32, H7 and
H55) gave proteolytic fragments with molecular masses very
close to those previously mentioned (Table 1). Despite
similarities in the molecular masses of these proteolytic
fragments, their respective elution profiles from the Superose




purifiedfrom human umbilical cord artery (HUAEC)
and human saphenous vein endothelial cells (HSVEC)
cultivated at subconfluence and confluence
In order to ascertain whether the thermolysin fragmenta¬
tion pattern of endothelial thrombospondin was unique, we
have compared the structural properties of thrombospondin
from foetal vein endothelial cells (HUVEC) with those of
thrombospondin purified from foetal artery and adult vein
endothelial cells.
The thermolysin digestion of thrombospondin purified
from the confluent foetal vein endothelial cells (HUVEC line
Hll P9) generated six main peaks, two of which eluted after
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ig. 1. Comparison of the thermolysin-generatedfragments of thrombo-
oondin purified from human umbilical cord vein endothelial cells
HUVEC) cultivated at subconfluence and confluence. (A) Thrombo-
pondin purified from the HUVEC line Hll P9. (B) Thermolysin
igests of Hll P9 endothelial thrombospondin purified from
onfluent cells. (C) Thermolysin digests of Hll P9 endothelial
irombospondin purified from subconfluent cells. The thermolysin/
irombospondin ratio was 1:20 (w/w). After 90 min of incubation at
7°C the thermolysin digestion of thrombospondin was terminated
y addition of 10 mM EDTA. A Superose 12 gel-permeation column
onnected to a FPLC system was equilibrated with 20 mM triethanol-
mine buffer (pH 7.4) containing 0.35 M NaCl. Samples of
irombospondin digests (0.5 — 0.7 ml) were directly injected onto the
alumn at a flow rate of 0.5 ml/min
the total volume of the column (Fig. 2A). The proteolytic
fragments corresponding to these peaks (120, 95, 53, 24, 15
and 10 kDa) (Table 1) had molecular masses very similar to
those observed after thermolysin digestion of thrombo¬
spondin purified from both confluent foetal artery (HUAEC
line H56) (Fig.2B and Table 1) and adult vein endothelial
cells (HSVEC lines LAY2 and SAP2) (Fig.2C and Table 1).
In addition, the thermolysin fragmentation patterns of
thrombospondin isolated from foetal artery (HUAEC line
H56 P5) and adult vein endothelial cells (HSVEC line LAY2
P5) were similar at subconfluence and confluence (Table 1).
However, when the thermolysin fragmentation patterns of
foetal and adult endothelial thrombospondins (Fig. 2 A—C)
were compared with that of platelet thrombospondin (Fig.
2D), clear differences were observed. Two proteolytic
fragments of 98 —82kDa and 18 — 15 kDa, respectively, were
absent after thermolysin digestion of platelet thrombospondin
(Table 1).
Isolation of thermolysin-generatedfragments
of thrombospondin purifiedfrom human oral (HOF),
foreskin (IIFF) and skin (HSF) fibroblasts
cultivated at confluence and subconfluence
Thrombospondin purified from the confluent adult oral
fibroblasts (HOF line CI) showed a single peak at 450 kDa
Table t. Thermolysin-generated fragments of human endothelial
thrombospondin obtained after gel-permeation chromatography on a
Superose 12 column
In the cell denominations P followed by a number indicates the
passage number. The molecular mass value of each proteolytic frag¬
ment of platelet thrombospondin represents an average obtained
throughout the course of this study
Origin Denomination Proteolytic fragments
of cells
kDa
HUVEC H24 P8 450 120 85 50 22 16 10
HUVEC H32 P4 450 120 98 54 25 18 10
HUVEC H7 P12 450 120 82 54 25 15 10
HUVEC H55 P6 450 120 82 52 20 16 10
HUVEC Hll P9a 450 115 87 50 20 15 10
HUVEC Hll P9 450 120 95 53 24 15 10
HUVEC Hll P10 450 135 84 47 21 15 10
HSVEC LAY2 P5a 450 120 90 54 24 15 10
HSVEC LAY2 P5 450 120 90 54 22 16 10
HSVEC SAP2 P5 450 115 95 54 24 15 10
HSVEC SAP2 P6 450 115 95 54 23 16 10
HUAEC H56 P4 450 110 85 45 23 17 10
HUAEC H56 P5a 450 120 90 54 25 15 10
HUAEC H56 P5 450 no 85 50 24 16 10
HUAEC H56 P6 450 110 87 47 22 17 10
Human platelets 450 110 50 25 12/10
a Cells cultured at subconfluence.
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Fig. 2. Comparison of the thermolysin-generatedfragmentsof thrombo¬
spondin purifiedfrom humanfoetal and adult endothelial cells with those
of thrombospondin purified from human platelets. (A) Thermolysin
digests of thrombospondin purified from human foetal vein
endothelial cells (HUVEC line Hll P9). (B) Thermolysin digests of
thrombospondin purified from human foetal artery endothelial cells
(HUAEC line H56 P5). (C) Thermolysin digests of thrombospondin
purified from human adult saphenous vein endothelial cells (HSVEC
line SAP2 P5). (D) Thermolysin digests of thrombospondin purified
from human platelets. Experimental conditions of protease digestion
and chromatography were similar to Fig. 1
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Table 2. Tliermolysin-generated fragments of human fibroblast
thrombospondin obtained after gel permeation chromatography on a
Superose 12 column
In the cell denominations I' followed by a number indicates the
passage number. The molecular mass value of each proteolytic frag¬
ment of platelet thrombospondin represents an average obtained





HOF CI P4" 450 200 115 92 50 22 15 10
HOF CI P4 450 230 100 84 50 24 15 10
HFF F34 P5 450 200 100 80 50 27 14 12
HFF F34 P6 450 230 110 80 54 27 13 10
HSF F5 Pl3» 450 220 105 85 54 24 17 10
HSF F5 P13 450 195 110 80 49 23 17 12
HSF F22 P15 450 230 115 90 50 21 17 10
Human platelets 450 110 50 25 12/10
450 120 85 54 25 18 10
MOLECULAR WEIGHTED.)
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3. Comparison of the thermolysin-generaledfragments of thrombo-
ndin purifiedfrom human oral, foreskin andforearm skin fibroblasts
tivated at confluence and subconfluence. (A) Thrombospondin
ified from human oral fibroblasts (HOF line CI). (B) Thermolysin
ests of thrombospondin purified from human oral fibroblasts
3F line CI). (C) Thermolysin digests of thrombospondin purified
m human foreskin fibroblasts (HFF line F34). (D) Thermolysin
„ests of thrombospondin purified from human forearm skin
fibroblasts cultivated at confluence (HSF line F5). (E) Same as (D)
cultivated at subconfluence. Experimental conditions of protease
digestion and chromatography were similar to Fig. 1
Cells cultured at subconfluence.
Immunological characterization of thermolysin-generated
fragments ofendothelial, fibroblast andplatelet
thrombospondins using a polyclonal antibody directed
against platelet thrombospondin
Isolated thermolysin-generated fragments of thrombo¬
spondin from human endothelial cells (HUVEC, HUAEC,
HSVEC), human fibroblasts (HOF, HFF, HSF) and human
platelets (HPL) were immunodetected in a competitive
radioimmunoassay using both 125I-labelled whole platelet
thrombospondin and a polyclonal antibody directed against
platelet thrombospondin. All the proteolytic fragments of
endothelial, fibroplast and platelet thrombospondins were
recognized by the polyclonal antibody (Fig. 4A and B).
when injected on a Superose 12 gel-permeation column
(Fig. 3 A). Thermolysin digestion of CI fibroblast thrombo¬
spondin generated five major peaks, two of which eluted after
the total volume of the column (Fig. 3B). The proteolytic
fragments corresponding to these peaks had molecular masses
of 230, 100, 84, 50, 20, 12 and 10 kDa (Table 2) and were
similar to those obtained after thermolysin digestion of
thrombospondin purified from confluent adult foreskin
fibroblasts (HFF line F34) (Fig. 3C) and adult skin fibroblasts
(HSF line F5) cultivated at confluence and subconfluence
respectively (Fig.3D — E and Table 2). Similar results were
obtained with thrombospondin purified from subconfluent
adult oral fibroblasts (Table 2). However, the elution profile
of these proteolytic fragments may vary considerably from
one cell line to another (Fig. 3).
Comparison of the thermolysin-generated fragments of
adult fibroblast thrombospondins with those of platelet
thrombospondin, clearly showed the absence of two pro¬
teolytic fragments (92—80 kDa and 17—13 kDa) from the
fragmentation pattern of platelet thrombospondin (Table 2).
An additional proteolytic fragment of 230 —200 kDa, present
in the fragmentation pattern of fibroblast thrombospondin,
was also observed after thermolysin digestion of endothelial
and platelet thrombospondins when using a higher protein
loading onto the Seperose 12 column (results not shown).
Immunological characterization of thermolysin-generated
fragments ofendothelial, fibroblast andplatelet
thrombospondins using three different monoclonal antibodies
(P10, MA-I, MA-II) directed against platelet
thrombospondin
Isolated thermolysin-generated fragments of thrombo¬
spondin from human endothelial cells (HUVEC, HUAEC,
HSVEC), human fibroblasts (HOF, HFF, HSF) and human
platelets (HPL) were also immunodetected in an enzyme-
linked immunosorbent assay using three monoclonal anti¬
bodies (P10, MA-I, MA-II). Monoclonal antibodies P10,
directed against an epitope located near the hemagglutinin
activity domain of platelet thrombospondin [31], and MA-I,
directed against a 47-kDa SDS/tryptic fragment of platelet
thrombospondin [30] essentially recognized two proteolytic
fragments (135 — 110 kDa, 98 — 82 kDa) ofendothelial throm¬
bospondin (Fig. 5 A —C) and three (230 — 195,115—100,92 —
80 kDa) of fibroblast thrombospondin (Fig.6A—C). A
strong immunodetection by P10 and MA-I was only observed
with the 110-kDa fragment of platelet thrombospondin
(Figs5D and 6D). Monoclonal antibody MA-11, directed
against an epitope located within the heparin-binding domain
of platelet thrombospondin [30], essentially recognized three
proteolytic fragments of endothelial (54— 47, 25 — 20, IS¬














































'ig.4. Immunological characterization of thermolysin-generated fragments of endothelial, fibroblast and platelet thrombospondins using a
ompetitive radioimmunoassay with a polyclonal antibody directed against whole platelet thrombospondin. (A) Isolated thermolysin-generated
'ragments of thrombospondin from human endothelial cells (HUVEC, HUAEC, HSVEC) and human platelets (HPL). (B) Isolated
hermolysin-generated fragments of thrombospondin from human fibroblasts (HOF, HFF, HSF) and human platelets (HPL). Proteolytic
'ragments of thrombospondins were mixed with 125I-labelled platelet thrombospondin and a rabbit polyclonal antibody directed against
whole platelet thrombospondin. After incubation overnight at 4°C, Sepharose-4B-coupled donkey anti-(rabbit IgG) was added and the tubes
shaken for 45 min at 20°C. Sepharose-bound material was then separated from that remaining in the liquid phase by sedimentation of the
solid phase through assay buffer containing 10% sucrose, and removal of the supernatant by aspiration. Tubes were counted in a gamma
counter. The fragments are indicated by their molecular mass in kDa. The molecular mass of undigested thrombospondin is 450 kDa [9].
HPL, human platelets
thrombospondins (Figs5A—C and 6A— C), and two
fragments (50 kDa, 22 kDa) of platelet thrombospondin, dif¬
ferent from those detected by P10 and MA-I (Figs 5D and
6D).
Analysis of the thermolysin digests of thrombospondins
by SDS/polyacrylamide gel electrophoresis under reducing
conditions indicated that these fragments of different molec¬
ular masses consisted of polypeptide chains held together by
disulphide bonds or non-covalent associations (results not
shown).
Gel FPLC ofhuman endothelial, fibroblast
andplatelet thrombospondin oligomers
before and after thermolysin digestion
To investigate further the structural differences observed
between the three forms of thrombospondin, their respective
degree of polymerization has been compared using a Superose
6 gel-permeation column.
Thrombospondin purified from human foetal vein
endothelial cells (HUVEC line H55 P4) showed three major
peaks with molecular masses of 3300 kDa, 1000 and 450 kDa
respectively (Fig. 7A). Concomitant with the disappearance
of the thrombospondin dimer (1000 kDa) and monomer
(450 kDa), thermolysin digestion of foetal vein endothelial
thrombospondin generated eight peaks, one of which eluted
after the total volume of the column (Fig. 7 B). The proteolytic
fragments corresponding to these peaks had molecular masses
of 200, 130, 80, 50, 26, 14 and 11 kDa respectively. The
thrombospondin heptamer (3300 kDa) was unaffected by
thermolysin (Fig. 7B).
Thrombospondin purified from human foreskin fibro¬
blasts (HFF line F34 P6) showed three major peaks with
molecular masses of 3300, 900 and 450 kDa, respectively
(Fig. 8 A). Exposure of F34 P6 fibroblast thrombospondin to
thermolysin resulted in a decrease of the thrombospondin
dimer (900 kDa) and monomer (450 kDa), and the con¬
comitant appearance of five major peaks, one ofwhich eluted
after the total volume of the column (Fig. 8 B). The proteolytic
fragments corresponding to these peaks had molecular masses
of 83, 54, 27, 13 and 10 kDa respectively. The thrombo¬
spondin heptamer (3300 kDa) was unaffected by thermolysin
(Fig. 8 B).
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Fig. 5. Immunological characterization of thermolysin-generated fragments of endothelial and platelet thrombospondins using an enzyme-linked
immunosorbent assay with three monoclonal antibodies (PIO, MA-I, MA-II) directed against different epitopes ofwhole platelet tlirombospondin.
Binding of monoclonal antibodies PIO, MA-I and MA-II to isolated thermolysin-generated fragments of thrombospondin purified from (A)
human umbilical cord vein endothelial cells, (B) human umbilical cord artery endothelial cells, (C) human saphenous vein endothelial cells
and (D) human platelets. Thermolysin-generated fragments of thrombospondins isolated from the Superose 12 gel-permeation column were
adsorbed to 96-well microtitre plates by incubating 48 h at room temperature, followed by extensive washing with phosphate-buffered saline
containing 0.1% (v/v) Tween 20 (washing buffer). Monoclonal antibodies PIO, MA-I and MA-II were then added to the fragments bound to
the microtitre plates for 1 h incubation at 37°C. After rinsing the microtitre plates with the washing buffer, goat anti-(mouse IgG) conjugated
with horseradish peroxidase was added for an additional 1 h incubation at 37°C. Following washing of the microtitre plates, the substrate
solution was added and the enzyme reaction was allowed to proceed for 10 min at room temperature in the darkness. Results showed the
binding ofmonoclonal antibodies PIO, MA-I and MA-II, with duplicate determinations for each proteolytic fragment. The black line showed
the level of non-specific binding for the second negative control (see Experimental Procedure). Thrombospondin fragments are indicated by
their molecular mass in kDa. The molecular mass of undigested thrombospondin is 450 kDa [9]
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Fig. 6. Immunological characterization of thermolysin-generated fragments offibroblast and platelet thrombospondins using an enzyme-linked
immunosorbent assay with three monoclonal antibodies (PIO, MA-I, MA-II) directed against different epitopes ofwhole platelet thrombospondin.
Binding of PIO, MA-I and MA-II to isolated thermolysin-generated fragments of thrombospondins purified from (A) human oral fibroblasts,
(B) human foreskin fibroblasts, (C) human forearm skin fibroblasts and (D) human platelets. Experimental conditions were similar to those
described in Fig. 5
Thrombospondin purified from human platelets showed
four major peaks with molecular masses of 3300, 2100, 990
and 450 kDa respectively (Fig. 9 A). However, only three
major peaks (3300, 900 and 450 kDa) were observed with
another platelet thrombospondin preparation when injected
onto the Superose 6 gel-permeation column under identical
experimental conditions (results not shown). Exposure ot
human platelet thrombospondin to thermolysin resulted in a
decrease of these four oligomers of thrombospondin and the
concomitant appearance of five major peaks, one of which
eluted after the total volume of the column (Fig.9B). The
proteolytic fragments corresponding to these peaks had mo-
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7. Gel FPLC of human endothelial thrombospondin oligomers
•re and after thermolysin digestion. Thrombospondin was purified
n human umbilical cord vein endothelial cells (HUVEC line
i P4) and an equal amount of protein (30 pg in 0.5 ml) was then
:ted onto the Sepharose 6 gel-permeation column before (A) and
r (B) thermolysin digestion. The thermolysin/thrombospondin
0 was 1:20 (w/w). After 90 min of incubation at 37 °C, the thermo-
1 digestion was terminated by addition of 10 mM EDTA. The
erose 6 gel-permeation column connected to a FPLC system was
librated with 20 mM triethanolamine buffer (pH 7.4) containing
M NaCl. The flow rate was 0.5 ml/min
O.D.
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:ig. 8. Get FPLC ofhuman fibroblast thrombospondin oligomers before
nd after thermolysin digestion. Thrombospondin was purified from
uman foreskin fibroblasts (HFF line F34 P6) and an equal amount
f protein (30 pg in 0.5 ml) was then injected onto the Superose 6 gel-
ermeation column before (A) and after (B) thermolysin digestion.
Experimental conditions were similar to Fig. 7
if'




Fig. 9. Gel FPLC of human platelet thrombospondin oligomers before
and after thermolysin digestion. Thrombospondin was purified from
thrombin-stimulated platelets and an equal amount of protein (30 pg
in 0.5 ml) was then injected onto the Superose 6 gel-permeation
column before (A) and after (B) thermolysin digestion. Experimental
conditions were similar to Fig. 7
lecular masses of 94, 48, 26 and 12 kDa respectively. When
using a Superose 12 column, thermolysin digestion of the same
platelet thrombospondin preparation generated five major
proteolytic fragments with molecular masses of 110, 50, 22,
12 and 10 kDa respectively (results not shown).
Oligomers of the three forms of thrombospondin were all
recognized by a polyclonal antibody and three monoclonal
antibodies (P10, MA-I, MA-II) directed against whole platelet
thrombospondin (results not shown).
DISCUSSION
In agreementwith previous studies [3, 5,6,25], endothelial,
fibroblast and platelet thrombospondins were found to be
immunologically indistinguishable since a polyclonal anti¬
body and three monoclonal antibodies (P10, MA-I, MA-II)
recognized all three forms of thrombospondin in their native
state. Moreover, when assayed in a radioimmunoassay, the
use of a polyclonal antibody which recognizes all the pro¬
teolytic fragments of endothelial, fibroblast and platelet
thrombospondins indicates that these three forms of
thrombospondin share common determinants. These results
are consistent with the fact that platelet and endothelial
thrombospondins have similar amino acid compositions [3].
The immunological identification by monoclonal antibodies
P10, MA-I and MA-II of the thermolysin-generated frag¬
ments of thrombospondins shows that these common
determinants were borne by similar fragments of endothelial,
fibroblast and platetelet thrombospondins. When analyzed
by SDS/polyacrylamide gel electrophoresis under reducing
conditions, these proteolytic fragments consisted of poly¬
peptide chains held together by disulphide bonds or non-
covalent associations, some of them being present within sev¬
eral proteolytic fragments (P. Clezardin, unpublished results).
Such an observation has also been reported by Lawler et al.
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[30] studying the structure of platelet thrombospondin after
trypsin or thrombin digestion. It is, therefore, conceivable that
the binding of P10, MA-I and MA-II to several proteolytic
fragments could be due to the fact that these fragments are
related and have arisen by successive cleavage of whole
thrombospondin when using non-denaturating conditions.
Beside these identical immunological properties, endo¬
thelial and fibroblast thrombospondins are, however,
structurally different from platelet thrombospondin since two
fragments of endothelial thrombospondin (98 — 82 kDa, 18 —
15kDa), equivalent to those of fibroblast thrombospondin
(92 —80 kDa, 17 —13 kDa), are not released from platelet
thrombospondin when digested with thermolysin. Using
trypsin digestion we recently reported such structural
differences between thrombospondins purified from platelets
and from foetal vein endothelial cells [25], However, since
qualitative and quantitative differences occurred in the
secretory phenotypes of foetal and adult endothelial cells
[27 — 29], we could not exclude from our preliminary study
the possibility that the structural differences observed were a
result of the foetal origin of the endothelial cells. The results
obtained in this study demonstrate that, whether the cells
are of foetal or adult origin, a unique proteolytic pattern is
obtained after thermolysin digestion of endothelial
thrombospondin.
Following the observation that a high intracellular degra¬
dation of unglycosylated thrombospondin occurs in human
endothelial cells when cultivated in the presence of
tunicamycin, Vischer et al. [36] suggest that the carbohydrate
moiety of thrombospondin does protect the glycoprotein
partially against proteolysis. Since changes in the glycosyla-
tion of glycoproteins take place in human cells as they
approach contluence [26] or senescence in culture [37], it was
conceivable that such changes in the carbohydrate moiety of
thrombospondin isolated from confluent cells could affect the
enzymatic proteolysis of this glycoprotein, and thus account
for the structural differences observed in our preliminary
study [25]. In the present work we did not investigate the
carbohydrate structures of endothelial, fibroblast and platelet
thrombospondins. However, we demonstrated that the
thermolysin-generated fragments of endothelial and fibro¬
blast thrombospondins were similar when isolated from sub-
confluent or confluent cells. Such results suggest that changes
in the glycosylation of thrombospondins isolated from
confluent cells, if any, are not detected under our experimental
conditions of chromatography, and thus do not account for
the structural differences observed between the three forms of
thrombospondin. Moreover, these results are in agreement
with the fact that both thrombospondins from cultured
endothelial cells and platelets have similar carbohydrate
contents [36],
To investigate further the structural differences observed
between endothelial, fibroblast and platelet thrombo¬
spondins, their respective degree of polymerization has been
compared by Superose 6 gel-permeation chromatography
under non-denaturing conditions. The three forms of
thrombospondin commonly elute over a broad molecular
mass range with major oligomers at 3300 kDa, 900 kDa
and 450 kDa. Similar results were previously reported by
Booth et al. [10] studying the degree of polymerization of
human platelet thrombospondin by Sepharose 2B gel-fil¬
tration chromatography. Despite thermolysin digestion, the
persistence of the 3300-kDa oligomer of endothelial or
fibroblast thrombospondin indicates that the 900-kDa and
450-kDa oligomers are degraded at a protease to thrombo¬
spondin ratio higher than that for platelet thrombospondin
oligomers, and thus favours the release of proteolytic
fragments from endothelial and fibroblast thrombospondins
smaller than those released from platelet thrombospondin.
Such an assumption could also explain the variability of the
elution profiles of the thermolysin-generated fragments from
one cell line to another since the amount of thrombospondin
recovered at 3300 kDa may also vary from one cell culture to
another (P. Clezardin, unpublished results). However, the fact
that the 3300-kDa oligomer of platelet thrombospondin is
degraded by thermolysin whereas its endothelial or fibro¬
blast counterpart is not degraded, suggests differential
conformational properties between platelet and the two other
forms of thrombospondin. McKeown-Longo et al. [38] re¬
ported that the addition of purified 125I-labelled platelet
thrombospondin to human lung fibroblasts resulted in the
degradation after 3 h of 60% of the radiolabeled
thrombospondin molecule. On the other hand, in pulse-chase
experiments designed to study the endogenous metabolism
of thrombospondin in human skin fibroblasts, Mumby et al.
[39] observed that the level of radiolabeled fibroblast
thrombospondin secreted into the medium remained constant
from 1 h to 12 h of chase time. The authors [39] related these
conflicting results between the two studies to differences in
cellular recognition of platelet versus fibroblast thrombo¬
spondin, or between thrombospondin labelled with 125I by
the chloramine T method versus metabolically labelled
thrombospondin. Such differences could also result from an
increased resistance to proteolysis of fibroblast thrombo¬
spondin due to conformational properties different from
those of platelet thrombospondin, as suggested by this study.
Further work is in progress to clarify the role of the conforma¬
tion of the thrombospondin molecule in the polymorphism of
endothelial and fibroblast thrombospondins versus platelet
thrombospondin.
Note. While this manuscript was under review, Dardik et al. [40]
reported, as an abstract, that the proteolytic pattern of endothelial
thrombospondin was similar but not identical to that of platelet
thrombospondin.
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Thrombospondin in Milk, Other Breast Secretions,
and Breast Tissue
JOAN DAWES, D. Phil., PHILIPPE CLEZARDIN, Ph.D.,
and DAVID A. PRATT, M.Sc.
The trimeric glycoprotein thrombospondin was
first isolated from the extracellular medium after
thrombin stimulation of platelets,1 but has since
been shown to be synthesized and secreted by a
wide range of cell types, including endothelial
cells,2,3 smooth muscle cells,4 fibroblasts,5 and
monocytes.6 In 1985 we reported that thrombo¬
spondin is also present in high concentrations in
milk7 and in some breast cyst fluids,8 where the low
levels of the other platelet a-granule proteins 0-
thromboglobulin and platelet factor 4 clearly indi¬
cate a nonplatelet source for thrombospondin.
However, the cell type responsible for the pro¬
duction of thrombospondin in the mammary gland
has not been identified, nor is there any indication
of the function of thrombospondin in this context.
This article describes two approaches to these ques¬
tions. In one, production of thrombospondin
during the initiation of lactation is examined and
the distribution of thrombospondin in different
milk fractions defined. Thrombospondin was also
purified from goat colostrum and its structure com¬
pared with the protein isolated from other sources.
The second approach involves the measurement of
thrombospondin in a range of breast secretions and
breast tissue samples in an attempt to analyze the
conditions under which it is synthesized and
secreted.
From the MRC/SNBTS Blood Components Assay Group,
Edinburgh, UK, and Facu/te de Medecine Alexis Carrel, Labora-
toire d'Hemobiologie, Lyon, France.
Reprint requests: Dr. Dawes, MRC/SNBTS Blood Compo¬
nents Assay Group, 2 Forrest Road, Edinburgh, EH1 2QW, UK.
MATERIALS AND METHODS
Samples
Human colostrum and milk were obtained by
manual expression and other breast secretions by
nipple aspiration, with the exception of fluid from
patients with galactorrhea, which were spontaneous
discharges. Breast cyst fluids were obtained by
needle aspiration, then centrifuged at 600 x g for
10 minutes and the supernatants stored at -20°C
until assayed.
Unpasteurized cow's milk was supplied by Jean
Robb, Department of Microbiology, University of
Edinburgh, and goat colostrum by Dr. Ken Brown,
ARC Institute of Animal Physiology, Cam¬
bridge, UK.
Breast tissue samples (1 g wet weight) were
homogenized in 5 ml 10 mM Tris buffer pH 8.0
containing 1.5 mM ethylene diaminetetraacetic acid
(EDTA) and 0.25 M sucrose, using a Silverson
homogenizer. They were centrifuged at 105,000 x g
at 4°C for 1 hour, and the resulting supernatant
was stored at -20°C.
Fractionation of Milk
Fresh unpasteurized bovine milk (1 liter) was
fractionated by a modification of the methods of
Mather9 and Shimizu and Yamauchi,10 which is
summarized in Figure la. The milk was warmed to
30°C and centrifuged at 2000 x g for 30 min,
maintaining the temperature at 30°C. The raw
cream (top layer) was removed and washed three
times at 30°C with 3 to 5 volumes of 10 mM Tris
buffer, pH 7.2, containing 140 mM NaCl. Washed
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FIG. 1. Milk fractionation procedure (A) and recovery (B) of thrombospondin (% total) in milk fractions.
cream was cooled and homogenized with an equal
volume of the buffer to give butter. The aqueous
phase was recovered by centrifugation at 2000 X g
for 30 minutes after melting the fat granules at
40°C. Milk fat globule membranes in the aqueous
phase were solubilized in 1% Triton X-100. The
whey fraction was centrifuged at 90,000 x g for 2
hours at 4°C to remove contaminating membranes
and residual lipid, and the pellet was solubilized in
1% Triton X-100. The volumes of all fractions were
measured and samples stored at — 20°C until
assayed.
days
FIG. 2. Thrombospondin (•) and total protein (O) concentrations (A) and relative thrombospondin concentrations (B) in
human colostrum and milk during the initiation of lactation. Parturition occurred at day 0 (vertical line).
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Purification and Structural Analysis
of Milk Thrombospondin
Whey was prepared from 300 ml goat colos¬
trum as previously described, after addition of
NaCl to a final concentration of 0.35 M. Polyvinyl¬
pyrrolidone (PVP) was then added to a final con¬
centration of 3% (w/v) before incubation at 20°C
for 15 minutes. Centrifugation at 35,000 x g for 60
min removed the complex of PVP with residual
lipid. The supernatant was applied to a heparin-
Sepharose column, which was washed with 15 mM
Tris buffer pH 7.4, containing 2 mM CaCl2 and
0.35 M NaCl before elution of the thrombospondin
at 0.55 M NaCl (Fig. 3). The eluate was further
purified on an anion exchange Mono Q column, as
described by Clezardin et al."
The product was compared with human platelet
thrombospondin by analysis on a Superose 12 HR
10/30 gel filtration column12 both before and after
digestion with thermolysin (Sigma) at a ratio of 1:20
(w/w) for 90 minutes at 37°C.
Assay of Thrombospondin
Thrombospondin was measured by radioimmu¬
noassay,13 using a polyclonal rabbit antiserum that
detects human, bovine, and goat thrombospondins.
FIG. 3. Affinity purification of thrombospondin from colos¬
trum on heparin-Sepharose. After defatting as described in
the text, 300 ml goat colostrum was applied to a heparin-
Sepharose column in 0.35 M NaCl. The peak eluted with 0.55 M
NaCl contained all the thrombospondin applied.
Statistical Analysis
Statistical analysis of differences between popu¬
lations was performed by the Wilcoxon-Mann-




The concentration of thrombospondin in
human colostrum and in milk during the initiation
of lactation is compared with the total protein con¬
tent in Figure 2a, which covers the period from 17
days prepartum to 5 days postpartum. Colostrum
contained as much as 70 to 80 /xg/ml thrombo¬
spondin, and this dropped to 4 /ig/ml as lactation
became established. The ratio of thrombospondin
to total protein over this period (Figure 2b) declined
almost tenfold from 2 to 0.25 /ig thrombospondin/
mg protein.
Distribution of Thrombospondin in Milk
When fresh unpasteurized cow's milk was frac¬
tionated according to the procedure summarized in
Figure la, more than 90% of the total thrombo¬
spondin content was recoverd in the aqueous phase
(Figure lb). There was no evidence that thrombo¬
spondin was a milk fat globule membrane glyco¬
protein.
Purification and Structural Analysis of
Thrombospondin from Colostrum
Thrombospondin was purified from goat colos¬
trum. The lipid content of the starting material
resulted in major problems for both affinity and gel
filtration chromatography, and this was minimized
by the use of NaCl and PVP. Goat colostrum
thrombospondin bound to heparin-Sepharose in the
presence of 0.35 M NaCl and eluted in 0.55 M NaCl
(Fig. 3). After further purification on an anion ex¬
change Mono Q column, the product was gel filter¬
ed on a Superose 12 column. It yielded a major
peak at 450 kd coincident with that obtained with
human platelet thrombospondin (Fig. 4), but the
colostrum protein contained more fragments of low
molecular weight (Table 1).
After thermolysin digestion of thrombospondin
from the two sources followed by gel filtration, the
fragmentation patterns were found to be completely
different (Fig. 5). The higher molecular weight deg-
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FIG. 4. Gel filtration of thrombospondin from goat colos¬
trum ( ) and human platelets ( ) on Superose 12.
FIG. 5. Gel filtration of thermolysin digests of thrombo¬
spondin from goat colostrum ( ) and human platelets
( ) on Superose 12.
radation products of human platelet thrombospon¬
din were absent from the digest of goat colostrum
thrombospondin, which contained several very
small fragments. This pattern is unique among the
thrombospondins from different sources examined
to date (Table 2).
Thrombospondin in Other
Breast Secretions
In the absence of lactation, small volumes of
fluid can be secreted by the breasts of healthy
women as well as by those with fibrocystic disease
and breast cancer. In galactorrhea the flow increases
considerably. All these secretions contained throm¬
bospondin in the range 1 to 145 /rg/ml, with a
median of 23 /tg/ml (Fig. 6), much the same as that
in milk and colostrum, and there was no significant
difference between concentrations in the different
types of secretion. Fluids from the type of breast
cyst containing high levels of Na+ contained con¬
centrations of thrombospondin in the same range,
(median, 7.6; range, 0.96-51.1 /tg/ml) although they
were significantly lower (p < 0.001) than the levels in
breast secretions. Thrombospondin levels in fluids
from cysts with comparatively higher K+ and lower
Na+ were much lower (median, 1.15; range, 0.06-
5.6 ng/ml), and very significantly different (p<10~6)
from those in any other breast fluids.
Thrombospondin in Breast Tissue
Few samples of normal breast tissue, usually
noninvolved tissue at the periphery of a malignancy,
have been obtained as yet. Flowever, most of these
contained less than 1 ^g thrombospondin/gm wet
weight of tissue, as did the two samples of benign
mammary dysplasia examined (Fig. 7). By contrast,
90% of the cytosols from malignant breast tissue
contained more than this concentration of thrombo¬
spondin (median, 15.5; range, 0.23-550 /rg/gm) and
the difference between the thrombospondin con¬
tents of malignant and nonmalignant tissues
(median, 0.66; range, 0.11-6.7 /tg/gm) was very
highly significant (p< 10~6).
TABLE 1. Fragments (% Total) in Freshly Isolated Thrombospondin
Fragments (kd)
Origin 450 IIP 80 30-40 10 <10 <10 <10
Human platelets 75.4 2.3 13.4 7.5 1.4 — — —
Goat colostrum 51.4 7.2 12.6 9.6 2.5 4.0 3.8 8.9
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TABLE 2. Thermolysin-Generated Fragments of Thrombospondins
from Different Sources
Origin Fragments (kd)
Human platelets 450 110 50 25 10
Human endothelial cells12 450 120 85 50 25 16 10
Human fibroblasts14 450 230 110 85 50 25 16 10













FIG. 6. Thrombospondin concentrations in human breast
secretions and breast cyst fluids. Breast secretions were from
healthy women ('•), and patients with breast cancer (O), fibro¬












FIG. 7. Thrombospondin concentrations in normal breast
tissue and breast cancer. Included with the normal values (•)
are two samples from benign dysplasia (O).
DISCUSSION
Thrombospondin is not a major milk protein in
that it constitutes only 0.2% of the total protein of
colostrum and 0.02% of that of milk. Serum pro¬
teins also include 0.02% thrombospondin, but in
body fluids in vivo the content is much lower; in
plasma, for instance, thrombospondin makes up
only 0.00015% of the total protein. Therefore in
relative terms the concentration of thrombospondin
in milk and other breast secretions is high, and this
raises the question of its function.
Milk fat, the melting point of which is lower
than body temperature, is dispersed in droplets that
are prevented from coalescing by a membrane con¬
sisting of phospholipid-protein complexes and rich
in glycoproteins.9 Thrombospondin was not, how¬
ever, associated with the milk fat globule membrane
but was localized in soluble form in the aqueous
phase.
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Apart from the necessity for removal of lipid
from the starting material, thrombospondin could
be purified from colostrum by the techniques al¬
ready developed for platelet-derived thrombospon¬
din. Its affinities for heparin and anion exchange
materials were the same as when the protein was
purified from other sources. It did, however, con¬
tain smaller fragments than platelet-derived throm¬
bospondin. These may have been the products of
uninhibited protease activity in the colostrum, since
very small fragments were also generated by diges¬
tion with thermolysin. The major differences be¬
tween the thermolysin digestion products of colos¬
trum thrombospondin and thrombospondins from
other sources indicate differences in amino acid
sequence. These may, however, be species- rather
than source-specific, since goat colostrum was used
in the absence of sufficient quantities of the human
material. Further analyses must be performed on
thrombospondin from human milk.
The pattern of thrombospondin secretion
during the initiation of lactation in man was very
similar to that already found in the goat, but the
concentration was lower.7 Although the absolute
concentrations of all proteins decrease during the
transition from colostrum to true milk production,
the relative concentrations of specific milk proteins,
such as a-lactalbumin, increase,15 whereas that of
thrombospondin decreased tenfold, resembling the
pattern of IgA production.15 This implies that syn¬
thesis of thrombospondin and the specific milk pro¬
teins are under separate control. Tissue plasminogen
activator (tPA) also occurs in milk in high concen¬
trations compared with blood, and its pattern of
production appears to resemble that of thrombo¬
spondin.16
A further similarity between tPA and thrombo¬
spondin in the breast is the increased levels asso¬
ciated with malignancy. Some breast cancer cytosols
contained thrombospondin concentrations in the
same range as normal tissue, but 65% were above
the normal range and in some the thrombospondin
levels were two orders of magnitude greater than
those in normal breast. Benign dysplasias, by con¬
trast, contained normal concentrations of thrombo¬
spondin. We are currently attempting to establish
the differences between cancer tissues with high and
low thrombospondin levels. The production of tPA
by breast cancer cells in culture is under hormonal
regulation,17 and if the same is true of thrombo¬
spondin, its concentration may be related to the
presence or absence of hormone receptors on the
malignant cells.
All breast secretions contained thrombospon¬
din in the concentration range found in colostrum
and milk and apparently reflect the same mechanism
of synthesis and secretion. Thrombospondin levels
in breast cyst fluids, however, varied with the type
of cyst. Those with higher thrombospondin concen¬
trations, the Na+ or group II cysts, are invariably
lined by thin attenuated epithelial cells,18 and it has
been inferred that their contents accumulate in a
passive manner, possibly as a transudate from
blood. It is quite clear that this cannot be the case
for thrombospondin, which is undoubtedly being
synthesized by the cells normally responsible for its
production in the breast. K+ or group I cysts are
usually lined by active apocrine cells,18 and since
the thrombospondin concentration in fluids from
these cysts is very low, it is unlikely that it is synthe¬
sized by apocrine cells. This conclusion is supported
by our finding (unpublished results) that thrombo¬
spondin levels in saliva (median, 144; range, 94-157
ng/ml) are within the normal plasma range.
SUMMARY
Colostrum and milk contained high concentra¬
tions of thrombospondin, although the concentra¬
tion relative to total protein content decreased as
lactation was established. Thrombospondin oc¬
curred in the aqueous phase of milk rather than as a
component of the milk fat globule membrane. It
could be purified from colostrum using established
procedures after removal of lipid from the starting
material. The intact protein had a molecular weight
of 450 kd, but the product contained small pep¬
tides, perhaps as a result of proteolytic activity in
the colostrum. Thrombospondin from goat colos¬
trum displayed a different proteolytic fragmentation
pattern from thrombospondins isolated from three
human sources, but this could be a species- rather
than tissue-specific difference.
Breast cancer cytosols contained significantly
more thrombospondin than cytosols from normal
tissue or benign dysplasias. Thrombospondin levels
in a variety of breast secretions all fell within the
range found in colostrum and milk, as did the
fluids from Na+ (group II) breast cysts. K+ (group
I) cysts, however, contained fluids with low throm¬
bospondin concentrations, eliminating apocrine cells
as the source of thrombospondin in the breast.
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Thrombospondin, a trimeric glycoprotein contained in the
telet a-granules, has been proposed as a marker of in vivo
telet activation. However, it is also synthesised by a range of
ler cells. The extraplatelet contribution to plasma levels of
ombospondin was therefore estimated by investigating the
ationship between plasma thrombospondin levels and platelet
int in samples from profoundly thrombocytopenic patients with
rrow hypoplasia, using the platelet-specific a-granule protein
hromboglobulin as control. Serum concentrations of both
iteins were highly correlated with platelet count, but while
sma p-thromboglobulin levels and platelet count also corre-
5d, there was no relationship between the number of platelets
i thrombospondin concentrations in plasma. Serial sampling of
ients recovering from bone marrow depression indicated that
plasma thrombospondin contributed by platelets is superim-
;ed on a background concentration of at least 50 ng/ml
ibably derived from a non-platelet source, and plasma throm-
;pondin levels do not simply reflect platelet release.
Introduction
Thrombospondin, a trimeric glycoprotein of 460,000 kD, was
originally identified as a platelet-release protein (1). Dawes et al.
(2) showed that its half-life in man is considerably longer than the
other a-granule proteins, P-thromboglobulin (P-TG) and platelet
factor 4 (PF4), and suggested that its concentration in plasma may
therefore be a useful indicator of in vivo platelet activation.
However, Lane et al. (3) compared the concentrations of these
three proteins in the plasma of patients with myeloproliferative
disorders, diabetes, liver disease and renal failure as well as a
group undergoing total hip replacement, and concluded that in
conditions which were not complicated by reduced clearance p-
TG was a more sensitive marker of platelet activation than
thrombospondin. Trzeciak et al. (4) also had difficulty relating
plasma concentrations of thrombospondin to platelet release in
clinical situations.
It is now recognized that thrombospondin is not a platelet-
specific protein, but can be synthesised in vitro by a range of cell
types including monocytes (5), fibroblasts (6), smooth muscle
cells (7) and endothelial cells (8). Thus, although nothing is
known of the rates at which these cells secrete thrombospondin in
vivo, it is possible that platelets may contribute only part of that
circulating in plasma. In this case plasma concentrations of
thrombospondin would not necessarily be related to platelet
release, which would explain the problems experienced in using
them as markers of in vivo platelet activation.
Correspondence to: Dr. J. Dawes, MRC/SNBTS Blood Components
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The contribution of platelets to plasma concentrations of
thrombospondin has been studied in thrombocytopenic patients
by relating plasma levels of thrombospondin and of the platelet-
specific protein (3-TG (9) to their platelet counts. Normal plasma
concentrations of thrombospondin were frequently present in the
absence of detectable levels of P-TG, clearly indicating that much
of the thrombospondin present in plasma can originate from
sources other than the platelets.
Patients and Methods
Patients
Details of patients are given in Table 1. Individual samples were taken
from 20 patients with profound marrow hypoplasia, usually following
chemotherapy, and serial samples from three of these during recovery
from severe bone marrow depression. In all cases chemotherapy was
followed by severe peripheral pancytopenia attributable to the marrow
hypoplasia. Chemotherapy in most cases was given according to the
Medical Research Council protocols for acute myeloblastic leukaemia and
acute lymphoblastic leukaemia, and the British National Lymphoma
Institute protocol for resistant non-Hodgkin's Lymphoma. Patients were
sampled prior to any platelet transfusion.
Blood Samples
To obtain plasma samples, venous blood (2.7 ml) was collected by
clean venepuncture into 0.3 ml of ice-cold platelet release inhibitor
solution (ETP) containing 78 mM EDTA, 10 mM theophylline and
0.33 pg/mi prostaglandin Ei (10). All necessary precautions were taken to
minimise ex vivo platelet release.
Serum was prepared by rapid centrifugation of whole blood after
incubation in glass tubes for 30 minutes at 37° C. All samples were stored
at -80° C before assay.
Assays
Concentrations of thrombospondin and P-TG were measured using the
radioimmunoassays described by Dawes et al. (2) and Bolton et al. (11)
respectively.
Results
The relationships between platelet count and plasma concen¬
trations of p-TG and thrombospondin in these patients are
illustrated in Fig. 1. When the platelet count was less than 10% of
normal values, plasma P-TG levels were well below the normal
range (20.1-68.5 ng/ml) reported by Dawes et al. (2) in themajority
of cases. Thrombospondin concentrations, however, were mainly
within or above the normal range (57.5-215.6 ng/ml). While there
was reasonable correlation between platelet count and plasma p-TG
concentration (r = 0.67; Fig. 1A), there was no relationship
between platelet count and plasma thrombospondin (r = —0.08;
Fig. IB).
These results contrast with the serum concentrations of P-TG
and thrombospondin (Fig. 2), which were both depressed to a
similar extent as the platelet count and were highly correlated
with it (P-TG, r = 0.89; Fig. 2 A; thrombospondin, r = 0.97;
Fig. 2B).
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Fig. 1 The relationship between
platelet count and plasma con¬
centrations of (A) p-TG and (B)
thrombospondin in patients with,
and during recovery from, severe
bone marrow depression
'le 1 Details of thrombocytopenic patients
tent Age Sex Diagnosis Chemotherapy Days post chemo¬
therapy sampled
38 M Resistant Hodgkin's Disease BNLI 10
16 F ALL UKALLX 12
25 F Resistant non-Hodgkin's Lymphoma BNLI 9
38 M Aplastic anaemia - -
46 F AML (remission re-induction) ME 11
78 M Myelofibrosis - -
7 32 F Resistant non-Hodgkin's Lymphoma BNLI 3
8 63 M Waldenstrom's macroglobulinaemia CHOP 5
9 32 M AML (remission consolidation) MAZE 19
and 11 to 24
10 88 F RAEB transformed to AML - -
11 79 F ALL UKALLX 12
12 53 M AML (remission consolidation) ME 18
13 49 F AML (remission induction) DAT -6 to 41




15 57 F PRV transformed to severe myelodysplasia Hydroxyurea 14
16 64 M Myeloma in escape Melphalan (2 mg/kg) 24
17 29 M AML (remission reinduction) MAT 12
18 74 F RAEB transformed to AML Etoposide 27
19 62 F CML Etoposide 7
20 76 M Hypoplastic AML Cytarabine 42
BNLI: Cyclophosphamide, Mesna, BCNU, Cytarabine, Etoposide; CHOP: Cyclosphosphamide, Doxorubicin, Vincristine, Prednisolone; DAT:
Daunorubicin, Cytarabine, Thioguanine; MAZE: Amsacrine, Azacytidine, Etoposide; ME: Amsacrine, Etoposide; MAT: Amsacrine, Cytarabine,
Thioguanine; UKALLX: Daunorubicin, Cytarabine, Etoposide, Thioguanine, Vincristine
Fig. 3 illustrates the time course of changes in platelet count
and plasma (Fig. 3A) and serum (Fig. 3B) concentrations of P-TG
and thrombospondin in one patient during recovery from marrow
hypoplasia; similar patterns were obtained with the other two
studied. Serum concentrations of the two proteins clearly
followed the platelet count to a minimum concentration which
reflected that of plasma. The plasma content of P-TG similarly
rose and fell with the platelet count, though measurement of low
values was limited by the sensitivity of the assay (5 ng/ml). While
there was some variation in plasma thrombospondin concentra¬
tion which did reflect changes in platelet count, the platelets fell
by 25-fold and thrombospondin by only 2-fold, never measuring
less than 50 ng/ml.
Discussion
Throughout these studies, serum concentrations of both P-TG
and thrombospondin correlated closely with the platelet count.
This result was expected, for both are released from the platelet
ct-granules during clotting.
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2 The relationship between
:let count and serum con-
rations of (A) p-TG and (B)
mbospondin in patients with,
during recovery from, severe
: marrow depression
Serum 8-TG pg/ml Serum thrombospondin pg/ml
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The relationship between plasma concentrations of the two
roteins and platelet count is, however, more complex. Although
tere was a correlation between plasma P-TG levels and platelet
runt, in 7 of the samples P-TG concentrations were within or
/en slightly above the normal range though the platelet counts
ere 10% or less of normal, and P-TG has never been identified
i any cell other than platelets and megakaryocytes. As the half-
fe of P-TG in plasma is about 100 min (12), these levels cannot
ipresent residual P-TG persisting from prior platelet transfu-
ons, and as the serum levels were those expected from the
platelet counts, they cannot be accounted for by a high platelet
P-TG content in these patients. They could, however, reflect
release from defective megakaryocytes, which appears to occur in
the grey platelet syndrome where plasma levels of P-TG are
elevated (13) although those of TSP and PF4 are within the
normal range (14). The possibility that the lack of correspondence
between platelet count and plasma P-TG concentration could
indicate an underlying complication of pathophysiological import¬
ance is currently being investigated. It must be emphasised,
however, that pharmacokinetic factors are important modulators
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the relationship between plasma (3-TG levels and platelet
jnt. It is clearly illustrated by the consecutive sampling of single
dents that this is essentially a dynamic situation and under such
cumstances platelet count and plasma (3-TG content cannot
relate perfectly as the kinetics of production and clearance of
: two are not identical.
No relationship was demonstrable between plasma thrombo-
undin concentrations and platelet count, and although consecu-
s sampling showed a tendency for the two to increase and
:rease together, this pattern was superimposed on a
Aground plasma thrombospondin concentration which never
I below 50 ng/ml. In the example illustrated (Fig. 3A) the
telet count dropped 25-fold and the plasma thrombospondin
ly 2-fold.
Thus plasma thrombospondin concentrations probably include
najor contribution from extra-platelet sources, of which the
icular endothelium may be the most important. Switalska et al.
) suggest on the basis of anecdotal observations that most
sma thrombospondin is derived from platelets, but do not
:sent any data to this effect. They also claim on a quantitative
.is that endothelial cells are unlikely to secrete thrombospondin
o circulating blood under physiological conditions, but fail to
e account of the likelihood that the kinetics of production
fer in vivo and in vitro, that adult endothelial cells secrete much
s thrombospondin in culture than the umbilical vein cells
•mally studied (16), and the unknown contribution of the
;rovasculature.
This demonstration of a background plasma thrombospondin
icentration independent of the presence of platelets provides
explanation of the poor performance of thrombospondin as an
icator of platelet release in disease (3). Not only does any
;ase have to be detected against this background, but in
lition the contribution from non-platelet sources may itself
y in different clinical conditions. Furthermore, a significant
iportion of the thrombospondin released from the a-granule
may not appear in the plasma, becoming associated with the
platelet surface (15, 17) or the fibrin clot (18). These factors
adequately account for the unsuitability of plasma thrombospon¬
din levels as a marker of platelet activation.
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Thrombospondin in Malignant and Non-malignant
Breast Tissue
DAVID A. PRATT,* WILLIAM R. MILLERf and JOAN DAWES*
*MRC/SNBTS Blood Components Assay Group, Edinburgh and f University Department of Clinical Surgery, Royal Infirmary,
Edinburgh, U.K.
Abstract—Cytosols ofmalignant breast tissue contained significantly higher levels of thrombos¬
pondin (TSP) and von Willebrand factor (vfVF) than non-malignant breast. TSP and vWF
content of human breast were significantly correlated whereas there was no correlation between
TSP and the platelet-specific protein fi-thromboglobulin ((3777). Whilst TSP in pre-menopausal
breast cancer was slightly lower than in post-menopausal breast cancer, it did not correlate with
oestrogen receptors (ER) or progesterone receptors (PR), but was negatively correlated with
tissue-type plasminogen activator (tPA), an oestradiol-inducible enzyme. Secretion of TSP by
MCF-1 cells was low and refractory to hormones. High levels of TSP appeared to be associated
with the centre of the tumour mass. It is suggested that activation of the endothelium may be
responsible, at least in part, for the high levels of TSP found in malignant breast tissue and
could be a factor in the growth and spread of breast cancer.
INTRODUCTION
Thrombospondin (TSP), a glycoprotein first
described in platelets and subsequently in a variety
of cell types, is incorporated into the extracellular
matrix ofsome cells in culture where it may function
as an adhesive protein (for reviews see Refs. [1-3]).
As a component of the extracellular matrix, TSP
has been shown to have an autocrine function,
augmenting the mitogenic response of smooth mus¬
cle cells to epidermal growth factor [4].
TSP has also been implicated in tumour cell
metastasis. For example it promotes the attachment
and spreading of several human cancer cells in
vitro [5-7] and a recent report shows that TSP
potentiates tumour cell metastasis in mice [8]. Spec¬
ific receptor sites for TSP have also been identified
on the membrane of platelets, endothelial cells and
a variety of human tumour cells [9], As a result,
TSP could be involved at several points in the
metastatic process through potential interactions of
malignant cells with extracellular matrix, endo¬
thelium or circulating platelets.
TSP is present in high concentrations in milk,
other breast secretions and in some types of cyst
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fluid [10]. We reported recently that TSP is a
component of the aqueous phase of milk, that its
level falls during the transition of colostrum to
mature milk and also that malignant breast had a
higher content of TSP than non-malignant breast
[11]. The increased TSP levels observed in these
studies did not reflect platelet activation since there
were no parallel changes in the platelet-specific
protein (3-thromboglobulin ((3TG). Tissue-type
plasminogen activator (tPA), the major plasmin¬
ogen activator (PA) in human milk, shows a similar
pattern of secretion during early lactation as does
TSP [12]. Increased levels of PA have also been
reported in breast tumours [13] where they correlate
with oestrogen receptors (ER) and progesterone
receptors (PR) [14], Moreover, production of PA
by breast cells in culture is regulated by oestradiol
and other steroid hormones [15-17],
Von Willebrand factor (vWF) is synthesized by
endothelial cells and megakaryocytes and is con¬
tained in platelet a-granules. vWF functions as a
carrier protein for coagulation factor VIII and
is thought to be involved in platelet—vessel wall
interactions [18]. Indeed, vWF is incorporated into
the extracellular matrix ofcultured endothelial cells
[19] where it may function as an adhesive protein.
Although not specific for endothelial cells, vWF has
been used as a marker of endothelial perturbation
in vitro [20—22] and as a criterion for endothelial
cell identification [23],
We have undertaken a more comprehensive study
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of TSP in the human breast and the factors which
may be responsible for the high levels which are
associated with malignancy. Our findings suggest
that endothelial activation may be responsible, at
least in part, for the elevated TSP in breast cancer
and this may have a role in regulating the growth
and spread of the malignant epithelium.
MATERIALS AND METHODS
Samples
Breast tissue cytosols from patients attending the
Edinburgh breast clinic (101 breast carcinoma, nine
benign mammary dysplasia, five fibroadenoma,
one gynaecomastia, one normal) were prepared by
homogenization of tissue in 20 mM Tris-HCl, pH
7.6, containing 0.25 M sucrose, 1 mM CaCl2,
2 mM MgClz, 10 mM KC1 at a dilution of either
1:5 (w/v) or 1:10 (w/v) using a Silverson homogen-
izer. They were centrifuged at 105,000 g at 4°C for
1 h and the supernatants stored at — 20°C.
Eleven breast tissue cytosols from five patients
with breast cancer were obtained at the time of
mastectomy by snap-freezing of washed tissue
samples followed by cryofragmentation using a
mechanical dismembrator, and preparation of a
supernatant from the tissue extract resuspended in
buffered saline. They were classified according to
whether the tissue had been taken from the centre
of the tumour (n = 5) or the surrounding non-
malignant tissue (n = 6).
Assays
TSP, PTG and vWF were measured by radioim¬
munoassays as previously described [24—26]. The
sensitivity of the radioimmunoassay for vWF was
22 ng/ml but it was not possible to specify a detection
limit due to the varying protein concentrations of
individual cytosols. tPA was measured by enzyme-
linked immunosorbant assay [27] by Dr.P. Gaffney
and the results have been published elsewhere [28].
ER was measured in low speed supernatants of
breast tissue homogenates as previously reported
[29]. PR was determined in the same high speed
supernatant used for TSP measurement as
described elsewhere [30].
Protein assays were performed by a dye-binding
method (Bio-Rad Laboratories Ltd., Watford,
U.K.) using a bovine serum albumin standard.
Cell culture
Briefly, MCF-7 human breast cancer cells (sub-
cultured from a stock obtained from Professor S.C.
Brooks, Michigan Cancer Foundation) were grown
on 10 cm2 plastic culture wells (Costar, Cambridge,
MA) in Eagle's MEM with Hank's BSS (Flow
Laboratories, Irvine, U.K.) supplemented with
NEAA, sodium pyruvate, L-glutamine, insulin,
penicillin, streptomycin and 10% FCS (Gibco, Pais¬
ley, U.K.). At confluence, the monolayer was
washed extensively with basal MEM to remove
serum components and then incubated with 2 ml/
well serum-free medium according to Barnes and
Sato [31 ] with orwithout the test substance. Culture
supernatants were decanted after 48 h, centrifuged
to remove cell debris and stored at — 40°C prior to
assay.
Statistical analyses
Statistical analysis of differences between popu¬
lations was performed by the Wilcoxon—Mann-
Whitney rank sum test. Correlations between
analytes were calculated by the Spearman rank
correlation test.
RESULTS
TSP, vWF and (3TG in breast cytosols
A wide range of TSP levels was found in breast
cytosols (Fig. 1). Highest levels were observed in
breast cancers (n = 101, median = 317 p,g TSP/g
cytosol protein, range = 17.4—23,400 p,g TSP/g
cytosol protein) and lowest in benign breast
(n = 15, median 21.7, range = 1.78-155). The


















Fig. 1. TSP in breast cancer and benign breast tissue. Open circles
represent fibroadenomas and one gynaecomastia is shown as a cross.
Horizontal lines indicate median values. The difference between cancers
and benigns was highly significant (P < 10~6).
















Fig. 2. vWF in breast cancer and benign breast tissue. Symbols as for
Fig. 1. The difference between cancers and benigns was significant
(P < io-4).
highly significant (P < 10~6). TSP in fibroaden¬
omas (n = 5, median = 21.7, range = 5.93-155)
was not significantly different from other types of
benign breast tissue (n = 10, median = 19.7, range
= 1.78-47.6) and therefore all benigns were con¬
sidered as a single group.
Measurement of vWF in breast cytosols revealed
a narrower range of concentrations compared with
TSP (Fig. 2), but higher levels of vWF were also
found in cancers (n = 101, median = 40.8 |xg
vWF/g cytosol protein, range = undetectable—392
|xg vWF/g cytosol protein) than in benigns (n = 15,
median = 14.0, range = undetectable-46.0). The
difference was significant (P < 10~4) although less
marked than for TSP. A plot of TSP against vWF
(Fig. 3) showed that they were significantly corre¬
lated (n = 116, rs = 0.484; P< 0.001).
(3TG was measured together with TSP in 20
breast cytosols (18 cancer, one benign, one normal)
and no correlation was observed between the two
(rs = —0.365; P > 0.10) (Fig. 4).
TSP and indicators of hormonal status in breast cancer
cytosols
Breast cancer cytosol TSP levels were compared
in a group of 92 patients classified according to
menopausal status (Fig. 5). TSP in breast cancer
cytosols from pre-menopausal women (n = 32,
median = 213.5 p.g TSP/g cytosol protein, range =
17.4—23400 p.g TSP/g cytosol protein) was slightly
lower than that in cancers from post-mcnopausal
women (n = 60, median = 367, range = 41.8-
12800), the difference just reaching statistical signi¬
ficance (P = 0.043).
TSP did not correlate with ER in breast cancers
(n = 98, rs = -0.0075; P > 0.20) nor with PR
(n = 33, rs = -0.146; P > 0.20) (Fig. 6a,b).
TSP secretion by MCF-l human breast cancer cells
Levels of TSP in the supernatants from MCF-7
cells in serum-free culture for 48 h are shown in
Table 1. Hormones (diluted into culture media from
cthanolic solution) were added at concentrations
previously shown to be maximally stimulatory for
MCF-7 [32, 33], No significant change in TSP
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Fig. 3. Relationship between TSP and vWF in breast tissue. Closed circles represent cancers and benigns are shown as open circles.
TSP and vWF were significantly correlated (rs = 0.484; P < 0.001).
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Fig. 4. Relationship between TSP and $TG in breast tissue. Symbols as
for Fig. 3. One normal breast is shown as a cross. TSP and $TG were
not correlated (rs = —0.365; P > 0.10).
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Testosterone (10-6 M) 95.7 (4.5)
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Fig. 5. Menopausal status and TSP in breast cancer tissue. Horizontal
lines represent median values. The difference between pre- and post¬
menopausal cancers was marginally significant (P = 0.043).
rank sum test) in the presence ofany of the subtances
tested, and the rate ofsecretion was low in compari¬
son with that reported for human endothelial cells
[34].
TSP and tPA in cytosols of tissue taken from different
locations within cancerous breast
Eleven breast tissue cytosols from five patients
with breast cancer were measured for their TSP
and tPA content. The tissue had been classified
according to whether it was taken from the centre of
the tumour mass ('centre') or from the surrounding
non-malignant tissue ('surround'). Comparison of
the TSP concentration in corresponding samples
from centre and surround (Fig. 7) showed that in
four out of the five patients, the centre (n = 5,
median = 1120 pg TSP/g cytosol protein, range
= 31.8-4480 pg TSP/g cytosol protein) contained
much higher levels than the surround (n = 6,
median = 50.9, range = 9.09-324). The differ¬
ence between the two srroups was significant
(P= 0.041).
On the other hand, in every case tPA in corres¬
ponding samples was lower in the centre (n = 5,
median = 1.86 pg tPA/g cytosol protein, range =
1.30-3.67 pg tPA/g cytosol protein) than in the
surround (n = 5, median = 7.18, range =
3.54—11.99) (Fig. 8). Again, the difference between
the two groups was significant (P = 0.008).
TSP and tPA were negatively correlated (n — 10,
rs = —0.576; P < 0.05) (not shown).
DISCUSSION
The elevated levels ofTSP and vWF in malignant
breast, and the correlation observed between these
proteins in breast tissue suggest that they may have
a common site ofsynthesis within the breast which is
stimulated in malignant disease. vWF is synthesized
by endothelial cells and megakaryocytes and is
contained in platelet a-granules [18]. It is incorpor¬
ated into the subendothclial matrix and thought to
be involved in interactions between platelets and
vessel walls. TSP is also synthesized by endothelial
cells and megakaryocytes, and is stored in platelet
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Fig. 6b. Relationship between TSP and PR in breast cancer tissue. TSP and PR were not correlated (rs = —0.146; P > 0.20).
a-granules, but has also been described in a wide
range of other cell types [1—3], Since the platelet a-
granule protein (3TG did not correlate with TSP in
breast cytosols, it is very unlikely that platelets are
the source of the high levels of TSP and vWF
in malignant breast. Increased vascularity and/or
stimulation of the endothelium could explain the
higher TSP and vWF content of cancer tissue
despite our finding that the difference between
cancer and benign samples was much greater for
EJC 25:2-L
TSP than for vWF (the median cytosolic vWF of
malignant breast was three times higher than non-
malignant breast, whereas for TSP it was 15 times
higher). TSP and vWF have been shown to be
located in different subcellular compartments in
endothelial cells where their secretion is separately
controlled [35]. However, it is possible that another
source within the breast, in addition to the endo¬
thelium, may be contributing to the very high level










Fig. 7. TSP in breast tissue from different locations within cancerous
breast. Lines connect corresponding samples taken from the centre of
the tumour mass ('centre') and the surrounding non-malignant tissue
('surround") ofthe cancerous breasts offivepatients. The difference between
the two groups was significant (P = 0.041).
The growth of certain breast cancers is hormon-
ally mediated. Approximately 30% ofbreast cancers
respond to hormone treatment and most of these
arc ER positive [36]. Since oestrogens are so closely
implicated in breast cancer, it was of interest to
investigate whether the high levels of TSP in malig¬
nant breast were related to any of the known indi¬
cators of hormonal status. A slight difference was
observed in the TSP content of breast cancers
from pre- and post-menopausal women, but no
correlation was found between TSP and ER or PR.
TSP was secreted only in small amounts by cultured
human breast cancer cells in a manner refractory to
steroid hormones and epidermal growth factor, and
therefore it seems unlikely that synthesis of TSP by
malignant epithelial cells regulated by oestrogens is
involved in causing the elevated levels found in
breast cancer.
Further evidence for the specific elevation ofTSP
in malignant breast came from the measurement of
TSP in tissue from different sites within the cancer-
u- 1 1
CENTRE SURROUND
Fig. 8. tPA in breast tissue from different locations within cancerous
breast. Lines connect corresponding samples as for Fig. 7. The difference
between the two groups was significant (P = 0.008).
ous breasts of a group of patients. Very high levels
of TSP (>500 p-g/g cytosol protein) were only seen
in tissue taken from the centre of the tumour mass;
levels in tissue taken from elsewhere within the same
breast were comparable to those found in benign
breast.
It was interesting that measurement of tPA in
these samples showed the opposite trend. Whilst
elevated PA levels in breast cancer have been
reported [13], some tumours contain predominantly
urokinase-type plasminogen activator (UKPA) and
others predominantly tPA [37] which makes early
studies in which only total PA was measured diffi¬
cult to interpret. However,it has been established
that tPA, rather than UKPA, is induced by oestra-
diol [14, 38] and our finding that TSP is inversely
correlated with tPA suggests that TSP and tPA
are not coordinately expressed by the malignant
epithelium.
In order to define the exact source and role of
TSP in the breast further studies are required. To
this end we are currently using immunocytochem-
ical techniques for the localization of TSP in situ
and attempting to characterize TSP isolated from
human breast.
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